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ABSTRACT 
Normal hematopoiesis is generated and maintained by rare hematopoietic stem cells (HSCs) 
through their capacity to self-renew and differentiate. This process is rigorously controlled, 
both by HSC-intrinsic molecular programs and extrinsic signals emitted by the local bone 
marrow (BM) microenvironment, the so-called HSC niche.  
The BM niche consists of many cellular elements, including mesenchymal stem cells (MSCs), 
and soluble factors secreted by the cells. The niche homeostasis is critical for maintenance of 
normal hematopoiesis, and disruption of this BM niche may lead to malignant hematopoiesis, 
including leukemia. On the other hand, once malignant hematopoiesis is established, the niche 
structure and composition can be altered to protect leukemia-initiating stem cell (LSC). The 
aims of the presented thesis were to investigate the role of the BM niche in development of 
myeloid malignancies.  
In study I, we analyzed expression of leukotriene (LT) signaling molecules in LSCs derived 
from chronic myeloid leukemia (CML) patients, and tested their response to pharmacological 
inhibition of LT signaling. By using single cell PCR, we found only low expression of ALOX5 
in patient BCR-ABL+ LSCs and BCR-ABL- HSCs. Moreover, in contrast to previous 
observations in mice and in liquid cultures in vitro, pharmacological inhibition of ALOX5 did 
not result in any significant growth suppression of CML LSCs in long-term culture initiating 
cell (LTC-IC) assay on a stromal cell layer. Furthermore, although expression of CYSLT1 was 
detected in the majority of analyzed LSCs, treatment with its antagonist, montelukast, did not 
significantly reduce the LTC-IC activity of LSCs. Thus, these results suggest that 
pharmacological inhibition of the LT pathway might not be sufficient to eradicate LSCs, 
particularly in the presence of BM stromal cells.  
In study II, we investigated the role of BM niche in pathogenesis of MDS/MPN by using a 
Sipa1-/- mouse model. We found that Sipa1 was expressed in BM stromal cells from mice and 
healthy humans, but was downregulated in these cells from patients with MPN and MDS/MPN. 
Additionally, Sipa1 deficiency in mice led to phenotypical and functional alterations in the BM 
cellular niche prior to disease development, and reciprocal transplantation experiments further 
confirmed that Sipa1-/- BM niche was a prerequisite for MDS/MPN development. Moreover, 
RNA sequencing analysis showed dysregulated expression of inflammatory cytokines and 
growth factors in the BM stromal cells from young, disease-free Sipa1-/- mice. Altogether, our 
data suggest that Sipa1 expression in the BM stromal cells is critical for maintaining BM niche 
homeostasis, and that Sipa1 deficiency in BM niche plays an instructive role in development 
of MDS/MPN in mice.  
Finally in study III, we prospectively characterized BM stromal cells in newly-diagnosed 
patients with CML. First of all, we discovered that patient’s BM stromal cells share similar 
immunophenotype as normal BM (NBM) counterparts, but that the CML BM niche 
composition was changed, showing increased frequency of endothelial cells. Moreover, we 
found alterations in functional properties of CML-derived MSCs, e.g. an impaired osteo-
chondrogenic differentiation potential, and an enhanced capacity to support NBM 
hematopoietic stem and progenitor cells in vitro. Even though no BCR-ABL fusion gene was 
detected in CML BM stromal cells, the RNA sequencing revealed cytokine dysregulation, 
particularly loss of CXCL14 in CML BM niche. Interestingly, restoration of CXCL14 
expression in stromal cells suppressed the growth of LSCs in LTC-IC assays, but promoted 
their differentiation. These results indicate that CXCL14 might help to eradicate LSCs and 
therefore serve as a new therapeutic candidate for CML treatment.  
To conclude, we herein showed that BM niche might contribute to myeloid malignancies in 
mice and human. Thus, targeting the dysregulated BM niche factors and the abnormal 
interaction between BM niche and LSCs could be a promising therapeutic approach to treat 
patients with myeloid malignancies.  
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1 INTRODUCTION 
1.1 NORMAL HEMATOPOIESIS 
Hematopoiesis is a continuous and dynamic process of developing the diverse blood cell 
repertoire in the bone marrow (BM) throughout whole postnatal life. Every day, the 
hematopoietic system of a healthy adult produces about one trillion new blood cells with 
different functions. Among these are white blood cells, involved in immune response, red blood 
cells, responsible for oxygen and carbon dioxide transport, and platelets, necessary for 
coagulation (Table 1). After discovering a big variety of cell morphologies within the BM, 
hematopoiesis was postulated to be organized as a cellular hierarchy derived from a common 
ancestor - hematopoietic stem cells (HSC) (Maximow, 1909 reviewed in Doulatov et al., 2012). 
Thereafter, the ability to regenerate the blood system by BM transplantation into patients 
exposed to irradiation, further suggested the existence of blood-forming cells in the BM 
(Jacobson et al., 1951). However, it was not until the utilization of animal models that 
hematopoiesis was proven to depend on the rare cell population of HSCs. For the first time, the 
existence of HSCs was experimentally demonstrated by Till and McCulloch, by showing that 
lethally irradiated mice could be rescued by transplantation of BM cells from normal donors 
(Till and McCulloch, 1961). Following that, the ability of HSCs to self-renew and differentiate 
was proven by Osawa and colleagues in single cell transplantation experiments (Osawa et al., 
1996). These early findings, as well as currently available methods of prospective isolation of 
HSCs (based on cell surface markers) and a range of functional assays, shaped the view of 
normal hematopoiesis as a differentiation hierarchy.  
Table 1. The variety of mature blood cells and their main functions.  
 
Blood cell type Main function  
Lymphocytes  
B cells Regulation of humoral immunity; production of antibodies 
T cells Regulation of cellular immunity; destruction of virus-infected cells 
NK cells Cytotoxicity against virus-infected cells and selected tumor cells 
Dendritic cells Antigen presentation; link between innate and adaptive immune responses 
Monocytes  
Macrophages Effective phagocytosis of pathogens, dead cells, cell fragments and other debris within tissues 
Granulocytes  
Neutrophils Phagocytic; defense against bacterial infections and fungi; recruits other immune cells to the site of infection 
Eosinophils Phagocytic; defense against larger parasites; participate in inflammatory response of allergic reactions and asthma 
Basophils Promotes inflammation; release histamine and heparin; attract other granulocytes to an infection site 
Mast cells Modulatory role in inflammatory responses, including allergy; contribute to immune tolerance; tissue repair and angiogenesis  
Erytrocytes Transport of oxygen and carbon dioxide between tissues and lungs 
Platelets Hemostasis; blood clotting, release of growth factors for tissue healing 
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The multipotent HSCs with self-renewal capacity reside on top of such a hematopoietic “tree”, 
while terminally differentiated mature blood cells can be found at the bottom of the hierarchy. 
HSCs have the ability to self-renew as well as to differentiate into hematopoietic progenitors. 
During differentiation, HSCs lose their self-renewal capacity and give rise to multipotent 
progenitors (MPPs) that retain multi-lineage potential. This classical model of hematopoiesis 
suggests early specification of lymphoid and myeloid lineages as the next step in 
developmental hierarchy. However, accumulating evidence from mouse studies indicate 
presence of myelo-lymphoid progenitors (MLPs), harboring potential to differentiate into both 
myeloid and lymphoid lineages but not megakaryocytic/erythroid (Mk/Er), suggesting that the 
first lineage separation occurs already between myeloid/lymphoid and Mk/Er lineages (Kohn 
et al., 2012; Lai and Kondo, 2006). Moreover, Mk/Er progenitors (MEPs) may bypass the 
lymphoid primed MPP stage and arise directly from HSCs (Adolfsson et al., 2005; Pronk et 
al., 2007; Yamamoto et al., 2013). Downstream of bipotent MLPs, myeloid-restricted cells 
named granulocyte-macrophage progenitors (GMPs) (Görgens et al., 2013) and common 
lymphoid progenitors (CLPs) can be found. GMPs give rise to granulocytes, monocytes and 
myeloid dendritic cells (Doulatov et al., 2010; Lee et al., 2015; Manz et al., 2002), while CLPs 
have the potential to generate B-cells, T-cells, NK cells and dendritic cells (Galy et al., 1995; 
Karsunky et al., 2008; Kondo et al., 1997). Moreover, recent mouse studies indicate that HSCs 
remain heterogenous and can be classified as HSCs with distinct lineage differentiation 
potentials (lineage-bias) without passing through distinct hierarchically organized progenitor 
populations (Carrelha et al., 2018; Ceredig et al., 2009; Eaves, 2015; Sanjuan-Pla et al., 2013; 
Velten et al., 2017), further suggesting that lineage commitment in the developmental hierarchy 
might not be as strict as initially thought (Doulatov et al., 2012; Nestorowa et al., 2016; 
Yamamoto et al., 2013). 
This complex hematopoiesis process requires strict mechanisms regulating HSC fates, 
including differentiation, self-renewal, proliferation and migration. And indeed, transition in 
cell fate is regulated by both cell-autonomous (intrinsic) and microenvironment-derived 
(extrinsic) factors. The intrinsic mechanisms include: transcription factors that control gene 
expression (Rojas-Sutterlin et al., 2014), epigenetic regulators that control the structure and 
organization of DNA and chromatin (Karnati et al., 2015; Mahmud et al., 2014), molecular 
regulators of the cell cycle (Matsumoto and Nakayama, 2013; Pietras et al., 2011), the proteins 
involved in regulation of cell division (Laurenti et al., 2015; Park et al., 2014) and anti-
apoptotic signals (Domen, 2000). In addition, HSCs postnatally receive signals from 
surrounding cells in the BM through direct cell-cell interactions and various factors secreted 
by the stromal cells (discussed more in section 1.3.)  
Importantly, defects in this complex regulatory network, such as acquisition of genetic 
mutations and disruptions in important signaling pathways, may cause transformation of 
hematopoietic cells into malignant cells, leading to blood disorders such as leukemia (Doulatov 
et al., 2012). Therefore, thorough understanding of the mechanisms that regulate normal HSCs 
is crucial for understanding the process of leukemogenesis. 
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1.2 MYELOID MALIGNANCIES 
Myeloid malignancies are a heterogenous collection of clonal hematopoietic disorders, 
disturbing myeloid blood lineages by abnormal cell expansion, abnormal differentiation, or a 
mixture of both. They arise as a consequence of a multistep process, involving accumulation 
of genetic and epigenetic lesions in HSCs and myeloid progenitors, which leads to 
perturbations in key processes, such as abnormal self-renewal, blockage of differentiation and 
excessive proliferation (Vardiman et al., 2009). The myeloid malignancies consist of acute and 
chronic myeloid neoplasms, that can be classified based on BM morphology and percentage 
of immature myeloid cells (blasts) in peripheral blood or BM (Swerdlow et al., 2017).  
Acute myeloid leukemia (AML) is the common form of leukemia in adults (accounting for 
80% of all acute leukemia in adults) mainly affecting people older than 60 years of age (Thein 
et al., 2013). It is a clinically and genetically heterogenous disease, arising from hematopoietic 
stem or progenitor cells that acquired numerous mutations or cytogenetic abnormalities. The 
treatment strategy consists of intensive induction chemotherapy, however is not very effective, 
with overall 5 year survival around 20% (Noone AM). AML can be distinguished from chronic 
myeloid malignancies by BM hypercellularity with accumulation of blasts (over 20% of 
nucleated cells) in the BM, and frequent anemia and thrombocytopenia (Vardiman et al., 
2009).  
On the other hand, chronic myeloid neoplasms are subdivided into four subgroups (Table 2): 
(1) myeloproliferative neoplasms (MPN), (2) myelodysplastic syndromes (MDS), 
(3) MDS/MPN overlap and (4) myeloid/lymphoid neoplasms with eosinophilia and 
rearrangements of PDGFRA, PDGFRB, or FGFR1, or with PMC1-JAK2 (Arber et al., 2016). 
In addition, mastocytosis is no longer considered a subgroup of the MPN, and is now a separate 
disease category (Arber et al., 2016).   
 Myeloproliferative neoplasms 
The MPNs comprise a group of clonal HSC disorders (listed in table 2), with combined 
incidence of six to ten cases per 100 000 people annually, that usually affect adults from 50 to 
70 years of age (Vardiman et al., 2009). MPNs are characterized by abnormal proliferation 
and expansion of one or more myeloid cell lineages (including granulocytic, erythroid and 
megakaryocytic) and often present with increased blood count and BM cellularity, 
splenomegaly and fairly effective hematopoietic maturation. Therefore, morphology of the 
BM cells, except megakaryocytes, is relatively normal and the frequency of the BM blasts in 
chronic phase is close to normal or slightly increased (below 10%) (Vardiman et al., 2009). 
MPNs can be distinguished from MDS and MDS/MPN by the absence of morphologic 
dysplasia (including dyserythropoiesis and dysgranulopoiesis) and the lack of monocytosis 
(Barbui et al., 2018). Moreover, abnormalities in the BM niche, including increased 
angiogenesis, fibrosis and thickening of bone trabeculae are often found, suggesting potential 
contribution of the BM niche to pathophysiology of the diseases (Hoermann et al., 2015). This 
thesis focuses mainly on BCR-ABL1-positive MPN, described below in section 1.1.2. 
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 Chronic Myeloid Leukemia  
Chronic Myeloid Leukemia (CML) is a MPN characterized by uncontrolled expansion and 
accumulation of myeloid cells in the BM (Figure 1), blood and other organs like the spleen. 
The disease accounts for overall incidence of one to two cases per 100 000 and constitutes 
around 15% of adult leukemia (Rohrbacher and Hasford, 2009). Clinically, the course of the 
disease includes three phases, characterized by increasing frequency of the blasts in blood or 
BM: chronic (<10%), accelerated (10-19%) and acute leukemia-like blast crisis (≥ 20%). The 
vast majority of the patients are diagnosed in the chronic phase, when white blood cell count is 
increased. At that time, patients can present with fatigue, weight loss, night sweats, palpable 
splenomegaly and anemia, or shown no noticeable symptoms. However a small group of the 
patients are diagnosed during the accelerated phase or acute leukemia-like blast crisis 
(Swerdlow et al., 2017).  
CML is caused by a reciprocal translocation in HSCs, between the Abelson (ABL) gene on 
chromosome 9 (region q34) and the Breakpoint Cluster Region (BCR) on chromosome 22 
(region q11). This t(9;22) translocation (also known as the Philadelphia chromosome) results 
in the BCR-ABL1 oncogene, encoding a constitutively active tyrosine kinase, and causes the 
transformation of HSCs into leukemic stem cells (LSCs) (Deininger et al., 2000). Given that 
tyrosine kinase ABL plays an important role in controlling the cell cycle, apoptosis and 
interactions of hematopoietic cells with the BM niche, the fusion gene BCR-ABL1 deregulates 
proliferation, apoptosis, differentiation and adhesion of LSCs. Moreover, the fusion tyrosine 
kinase activity modulates response to DNA damage and extends activation of cell cycle 
checkpoints when exposed to chemotherapeutic drugs, prolonging time for DNA repair. BCR-
ABL1 expression can also facilitate genomic instability, possibly by generation of reactive 
oxygen species (ROS) and enhanced spontaneous DNA damage in tumor cells (Penserga and 
Skorski, 2006). The genomic instability and accumulation of new genetic aberrations might in 
turn lead to acquired drug resistance and malignant progression (Goldman and Melo, 2008). 
Figure 1. The BM biopsy of CML patient at diagnosis (chronic phase) showing hypercellularity with 
increased granulopoiesis, eosinophilia and dysplastic megakaryocytes. Pictures courtesy of Monika 
Klimkowska. 
Development of imatinib – a tyrosine kinase inhibitor (TKI) – revolutionized CML treatment, 
as the majority of treated patients achieve clinical remission and dramatic reduction in BCR-
4x 40x 
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ABL1 transcript level (also referred to as molecular remission) (Druker et al., 2001; Hughes et 
al., 2003). Imatinib effectively targets cycling BCR-ABL1+ leukemic cells, but not quiescent 
LSCs with leukemia-initiating capacity (Corbin et al., 2011). As a result, BCR-ABL1+ LSCs 
persist in the BM of patients who are in deep remission and may contribute to molecular relapse 
after treatment cessation (Chomel et al., 2016; Chu et al., 2011). Thus, most of the CML 
patients in the chronic phase are not cured and require a life-long TKI therapy (Saussele et al., 
2018). To achieve treatment-free remission, it is important to better understand and target 
additional pathways responsible for LSC retention. 
Studies have shown that survival of CML LSCs does not depend on BCR-ABL1 kinase 
activity, which suggests that other mechanisms might contribute to LSC persistence 
(summarized in Figure 2) (Hamilton et al., 2012).  
One of the pathways related to LSC resistance is PI3K/AKT/FOXO, as BCR-ABL1 
upregulates PI3K/AKT signaling and leads to AKT-mediated phosphorylation of FOXO 
transcription factors, which results in their cytoplasmic localization and inactivation. 
Consequently, inhibition of BCR-ABL1 activity by TKI downregulates PI3K/AKT signaling 
in LSCs, and leads to re-localization of FOXO to the nucleus, where it can actively regulate 
transcription of BCL6. This is important, as the aberrant upregulation of BCL6 confers 
protective, pro-survival effect to CML cells by repressing the tumor suppressor p53 and the 
cell cycle inhibitor CDKNA2A (also known as ARF) (Hurtz et al., 2011; Pellicano et al., 2014). 
In addition, TGF-β-FOXO axis has been shown to maintain LSCs, whereas blocking of the 
TGF-β pathway seems to reverse the nuclear localization of FOXO and inhibits clonogenic 
activity of LSCs (Naka et al., 2010; Pellicano and Holyoake, 2011). 
The Hedgehog pathway, specifically, activation of smoothened (SMO), a G-Protein-Coupled 
Receptor, has also been implicated in regulation of LSC self-renewal and proliferation. SMO 
activation causes activation of another transcription factor – GLI1, which in turn leads to 
degradation of TP53. Repression of p53 targets results in reduced apoptotic responses and 
possibly cell-cycle arrest in CML (Abraham et al., 2016). In line with that, deletion of SMO, 
as well as its pharmacological inhibition in a CML mouse model, resulted in loss of LSCs 
(Dierks et al., 2008; Irvine et al., 2016; Zhao et al., 2009). 
Several lines of evidence indicates the JAK/STAT pathway as an important player in the 
regulation of LSC survival (Traer et al., 2012). It has been shown that pharmacological 
inhibition of JAK2 results in a loss of LSC in vitro and in vivo (Gallipoli et al., 2014). 
Additionally, a heterozygous mutation in STAT5a attenuates the CML-like disease in mouse 
models (Ye et al., 2006), while RNA inhibition of STAT5 impairs BCR-ABL1+ colony 
formation (Scherr et al., 2006). Activation of STAT3 has also been implicated to have a 
protective effect on CML cells after exposure to TKI (Bewry et al., 2008), and it has been 
shown that combined inhibition of BCR-ABL1 and STAT3 leads to the loss of otherwise 
resistant LSCs (Eiring et al., 2015).  
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Moreover, Wnt signaling and its key mediator – β-catenin, are involved in LSC survival. TKI 
therapy-related upregulation of CD27 signaling has been shown to result in re-localization of 
β-catenin to the nucleus and activation of NOTCH and c-MYC genes (Riether et al., 2015; 
Schürch et al., 2012). In agreement, loss of β-catenin in a CML mouse model causes inhibition 
of LSC self-renewal and impairs development of the disease (Zhao et al., 2007). Similarly, 
pharmacological inhibition of β-catenin combined with TKI treatment leads to the loss of LSCs 
(Heidel et al., 2012). In addition, β-catenin levels can be regulated by enzymes involved in fatty 
acid metabolism, namely arachidonate 5- and 15-lipoxygenase (5-LO and 15-LO encoded by 
Alox5 and Alox15, respectively), which have been found to be upregulated in LSCs (Chen et 
al., 2009). Deficiency of Alox5 or Alox15, as well as their pharmacological inhibition, affects 
division and apoptosis of LSCs, and attenuates CML onset in mice (Chen et al., 2009). 
Moreover, combining TKI and a 15-LO inhibitor seems to have synergistic effect on human 
LSCs in liquid culture in vitro, possibly mediated through the P-selectin SELP, which is 
otherwise repressed to promote LSC survival (Chen et al., 2014). However, treatment with the 
5-LO inhibitor, zileuton, seems to have only minor effect on survival of human LSCs in 
presence of stromal cells in vitro (Dolinska et al., 2017), suggesting a BM niche-mediated 
mechanism of the drug resistance. 
Although abovementioned mechanisms were initially thought to be cell-autonomous, there is 
an increasing evidence suggesting an important role of BM niche in the pathogenesis of 
myeloid neoplasms, as well as its contribution to drug resistance (as described in section 1.4).  
Figure 2. Critical pathways that contribute to CML LSCs persistence. Originally published by Holyoake 
and Vetrie, 2017, and reprinted with permission from American Society of Hematology. 
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1.3 THE BM MICROENVIRONMENT IN NORMAL HEMATOPOIESIS 
As mentioned before, hematopoiesis is tightly regulated by autonomous (cell-intrinsic) 
mechanisms, but also, and to large extent by non-autonomous (extrinsic) signals derived from 
the BM microenvironment, also called the BM niche (Zon, 2008). The niche signals can in turn 
trigger cell intrinsic mechanisms that may lead to alterations of HSC fates. The concept of HSC 
niche was first suggested by Schofield, who defined it as a specialized microenvironment 
within bone cavity that supports HSCs and maintains their functions (Schofield, 1978). 
Accumulated evidence from mouse studies demonstrates that the BM niche is critical for 
regulation of HSC fates, including differentiation, self-renewal, quiescence and migration by 
production of soluble factors and adhesive interaction (Morrison and Scadden, 2014; Yu and 
Scadden, 2016). Up to date, many cellular components of the BM niche have been identified, 
such as mesenchymal stem cells, osteoblasts, endothelial cells, adipocytes, sympathetic 
nervous system, megakaryocytes, macrophages and more (Figure 3) (Morrison and Scadden, 
2014; Park et al., 2012b). In addition to extracellular matrix proteins, numerous cytokines and 
growth factors, as well as factors such as oxygen and mineral concentrations, have been 
indicated to play an important role in the interaction between HSCs and other cells present 
within the BM niche (Camacho et al., 2017; Hoggatt, 2016). The BM HSC niche has been 
categorized based on the respective cellular niche component, as described below. 
 Hypoxia  
The physiological condition of the BM niche is generally considered to be hypoxic (Spencer et 
al., 2014), raising the possibility that low oxygen tension is important for maintaining HSCs 
(Eliasson and Jönsson, 2010). Several studies show that low oxygenic-niche derived BM 
hematopoietic cells have higher repopulation capacity (Parmar et al., 2007; Winkler et al., 
2010a) and that pre-incubation of HSCs and progenitor cells in hypoxia has favorable effect on 
the proliferation of mouse BM-derived colony-forming cells (Eliasson et al., 2010), providing 
evidence for the important role of oxygen tension for HSCs activity. Moreover, it has been 
shown that hypoxia regulates HSCs through stabilization of hypoxia-inducible factor 1α (HIF-
1α) (Semenza, 2014), which acts as transcriptional regulator of numerous genes important for 
hematopoiesis. HIF-1α regulates proliferation and survival (Lin et al., 2006), homing (through 
the CXCL12-CXCR4 axis) (Ceradini et al., 2004), secretion of angiogenic factors, like VEGF 
(Levy et al., 1995), and protection of hematopoietic cells from damage caused by accumulation 
of ROS (Jang and Sharkis, 2007; Kirito et al., 2009). In a mouse model, conditional deletion 
of Hif1α leads to progressive loss of long term quiescent HSCs, which is associated with loss 
of HSCs under various stress conditions (Takubo et al., 2010). Similarly, Hif1α-/- mice show a 
selective loss of quiescent endosteal HSCs expressing GRP78 (Miharada et al., 2011). 
Similarly, deficiency of aryl hydrocarbon receptor nuclear translocator (ARNT), an important 
regulator of hypoxia-related factors, leads to HSCs apoptosis (Krock et al., 2015). Taken 
together, these studies suggest that hypoxia might play an important role in maintaining HSCs 
features. However, to improve the therapeutic expansion of HSCs, we need to learn more about 
the molecular mechanisms of hypoxia-mediated regulation. 
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Figure 3. The BM niche is composed of multiple different cell types that contribute to the regulation of 
hematopoiesis. Modified, originally published by Krause and Scadden, 2015, and reprinted with 
permission from Hematologica; copyright Ferrata Storti Foundation.  
 Mesenchymal Stem Cells  
After the discovery of HSCs, the adult BM was shown to contain another population of 
multipotent cells. In the series of studies, Friedenstein et al. demonstrated that rodent BM 
contains plastic-adherent cells with the ability to form fibroblastoid colonies, differentiate into 
bones and reconstitute the hematopoietic niche in vivo after subcutaneous transplantation 
(Friedenstein et al., 1968). Subsequently, these adherent BM cells were shown to support 
hematopoietic cells in long term cultures in vitro (Dexter et al., 1977). Similar cells, with the 
capacity to form fibroblast-like colonies (CFU-F) (Castro-Malaspina et al., 1980) and 
differentiate into osteogenic, adipogenic and chondrogenic lineages in vitro, were also detected 
in human BM aspirates (Gartner and Kaplan, 1980). However, due to their undefined features, 
these cells were not termed as Mesenchymal Stem Cells (MSCs) until 1991 (Caplan, 1991). 
Later on, the in vivo differentiation, but not self-renewal, of human BM-derived MSCs, was 
formally demonstrated by transplantation of single colony-derived BM MSCs into 
immunodeficient mice where they formed bones (Kuznetsov et al., 1997). Nevertheless, the 
stem cell identity of the retrospectively defined mesenchymal cells with CFU-F capacity 
remains very poorly defined. Therefore, the International Society for Cellular Therapy (ISCT) 
has recommended the term Multipotent Mesenchymal Stromal Cells to describe plastic-
adherent, CFU-F forming cells, thereby keeping the acronym MSC in use (Horwitz et al., 
2005). The ISCT has also introduced minimal criteria to define human MSCs, including: 
1) plastic adherence under standard conditions; 2) ability to differentiate into osteoblasts, 
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adipocytes and chondrocytes; 3) expression of CD105, CD73 and CD90 surface markers as 
well as 4) lack of expression of hematopoietic markers such as CD45, CD34, CD14, CD11b, 
CD79α, CD19 and HLA-DR (Dominici et al., 2006). However, these criteria have not been 
sufficient to fully understand functions of different MSC populations in vivo, particularly 
because in vitro cultivation alters both, the immunophenotype and the global gene expression 
profile of freshly isolated, native MSCs (Qian et al., 2012; Tormin et al., 2011; Churchman et 
al., 2012; Quirici et al., 2002; Harichandan et al., 2013). Therefore, the prospectively isolated 
and characterized cells might better represent native MSCs in vivo.  
Prospective isolation of human MSCs using cell surface markers  
Different markers have been described to label human MSCs in the BM. These markers can be 
used either alone, or in combination with others, to prospectively isolate MSCs.  
CD271, also known as The Low Affinity Nerve Growth Factor Receptor (LNGFR), is 
expressed by BM stromal cells adjacent to sinusoids (Cattoretti et al., 1993) and therefore it is 
used to identify MSCs. CD271+ cells are capable to form CFU-F (Quirici et al., 2002) and to 
differentiate into osteoblasts, adipocytes and chondrocytes in vitro (Jones et al., 2006). 
Moreover, freshly isolated CD271+ cells express CXCL12, ANGPTL1, SP7 and FABP4, 
suggesting their multilineage potency and hematopoiesis supportive properties in vivo 
(Churchman et al., 2012).  
CD146, known as Melanoma Cell Adhesion Molecule (MCAM), is also expressed by BM 
MSCs that form CFU-F, self-renew and provide support for hematopoietic cells when 
transplanted as heterotopic ossicles into immunocompromised mice (Sacchetti et al., 2007; 
Tormin et al., 2011).  
CD44 Within the non-hematopoietic and non-endothelial population of adult BM, primitive 
and highly clonogenic MSCs can be distinguished based on lack of the CD44 expression, while 
more mature cells, which are unable to form CFU-F, are CD44+ (Qian et al., 2012).  
Others In addition to the markers described above, other studies have suggested CD90 and 
CD106 to be expressed by human BM MSCs (Mabuchi et al., 2013). Moreover, co-expression 
of CD146 and CD105 (Isern et al., 2013), or CD140A, CD51 and Nestin (Pinho et al., 2013), 
marks MSCs with clonogenic capacity, multilineage differentiation potential and the capacity 
to support HSC expansion in vitro. However, the immunophenotype of MSCs might be 
developmentally regulated. For example, the CD140A+CD51+ seems to mark MSCs in fetal 
BM, whereas the CD140A- stromal cells are enriched for CFU-F in adult BM (Li et al., 2014). 
Prospective isolation of murine MSCs using cell surface markers  
There are several markers suggested to label MSCs in mouse BM, which can be used to 
prospectively isolate MSCs and mesenchymal progenitors (Figure 4).  
CD140A and SCA-1 First reports show that, within the non-hematopoietic population, 
CD140A+SCA-1+ cells (PαS) have MSC characteristics, including CFU-F activity and 
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multilineage differentiation potential in vitro, as well as self-renewal and differentiation 
capacity in vivo. Additionally, PαS cells show high expression of genes important for HSC 
regulation, including Cxcl12 and Angptl1, further supporting their role in the BM niche. 
Interestingly, the single-positive SCA1+ or double-negative (CD140A-SCA-1-) populations 
seem to consist of more committed progenitor cells with restricted differentiation capacity 
(Morikawa et al., 2009a; Morikawa et al., 2009b).  
CD44  Just like in human, native MSCs in murine BM can be identified based on lack of 
CD44 expression. The CD44- MSCs show high clonogenic activity, trilineage differentiation 
potential in vitro and expression of genes involved in regulation of HSC fate, such as Angptl1, 
Nestin, Col1a1, Fmod and Nov (Qian et al., 2012).  
CD105 Moreover, CD105 expression labels a population with self-renewal potential and the 
ability to transfer the BM niche after transplantation under kidney capsule of adult mice (Chan 
et al., 2013). However, these cells have an osteo-lineage restricted differentiation potential 
(Chan et al., 2013) that overlaps with Nestin+ cells (Isern et al., 2013).  
CD140A and CD51  In addition to these markers, Pinho et al. suggests a combination of 
CD140A and CD51 expression to identify murine MSCs. The majority of CD140A+CD51+ 
cells, which are Nestin+ but SCA1- (Mendez-Ferrer et al., 2010), have self-renewal and 
trilineage differentiation capacity in vitro. Furthermore, these MSCs have high expression of 
HSC niche-associated genes, including Cxcl12, Scf, Angptl1, Vcam1, suggesting their 
hematopoiesis supportive properties (Pinho et al., 2013).  
Characterization of MSCs and progenitors using genetically engineered mouse models  
Similarly to studies on hematopoiesis, much of our understanding of MSC functions has been 
attained from mouse models. Genetically modified mice are crucial tools, allowing gene-
specific labeling of MSCs (Figure 4), to subsequently investigate their properties, localization 
and role in the BM niche in vivo.  
Nestin Nestin-GFP model was the first one suggested for labeling MSC population within 
non-hematopoietic BM cells (Mendez-Ferrer et al., 2010). Perivascular Nestin+ cells have 
CFU-F activity, the potential to differentiate into three lineages in vitro and can self-renew in 
vivo. In addition, Nestin+ MSCs express high levels of Kitl, Cxcl12 and Angptl1 – the genes 
involved in HSC maintenance. Moreover, the depletion of Nestin+ cells compromises the 
frequency of HSCs and hematopoietic progenitor cells in the BM, and mobilizes hematopoietic 
cells to the spleen, suggesting an important role of the Nestin+ cells in maintaining normal 
hematopoiesis (Mendez-Ferrer et al., 2010). However, the impact the cytokines derived from 
these mesenchymal progenitor cells may have on hematopoiesis remains controversial. The 
specific deletion of Cxcl12 (Ding and Morrison, 2013b) or Scf (Ding et al., 2012) from Nestin+ 
cells does not affect HSC frequency or function in the BM, but leads to reduced frequency of 
HSCs and hematopoietic progenitor cells in the spleen. These studies suggest that CXCL12 
and SCF produced by Nestin+ cells might not be necessary for normal hematopoiesis in the 
BM, but SCF may be important for HSC migration or extramedullary hematopoiesis in the 
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spleen. However, the exact effect of Nestin+ cell depletion on HSC functionality and 
heterogeneity in the BM requires further characterization at the single cell level. 
LepR Other studies use Leptin Receptor (LepR) as a marker of primitive MSCs in the BM 
of adult mice (Zhou et al., 2014). Multipotent LepR+ cells represent a rare cell population 
(approximately 0.3%) with the capacity to form CFU-F and to differentiate into osteoblasts, 
adipocytes and chondrocytes in vitro and in vivo (Zhou et al., 2014). Moreover, the majority of 
BM stromal cells expressing SCF or CXCL12, co-express LepR. Studies have shown that 
specific deletion of Scf (Ding et al., 2012) and Cxcl12 (Ding and Morrison, 2013b) from the 
LepR+ cells leads to a depletion of HSCs and certain progenitor cells and their release to the 
circulation, indicating that these MSCs are an important player in HSC regulation. Moreover, 
in vivo fate-mapping shows that LepR+ MSCs give rise to most of the bones and adipocytes in 
the BM, and contribute to post-injury recovery (Zhou et al., 2014). During differentiation into 
mature osteoblasts, LepR+ cells lose LepR expression  (Mizoguchi et al., 2014). In line with 
that, conditional deletion of Foxc1, a transcription factor important for development and 
maintenance of the mesenchymal cells, from LepR+ cells diminishes HSC pool in the BM, 
providing additional evidence that LepR+ MSCs are a key component of the HSC niche 
(Omatsu et al., 2014).  
Prx1  Similarly to LepR+ MSCs, Paired related homeobox gene 1 (Prx1)+ cells show MSC 
characteristics. Prx1+ MSCs are highly enriched in CFU-F activity, have the ability to 
differentiate into osteoblasts and adipocytes in vitro and can secrete CXCL12 (Greenbaum et 
al., 2013). Notably, depletion of Cxcl12 from Prx1+ MSCs results in the loss of HSCs with 
long-term repopulation capacity, as well as lymphoid progenitors in the BM (Ding and 
Morrison, 2013b; Greenbaum et al., 2013). Interestingly, deletion of LepR from Prx1+ MSCs 
leads to increased bone formation at the expense of adipogenic differentiation (Yue et al., 
2016), indicating the role of LepR in BM MSCs in tissue homeostasis. 
Ebf2  Furthermore, Early B cell factor 2 (Ebf2), a transcription factor from the Ebf family 
but not expressed in hematopoietic cells, marks the MSC population in mouse BM (Qian et al., 
2013). Ebf2+ MSCs have high self-renewal (reflected in CFU-F frequency) and multilineage 
differentiation capacity, both in vitro and in vivo. Moreover, genes important for HSC 
maintenance, including Angptl1, Fmod, Nestin, Nov, N-cadherin and Runx2, are highly 
enriched in Ebf2+ MSCs, suggesting the hematopoiesis supportive properties of the cells (Qian 
et al., 2013). In vitro co-culture experiments show that Ebf2-deficient stromal cells have 
detrimental effects on normal HSCs and, in line with that, Ebf2-/- mice are described with 
decreased numbers of HSCs and progenitor cells, as well as declined lymphopoiesis. 
Importantly, transplantation experiments indicate that BM niche-dependent mechanisms lead 
to such abnormalities in hematopoiesis (Kieslinger et al., 2010). 
CAR  Another stromal cell population, localized in close proximity to HSCs and therefore 
suggested as an important component of the BM niche, is composed of CXC12-abundant 
reticular cells (CAR cells). The term CAR cells refers to a heterogeneous population of BM 
stromal cells with high expression of CXCL12 (Sugiyama et al., 2006) and SCF (Omatsu et 
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al., 2010). In fact, deletion of the CXCL12 receptor, CXCR4, results in a reduction of HSC 
frequency and higher sensitivity to myelotoxic drugs (Sugiyama et al., 2006). Consequently, 
ablation of CAR cells impairs production of SCF and CXCL12, and leads to a reduction of 
quiescent HSCs and an increased expression of early myeloid genes (Omatsu et al., 2010). 
Nevertheless, freshly isolated CAR cells do not have CFU-F capacity, but they express genes 
involved in osteogenic and adipogenic differentiation (Omatsu et al., 2010), suggesting they 
are a population consisting of adipo-osteogenic progenitors and mature stromal cells. 
Others  More studies suggest that other populations, such as Myxovirus resistance-1 (Mx1) 
(Park et al., 2012a) and bone morphogenetic protein (BMP) antagonist Gremlin 1 (Grem1) 
expressing cells (Worthley et al., 2015), contribute to the formation of the mesenchymal niche. 
Non-hematopoietic Mx1+ cells can form CFU-Fs, however with significantly lower frequency 
than abovementioned LepR+ or Prx1+ MSCs. They also exhibit the capacity to differentiate into 
adipocytes, osteoblasts and chondrocytes in vitro, thereby fulfilling criteria for MSCs. 
Nevertheless, in vivo, Mx1+ cells seems to have restricted differentiation capacity to osteoblasts 
only, and therefore they are considered to be an osteoprogenitor population (Park et al., 2012a). 
Likewise, Grem1+ cells have been shown to have self-renewal capacity (measured by CFU-F 
assays), and to be able to differentiate in vitro towards osteoblasts and chondrocytes, but not 
adipocytes. Comparably to Mx1+, Grem1+ cells merely contribute to bone formation and 
healing in vivo, and for that reason they are also considered to be an osteo-restricted progenitor 
population (Worthley et al., 2015). 
Taken together, these studies provide strong evidence that MSCs and mesenchymal progenitors 
are components of the BM niche and may be the key players in regulation of normal HSCs and 
hematopoietic progenitor cells. However, it is still not fully understood how the described MSC 
populations (labeled by different markers) relate to one another, and more studies are needed 
to clarify reported differences in marker expressions and properties. 
Figure 4. Relationship between various BM MSC and mesenchymal progenitor cell populations, 
defined by different marker expression.  
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 Osteoblastic niche  
Early mouse studies have shown that many HSCs localize close to the inner bone surface – the 
endosteum (Gong, 1978; Lord et al., 1975). Given that osteolineage cells line the endosteal 
region, they are the first cell population proposed as BM cellular niche. Demonstration of 
osteoblasts ability to support growth of human HSCs in vitro by producing cytokines, further 
highlighted the role of the endosteal niche in hematopoiesis regulation (Taichman et al., 1996; 
Taichman, 1994). However, transgenic mouse models were needed to prove that hypothesis 
and to provide the first evidence in vivo.  
Two hallmark studies, performed at the beginning of the previous decade, have demonstrated 
the essential role of osteoblastic cells in HSC expansion and maintenance in mice. The first of 
them shows that constitutive activation of parathyroid hormone receptor (PTHR) in 
osteolineage cells leads to the activation of Notch signaling and an increase in numbers of 
osteoblastic cells, as well as HSCs and progenitor cells (Calvi et al., 2003). In line with these 
findings, activation of Notch signaling results in increased number of HSCs (Stier et al., 2002). 
Another study presents a similar, parallel increase in the numbers of osteoblastic cells and 
HSCs after the deletion of BMP receptor 1A from Mx1+ osteoprogenitors, thus suggesting that 
BMP signaling in osteoblasts is another important player in the regulation of HSCs (Zhang et 
al., 2003). Since then, more studies using different transgenic mouse models have demonstrated 
osteoblast-mediated regulation of HSCs, and suggest the underlying mechanisms and signaling 
pathways. One of the examples is the conditional ablation of Col2.3-labeled osteoblast lineage, 
which results in reversible BM hypocellularity, a decreased number of HSCs and increased 
extramedullary hematopoiesis (Visnjic et al., 2004). Similarly, preventing osteolineage 
differentiation by depletion of Osterix+ cells, leads to loss of hematopoiesis in the BM of adult 
mice (Zhou et al., 2010). Moreover, overexpression of Wnt signaling inhibitors (Dkk1 or Wif1) 
in Col2.3-labeled osteoblasts leads to the increased cycling of HSCs (Fleming, 2008; Schaniel 
et al., 2011). A more recent study also shows that depletion of Col2.3-expressing osteoblast 
leads to reduced HSC quiescence, long-term engraftment and secondary repopulating capacity, 
and points to a potential role of osteoblast-derived Jagged-1 in hematopoiesis regulation 
(Bowers et al., 2015). In addition, several other molecules produced by osteoblasts contribute 
to HSC fates regulation. One of them is osteopontin (OPN), which binds to integrin αvβ1/CD51 
and CD44 on the surface of HSCs, and plays an important role in cell adhesive interaction as 
well as proliferation and mobilization of HSCs (Nilsson et al., 2005). Consistent with this 
report, deletion of Opn in mice causes an increase in number of HSCs, showing that OPN is a 
negative regulator of HSCs (Stier et al., 2005). Osteoblasts can also express agrin, a regulator 
of neuromuscular and immunologic synapses, that binds to the α-dystroglycan receptor on 
hematopoietic progenitor cells, and thereby modulates their survival and proliferation. Lack 
of that direct cell-cell interaction in Argin-/- mice leads to apoptosis of HSCs and disturbs 
hematopoiesis (Mazzon et al., 2011). Furthermore, it has been also shown that the endosteal 
niche retain HSCs within the BM by high concentration of calcium, as HSCs deficient in 
calcium-sensing receptors were found mainly in the circulation (Adams et al., 2006). 
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However, several lines of evidence question the direct effect of osteolineage cells on HSC 
regulation. It has been shown that osteoblastic N-cadherin is not required for HSC regulation 
under steady state (Bromberg et al., 2012; Kiel et al., 2007). Moreover, the specific deletion of 
CXCL12 from Osterix+ osteoprogenitors (Greenbaum et al., 2013) and Col2.3-expressing 
osteoblasts (Ding and Morrison, 2013b) had little or no effect on HSC proliferation or 
mobilization. Similarly, osteoblast-specific deletion of SCF does not affect HSC frequency or 
function (Ding et al., 2012). There is also an evidence suggesting that osteoblasts support 
lymphopoiesis rather than HSCs. Depletion of Col2.3-expressing osteoblasts reduces number 
of B-cell precursors (Zhu et al., 2007), while deletion of CXCL12 from the same osteoblasts 
leads to loss of lymphoid progenitors but does not affect HSC number (Ding and Morrison, 
2013b). Osteoblasts are also associated with regulation of erythropoiesis (Rankin et al., 2012) 
and megakaryopoiesis (Xiao et al., 2017). These findings indicate that osteoblasts might be 
more involved in the regulation of more committed hematopoietic progenitors, rather than of 
the HSCs. The discrepancy between abovementioned reports might be due to specificity of the 
conditional, gene-modified mouse models used in the studies, as well as difficulties to 
distinguish osteoblasts and osteoprogenitors from more primitive mesenchymal progenitors 
and MSCs, as markers for these populations have overlapping expression pattern (Nakamura 
et al., 2010).  
Other cells found in the endosteal niche, including bone-embedded osteocytes and bone-
degrading osteoclasts, also affect hematopoiesis. Osteocytes, which are terminally 
differentiated osteoblasts, can regulate myelopoiesis through Gsα, subunit of G proteins 
(Fulzele et al., 2013). It has been shown that  mice lacking Gsα in osteocytes display dramatic 
increase of myeloid cells in the BM, peripheral blood and spleen. Moreover, conditioned media 
from Gsα-deficient osteocytes stimulates myeloid colonies in vitro, while treatment with anti-
G-CSF neutralizing antibody blocks that effect (Fulzele et al., 2013). Furthermore, G-CSF-
mediated mobilization of HSCs and hematopoietic progenitors to the circulation is impaired 
in osteocyte-ablated mice (Asada et al., 2013). In contrast, osteoclasts promote egress of 
HSCs and progenitor cells from the BM (Kollet, 2006). Besides that, pharmacological 
inhibition of osteoclast activity is associated with a reduced number of HSCs, as well as 
delayed hematopoiesis reconstitution in irradiated recipients (Lymperi et al., 2011). 
 Vascular niche 
Despite the fact that HSCs can be found in the endosteum region, increasing evidence suggest 
that vascular niche plays an important role in regulation of hematopoiesis and HSCs. The 
vascular niche is located closer to the central zone of the BM, and is composed of endothelial 
cells (ECs), which line the lumen of blood vessels (Potente et al., 2011; Morrison and Scadden, 
2014). Anatomic proximity of HSCs (Kiel et al., 2005), including the majority of quiescent 
HSCs with long-term repopulating capacity (Acar et al., 2015), to sinusoidal vessels suggests 
an important role of vascular niche in regulation of hematopoiesis. However, around 10% of 
quiescent HSCs are more closely associated with arterioles (Kunisaki et al., 2013). These 
perisinusoidal and periarteriolar vascular niches differ in terms of local oxygen concentration, 
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permeability of the blood vessels, and the capacity of hematopoietic cells to migrate through 
the walls. More leaky sinusoids represent an exclusive site for hematopoietic cells trafficking 
between the BM and circulation. Because of that, HSCs might be more exposed to blood 
plasma, and thus, to an elevated level of ROS (Itkin et al., 2016). Measurements of oxygen 
tension within the BM of live animals show the perisinusoidal niche is also the most hypoxic 
region in the BM (Spencer et al., 2014). On the other hand, small arterioles seem to be more 
resistant to irradiation-induced damage compared to the sinusoids, suggesting that 
periarteriolar vessels might play an important role in vasculature regeneration, as well as 
hematopoiesis recovery after irradiation (Kusumbe et al., 2014). Moreover, arterioles are 
ensheathed by a population of pericytes expressing neural/gial antigen 2 (NG2), which seems 
to maintain HSCs quiescence, since depletion of these NG2+ cells leads to reduction of HSCs 
with long-term repopulating capacity and increase of cycling HSCs (Kunisaki et al., 2013). It 
has been shown that distinct mechanisms are involved in the regulation of HSCs by the 
perivascular cells. Deletion of CXCL12 from NG2+ pericytes induces mobilization of quiescent 
HSCs to the circulation, and therefore results in a reduction of HSC numbers in the BM 
(Kunisaki et al., 2013). On the other hand, deletion of SCF from NG2+ cells is not associated 
with reduced numbers of HSCs (Asada et al., 2017). 
Regardless of the type of blood vessels, ECs are an indispensable part of the BM niche. The in 
vivo functional contribution of ECs to HSC regulation was first demonstrated by use of a Tie2-
Cre mouse model with conditional deletion of gp130 cytokine receptor, mediating signals from 
IL-6 family. Wild-type recipient mice displayed normal hematopoiesis after transplantation of 
gp130-deficient BM, but not the other way around, suggesting a role of EC-mediated IL6 
signaling in hematopoiesis (Yao et al., 2005). Moreover, inhibition of Tie2-angiopoietin 
signaling in the vascular niche affects vascular regeneration and delays hematopoiesis recovery 
after myelosuppression, indicating an important role of ECs in hematopoiesis recovery in vivo 
(Kopp et al., 2005). Later studies by Hooper et al. also demonstrated that conditional deletion 
of vascular endothelial growth factor receptor 2 (Vegfr2) in adult mice impairs regeneration of 
sinusoidal ECs and HSC reconstitution after myelosuppression (Hooper et al., 2009). Similarly, 
inhibition of VEGFR2 using blocking antibodies also leads to impaired HSC engraftment after 
lethal irradiation (Hooper et al., 2009). Moreover, treatment with anti-VE cadherin neutralizing 
antibodies inhibits vessel formation in mice after irradiation, and interferes with hematopoietic 
recovery (Avecilla et al., 2003; Salter et al., 2009). In line with that, Tie2-specific deletion of 
Bak1 and Bax, genes promoting apoptosis, protects ECs from irradiation-mediated damage and 
at the same time promotes hematopoietic regeneration (Doan et al., 2013b). Moreover, BM 
hematopoiesis recovery after irradiation can be improved by infusion of endothelial progenitor 
cells (Li et al., 2010; Salter et al., 2009) Additionally, infusion of young ECs improves 
engraftment of aged HSCs, suggesting an important role of EC also during aging processes 
(Poulos et al., 2017). These findings together demonstrate that ECs are crucial for 
hematopoiesis regenerations.  
Many other studies show molecular mechanisms underlying the EC-mediated regulation of 
HSC expansion and differentiation. It has been reported that ECs could induce HSC expansion 
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in vitro, and long-term repopulation in vivo, by expression of angiocrine factors, e.g. Notch 
ligands (Butler et al., 2010). Activation of AKT signaling in ECs regulates HSC self-renewal 
through expression of CXCL12 and SCF. It also leads to activation of MAPK signaling in ECs, 
which in turn supports HSC differentiation in vivo (Kobayashi et al., 2010). Furthermore, EC-
specific deletion of Notch ligand, Jagged-1, leads to reduction in HSC number and inhibits 
hematopoietic regeneration after irradiation (Poulos et al., 2013), whereas expression of 
Jagged-2 in ECs contributes to hematopoietic recovery after myelosuppression (Guo et al., 
2017). In line with that, activation of endothelial Notch signaling in aged mice restores the 
number of ECs, and increases functionality of HSCs and progenitor cells (Kusumbe et al., 
2016). Another signaling pathway important for HSC regulation within BM vascular niche is 
NF-κB. EC-specific inhibition of NF-κB results in increased self-renewal and regenerative 
capacities of HSCs. Consistently, injecting ECs with inhibited NF-κB signaling into irradiated 
mice reduces the radiotherapy-related damage to the hematopoietic system (Poulos et al., 
2016).  
Studies using EC-specific cytokine deficient mice demonstrated that BM ECs contribute to 
hematopoiesis through production of key HSC niche factors and angiocrine factors (Yu and 
Scadden, 2016). EC-specific deletion of SCF (Ding et al., 2012) or CXCL12 (Ding and 
Morrison, 2013a; Greenbaum et al., 2013) results in HSC reduction and decreases their long-
term repopulating activity. What is more, conditional deletion of Il7 in ECs affects B-
lymphopoiesis, suggesting that endothelial niche can regulate HSC function and fate (Cordeiro 
Gomes et al., 2016). Moreover, BM ECs can support hematopoiesis via expression of specific 
surface markers, including E-selectins, P-selectin, VCAM-1 and ICAM1. Deficiency in E-
selectins induces quiescence of HSCs, and improves their survival after irradiation or 
chemotherapy, proving that E-selectins promote HSC proliferation (Winkler et al., 2012b). 
Likewise, EC-derived heparin-binding growth factor, pleiotropin (PTN), and epidermal growth 
factor (EGF) are important players in the regeneration of HSCs following myeloablation. It has 
been shown that PTN deficiency or administration of anti-PTN antibodies might lead to 
impaired HSC maintenance and hematopoietic regeneration following myelosuppression 
(Himburg et al., 2012). Consistent with this finding, systemic treatment of irradiated mice with 
PTN supports expansion of HSCs in vivo (Himburg et al., 2010). Likewise, administration of 
EGF promotes recovery of HSCs and improves survival of mice after irradiation. By contrast, 
mice lacking the EGF Receptor in hematopoietic cells present with increased HSC apoptosis 
and delayed BM recovery compared to wild type mice (Doan et al., 2013a). 
Taken together, ECs contribute to hematopoiesis maintenance and regulate HSC function 
through direct cell-cell contact, cytokines and angiocrine factors, as well as through indirect 
pathways. Moreover, the endothelial niche is crucial for hematopoietic system recovery after 
hematopoietic insult.  
 Adipocytes  
Adipocytes, also called the yellow marrow, reside in the bone cavity (mainly in the diaphysis 
area) and gradually replace hematopoietic cells in human BM during aging (Tuljapurkar et al., 
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2011). Initially it was suggested that adipocytes are simply occupying space within BM without 
any regulatory function (Gimble, 1990; Gimble et al., 1996). However, the negative correlation 
between yellow marrow abundance and decreasing functionality of HSCs, as well as several in 
vitro studies, all indicate that adipocytes are negative regulators of hematopoiesis (Hoggatt, 
2016; Naveiras et al., 2009; Omatsu et al., 2010). In addition to reduced numbers of HSCs and 
progenitors in adipocyte-rich marrow in mice, it has been shown that inhibition of 
adipogenesis, by treatment with peroxisome proliferator-activated receptor gamma (PPARγ) 
inhibitor, leads to better HSC engraftment in the BM (Naveiras et al., 2009), and improves 
recovery after chemotherapy (Zhu et al., 2013). Moreover, “fatless” mice, which are genetically 
incapable of forming adipocytes, show higher engraftment of HSCs in the BM compared to 
wild-type controls (Naveiras et al., 2009). Recent study suggested that adipocytes suppress 
hematopoiesis and BM regeneration by excessive expression of dipeptidyl peptidase 4 
(DPP4/CD26), which is involved in processes of apoptosis and immune response (Ambrosi et 
al., 2017). However, enhanced adipogenesis by treatment with triglitazone has no effect on the 
frequency of HSCs in the BM under homeostatic conditions, suggesting that adipocytes might 
not be a part of the functional BM niche during homeostasis (Spindler et al., 2013). In line with 
that, Zhou et al. has shown that adipocytes produce SCF, which has no effect on HSCs under 
steady-state, but it is required for HSC engraftment after transplantation. Consequently, 
“fatless” mice in this study display normal HSC number under normal conditions, but impaired 
recovery after BM transplantation. These findings suggest that adipocytes might be a pro-
regenerative component of the BM niche. It is important to note that the Adipoq-Cre/ER+ 
mouse model used in this study cannot distinguish whether the observed effects are mediated 
by mature adipocytes or immature (LepR+) progenitors (Zhou et al., 2017) in this study. Further 
studies are needed to better understand the roles of adipocytes in hematopoiesis regulation.  
 Sympathetic nervous system (SNS)  
BM is highly innervated with sympathetic nerves that can regulate HSCs (Hanoun et al., 2015; 
Katayama et al., 2006; Kunisaki et al., 2013). The SNS is composed of non-myelinating 
Schwann cells that present regulatory BM niche functions. They have been reported to produce 
cytokines and express cytokine receptors, and thus affecting the microenvironment where they 
are located (Gordon, 2014; Ozaki et al., 2008; Höke et al., 2006). As a source of active  
TGF-β, the Schwann cells can maintain HSC quiescence and regulate their activation 
(Yamazaki et al., 2009). Consequently, BM denervation leads to decreased TGF-β signaling 
and causes loss in the quiescent HSC pool (Yamazaki et al., 2011).  
Sympathetic signals are involved in HSC mobilization mediated by G-CSF, regulation of 
CXCL12 expression in the BM, and HSC retention through circadian oscillations (Casanova-
Acebes et al., 2013; Katayama et al., 2006; Lucas et al., 2008; Méndez-Ferrer et al., 2008). 
Even though sympathectomy, caused by treatment with neurotoxin, does not affect HSC 
number, it impairs their mobilization from the BM (Katayama et al., 2006; Lucas et al., 2008; 
Afan et al., 1997). Moreover, chemotherapy-induced sensory neuropathy inhibits 
hematopoiesis and BM regeneration. Consequently, protection of SNS and its regeneration 
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from chemotherapy-related injury improves hematopoietic recovery (Lucas et al., 2013). As 
HSCs express catecholaminergic receptors, they can directly receive and respond to 
sympathetic catecholamine signals (Spiegel et al., 2007). It has been shown that treatment of 
HSCs with dopamine agonists and norepinephrine can increase colony formation in vitro and 
improve engraftment in vivo (Kalinkovich et al., 2009; Spiegel et al., 2007). Moreover, loss of 
SNS nerves in the BM of young mice leads to premature aging of HSCs, while administration 
of a symphathomimetic drug to old mice rejuvenates functions of aged HSCs in vivo, 
suggesting an important role of the SNS in HSC aging (Maryanovich et al., 2018). However, 
the underlying molecular mechanisms remain poorly understood. 
 Megakaryocytes 
Megakaryocytes (MKs) are hematopoietic cells adjacent to the BM sinusoids. They co-localize 
with HSCs and regulate their fate under steady-state as well as in response to stress (Bruns et 
al., 2009; Bruns et al., 2014; Heazlewood et al., 2013; Zhao et al., 2014). In vivo ablation of 
MK cells leads to activation of quiescent HSCs and reduced levels of TGF-β1 in the BM. 
Interestingly, conditional deletion of Tgfb1 from MKs similarly affects activation and 
proliferation of HSCs, while treatment with TGF-β1 restores HSC quiescence in MK-
depleted mice, suggesting that MKs regulate HSC fate through TGF-β signaling under 
steady-state (Zhao et al., 2014). In response to stress, MK-derived fibroblast growth factor 1 
(FGF1) prevails over TGF-β signals and stimulates HSC expansion. Hence, ablation of MKs 
under stress condition may inhibit HSC expansion. (Zhao et al., 2014). Additionally, MKs 
can regulate the HSC pool size via secretion of CXCL4 (also named platelet factor 4/PF4) as 
Cxcl4-/- mice present an increased number of HSCs and that injection of CXCL4 into mice 
leads to a reduction in HSC number as a consequence of their increased quiescence (Bruns 
et al., 2014). Notably, conditional ablation of CXCL4-expressing MKs leads to reduced levels 
of thrombopoietin (THPO) in the BM – another cytokine important for HSC maintenance 
(Qian et al., 2007) – and egress of HSCs from the BM. This study shows that perturbed cell 
cycle activity of HSCs, caused by MK depletion, can be restored by THPO administration, 
suggesting its important role in MK-mediated regulation of HSC quiescence (Nakamura-
Ishizu et al., 2014). Under stress condition, MKs are required for both, hematopoietic 
regeneration and osteogenesis. After radioablation, MKs are recruited to the endosteum, 
where they produce platelet-derived growth factor-β (PDGF4) and stimulate osteoblast 
expansion to promote hematopoietic recovery (Olson et al., 2013). Blocking the THPO 
receptor (MPL) reduces MK migration to the endosteum, and subsequenty HSC engraftment 
(Olson et al., 2013). Overall, these observations confirm that MKs contribute to the BM niche 
and indirectly regulate HSC quiescence and function through production of multiple factors.  
 Macrophages 
The BM contains various macrophages (MΦs) with different functions. They line the endosteal 
surface and participate in bone mineralization, thus, they are often termed as osteomacs 
(Alexander et al., 2011; Chang et al., 2008; Pettit et al., 2008). While studying HSC 
mobilization to peripheral blood using G-CSF, Winkler et al. observed reduced number of 
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MΦs, indicating they play a role in HSC trafficking (Winkler et al., 2010b). Following that, 
depletion of CD169+ MΦs was associated with HSC mobilization and reduction in 
erythroblasts numbers in the BM under steady-state conditions, as well as after myeloablation 
and acute blood loss in a hemolytic anemia model (Chow et al., 2011). Later findings suggest 
that CD169+ MΦs secrete oncostatin M (OSM), which stimulates stromal cells to express 
CXCL12, which interacts with CXCR4 on HSC and therefore keeps them in the BM niche 
(Albiero et al., 2015). In line with these findings, treatment of diabetic mice with CXCR4 
antagonist (Chow et al., 2011) or OSM blocking antibodies (Albiero et al., 2015) improves G-
CSF-mediated mobilization of HSC to the circulation. Taken together, these studies indicate 
that BM MΦs can support erythropoiesis, regulate HSC retention and influence other BM niche 
cells via production of soluble factors.  
 Complex cross-talk between cellular components of the BM niche 
As described above, the BM niche consists of different, partially redundant, cellular niche 
components that interact with HSCs and control their fate (Hoggatt, 2016). However, BM 
niche cells can also regulate and depend on one another.  
In line with that, deletion of Angpt1 from LepR+ stromal and hematopoietic cells increases 
vascular leakiness (Zhou et al., 2015). Moreover, decline of Endomucinhigh ECs is associated 
with a reduction in osteoprogenitor cells in aged mice. By contrast, expansion of ECs leads 
to increased bone formation, indicating the coupling of angiogenesis and osteogenesis 
(Kusumbe et al., 2014). Furthermore, mice with disrupted Notch signaling in ECs present 
with decreased bone mass and defective release of Noggin, an antagonist of bone 
morphogenetic proteins, from ECs. Interestingly, administration of Noggin restores number 
of osteoprogenitors and bone growth in mutant mice, pointing out that EC-specific Notch-
mediated mechanisms regulate both blood vessel and bone formation (Ramasamy et al., 
2014). Paracrine cross-talk between osteolineage cells and ECs has been shown to be 
important under stress condition too, for example after hematopoietic injury. Under steady 
state, Osx+ cells produce Dkk1 protein, a Wnt inhibitor, which induces secretion of EGF by 
ECs to promote BM regeneration after irradiation (Himburg et al., 2016). Moreover, 
osteoblasts support megakaryopoiesis by secreting IL-9 as shown by mouse models where 
IL-9 administration stimulates platelets production and accelerates platelet recovery after 
chemotherapy (Xiao et al., 2017). On the other hand, norepinephrine produced by the SNS 
regulates CXCL12 release by acting on β3 adrenergic receptors on stromal cells (Méndez-
Ferrer et al., 2008). Sympathetic nerves in turn receive physical support from arterioles in the 
BM (Kunisaki et al., 2013). Moreover, neutrophils seem to be indirectly involved in the 
regulation of HSC trafficking. After entering the BM, aged neutrophils are phagocytosed by 
MΦs, that interact with the stromal cells leading to downregulation of CXCL12, and thus, 
egress of HSCs to the circulation (Casanova-Acebes et al., 2013). Depletion of CD169+ MΦs 
was also accompanied with decreased osteoblasts numbers (Chow et al., 2011). Similar studies 
confirmed that MΦs support osteolineage cell function through production of soluble factors 
(Christopher et al., 2011).  
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Taken together, these studies indicate evidence that various BM niche cells act together to 
provide an interactive unit for hematopoiesis regulation. Therefore, ablation of one population 
or removal of soluble factors might affect other cellular components of the BM niche and 
overall tissue integrity.  
 
1.4 THE BM MICROENVIRONMENT IN MYELOID MALIGNANCIES  
Similarly to normal HSCs, LSCs also reside in a specific microenvironment that regulates their 
functions. Recently, our understanding of the BM niche modifications and their contribution to 
abnormal hematopoiesis has advanced thanks to studies using transgenic mouse models. The 
strong evidence that BM niche plays an important role in myeloid malignancies revived the 
“seed and soil” hypothesis, proposed by Stephen Paget over hundred years ago to describe the 
relationship between environment (soil) and tumor cells (seeds) in metastasis (Goulard et al., 
2018).  
 Interaction between the BM niche and malignant cells 
Interaction with BM niche is crucial for leukemic cell growth (summarized in Figure 5), as it 
can mediate their resistance to treatment (Jacamo and Andreeff, 2015). It has been implicated 
by in vitro studies, where treatment with either JAK2 inhibitor, or ALOX5 inhibitor, reduces 
the growth of malignant cells only in the absence of stromal cells (Manshouri et al., 2011; 
Yektaei-Karin et al., 2017), but does not show the same effect when primary CML LSCs are 
co-cultured with stromal cells (Dolinska et al., 2017). 
One of the mechanisms controlling LSC survival is the adhesive interaction with the BM niche  
(Schepers et al., 2015). Studies have shown that expression of cell surface glycoprotein CD44, 
which binds to extracellular matrix proteins and osteopontin, is increased in CML cells and 
mediates their homing and engraftment. Moreover, this study shows that treatment with an 
antibody against CD44 inhibits CML development in wild-type recipients (Krause et al., 2006). 
Similarly, high expression of CD44 is important for AML induction or relapse in murine model 
(Quéré et al., 2010), and is required for homing of human AML leukemic cells in 
immunodeficient mice (Jin et al., 2006b). Different studies have shown that E-selectins, which 
are crucial for engraftment of CML cells (Krause et al., 2014), are also highly expressed on 
ECs in AML BM and promote chemoresistance in the vascular niche (Winkler et al., 2012a). 
Another family of cell adhesion receptors – integrins – also regulate leukemic cell functions in 
vitro and in vivo. It has been shown that integrin β1 can regulate proliferation of CML cells 
through adhesion to BM stromal cells and components of the extracellular matrix, such as 
fibronectin, (Bhatia et al., 1996; Bhatia et al., 1994; Lundell et al., 1997). Furthermore, 
interaction of a leukemic cell line with fibronectin mediates downregulation of proapoptotic 
factor Bim1, and leads to treatment resistance of LSCs (Hazlehurst et al., 2007). Similarly, 
integrin β3 is involved in AML development (Miller et al., 2013) and enhancement of Wnt 
signaling in AML cells (Yi et al., 2016). Moreover, integrin α4β1, also called very late antigen-
4 (VLA4) can bind to vascular cell adhesion molecule 1 (VCAM1) (Jacamo et al., 2014) or 
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fibronectin (Matsunaga et al., 2003), and thus, induce chemoresistance of AML cells. In 
addition, glycoprotein CD98, which binds to integrins, enhances the interaction between AML 
and BM stromal cells, and thereby promotes maintenance and proliferation of leukemic cells 
(Bajaj et al., 2016). Notably, CD98 deficiency increases survival of the AML mice, whereas 
treatment with the anti-CD98 antibody inhibits growth of human AML cells in xenograft 
models (Bajaj et al., 2016). Similarly, CD82 mediates adhesion of human AML leukemic 
stem/progenitor cells to the extracellular matrix, and anti-CD82 treatment in combination with 
chemotherapy prolongs survival of mice transplanted with human AML cells (Nishioka et al., 
2015). In addition, studies show that interaction with the BM stromal cells induces expression 
of Galectin-3 (Gal-3) in CML cell lines, promotes leukemic cell proliferation and subsequently 
leads to TKI resistance in vitro. In line with these findings, Gal-3 overexpression in vivo 
promotes lodgement of CML cells in the BM niche (Yamamoto-Sugitani et al., 2011). 
Similarly, AML cells induce expression of growth arrest-specific gene (Gas6) in the BM niche 
to further promote their own proliferation (Janning et al., 2015). The same regulatory axis has 
been shown to support the self-renewal of CML LSCs (Jin et al., 2017). Another adhesive 
molecule, N-cadherin, mediates adhesion of CML cells to the BM niche, and might induce TKI 
insensitivity of leukemic cells by activation of β-catenin and increased Wnt signaling (Zhang 
et al., 2013). 
Moreover, the BM niche can promote disease progression through abnormal cytokines and 
chemokines production (Figure 5) (Camacho et al., 2017). For example, CXCL12-CXCR4 
signaling between the BM niche and AML cells can promote leukemic cell survival, as shown 
by decreased leukemia burden and prolonged survival of AML mice after treatment with 
CXCR4 antagonists (Nervi et al., 2009; Tavor et al., 2004; Zeng et al., 2009). In CML, CXCR4 
upregulation increases survival of quiescent LSCs in vitro by stimulating migration of leukemic 
cells towards BM stromal cells (Tabe et al., 2011), and thus, inhibition of CXCL12-CXCR4 
restores sensitivity of LSCs to TKI in vitro (Vianello et al., 2010). Furthermore, it has been 
shown that CML LSCs have higher expression of IL-1 receptor, suggesting that IL-1 signaling 
contributes to their maintenance (Zhang et al., 2016). In line with that, treatment with IL-1 
receptor antagonists suppresses the growth of CML LSCs, and displays an additive effect when 
combined with TKI treatment (Zhang et al., 2016). Similarly, LSCs from AML patients 
overexpress CXCR2, a receptor for proinflammatory cytokine IL-8, which has been shown to 
promote their proliferation (Schinke et al., 2015). Also, tumor necrosis factor α (TNFα), an 
inflammatory cytokine often increased in myeloid malignancies, enhances proliferation and 
survival of malignant cells (Gallipoli et al., 2013).  
Additionally, a mitochondrial transfer from the BM stromal cells to AML cells, but not normal 
CD34+ hematopoietic stem/progenitor cells, leads to increased chemoresistance (Moschoi et 
al., 2016). Inhibition of NADPH oxidase 2 (NOX2)–derived superoxide prevents this 
mitochondrial transfer, and leads to increased apoptosis of leukemic cells and prolonged 
survival of mice transplanted with patient-derived AML cells (Marlein et al., 2017) 
. 
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Figure 5. Malignant cells interact with their BM niche through multiple pathways. Modified, originally 
published by Krause and Scadden, 2015, and reprinted with permission from Hematologica; copyright 
Ferrata Storti Foundation. 
 
 The BM niche-remodeling by malignant cells  
LSCs are known to share many biological properties with normal HSCs (Kreso and Dick, 
2014). Given that normal hematopoiesis is impaired in patients with hematological 
malignancies, it has been postulated that LSCs can outcompete HSCs and remodel the BM 
niche into a self-reinforcing, malignant microenvironment (Hanahan and Coussens, 2012; Tabe 
and Konopleva, 2017). Therefore, the BM niche might be responsible for leukemic relapse and 
disease progression (Ishikawa et al., 2007).  
1.4.2.1 The BM niche remodeling in CML 
In a transgenic CML mouse model, the abnormal BM microenvironment produces significantly 
more cytokines that selectively support malignant cell growth over healthy HSCs (Zhang et al., 
2012). CML cells produce higher levels of G-CSF, which in turn causes decreased expression 
of CXCL12 by the BM niche cells. Moreover, eradication of leukemic cells, using imatinib 
treatment, partially corrects the cytokine expression pattern, suggesting that BM niche 
remodeling was induced by leukemia (Zhang et al., 2012). Similarly, increased levels of GM-
CSF, IL-6 and IL-1α can be found in the serum of CML mice (Welner et al., 2015). Moreover, 
exposing normal HSCs to CML cells leads to increased myeloid differentiation capacity and 
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reduced self-renewal potential of the HSCs, as well as altered gene expression patterns in 
hematopoietic progenitor cells. Interestingly, treatment with anti-IL-6 blocking antibody 
attenuates CML onset, suggesting that BCR-ABL1+ leukemic cells promote the disease and 
affect normal hematopoiesis through IL-6 signaling. It is important to note here that patient-
derived CML cells impose similar changes on normal HSCs and hematopoietic progenitors in 
culture, which further confirms that both mouse and human LSCs have the capacity to modulate 
surrounding cells in the BM niche (Welner et al., 2015). Moreover, CML cells promote 
secretion of PIGF by BM stromal cells during co-culture (Schmidt et al., 2011). In this study, 
increased PIGF level stimulates angiogenesis and proliferation of the leukemic cells. 
Consequently, treatment with PIGF antagonist prolongs the survival of CML mice and has an 
additive therapeutic effect when combined with imatinib, indicating the capacity of CML 
leukemic cells to reprogram the BM niche to promote progression of the disease (Schmidt et 
al., 2011). Using a similar CML mouse model, Schepers et al. shows that CML cells can 
remodel the BM endosteal niche, which consists of increased fraction of osteoblasts with 
altered gene expression pattern and compromised capacity to support normal HSCs (Schepers 
et al., 2013). Also, the ablation of osteoblasts has been shown to significantly accelerate 
development of leukemia, and reduces survival of CML mice. In this study, the CML BM niche 
affects cycling of hematopoietic cells through higher expression of a Notch ligand, Jagged-1 
(Bowers et al., 2015). 
1.4.2.2 The BM niche remodeling in AML 
We have recently shown the dynamics of BM niche remodeling by the AML leukemic cells 
(Xiao et al., 2018b). The AML-induced BM cellular and molecular alterations are strongly 
correlated with leukemia burden. Changes in the expression of important hematopoiesis-
supportive niche factors appear 14 days post transplantation, but before massive expansion of 
leukemic cells. Moreover, in vivo fate-mapping experiments reveal that the Ebf2+ MSC 
population is an important player in leukemic niche formation, however, depletion of Ebf2+ 
cells before AML onset enhances leukemia engraftment and accelerates disease progression. 
This data suggests that native BM MSCs may initially have a leukemia-suppressive role, and 
could later be reprogrammed by AML cells to promote the disease (Xiao et al., 2018b). 
Moreover, MLL-AF9 leukemic cells can trigger MKs to express higher levels of Tgfb1 upon a 
co-culture in vitro. Interestingly, an increased level of TGF-β1 can be found in the AML BM, 
where it seems to inhibit proliferation of normal HSCs, and leads to defective hematopoiesis 
in vivo (Gong et al., 2018). AML cells can also inhibit the activity of osteoblastic cells (as 
measured by decreased levels of osteocalcin) and cause a decrease in mineralized bone volume. 
Increased CCL3 levels, found in AML cells from mice and patients, might be involved in that 
phenotype (Frisch et al., 2012). In line with these finding, osteoblast ablation inhibits normal 
hematopoiesis, and increases MLL-AF9 leukemia burden. Accordingly, restoration of the 
osteoblast population, by pharmacological treatment, reduces the leukemic burden and 
prolongs survival of leukemic mice (Krevvata et al., 2014). Furthermore, MLL-AF9-induced 
AML mice have decreased numbers of pericytic NG2+ cells and lower density of sympathetic 
nerves (Hanoun et al., 2014). This in turn causes expansion of Nestin-GFP+ MSCs with 
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increased commitment towards osteolineage, however, they are unable to differentiate into 
mature osteoblasts. Moreover, decreased expression of the genes regulating HSC maintenance 
and retention in the BM niche cells leads to reduced repopulation ability of HSCs, and their 
mobilization out to peripheral blood and spleen. These data indicate that AML cells modulate 
the BM niche to promote leukemia at the expense of normal hematopoiesis via disruption of 
SNS and expansion of immature mesenchymal progenitors (Hanoun et al., 2014).  
1.4.2.3 The BM niche remodeling in MPN 
MPN cells are also able to reinforce the disease by altering the BM niche composition. In 
contrast to AML, JAK2V627F MPN mice show a decrease of Nestin+ MSCs and Schwann cells 
(Arranz et al., 2014). In this model, mutated hematopoietic cells produce IL-1β, which triggers 
BM neural damage and compromises MSC survival. In line with these findings, depletion of 
Nestin+ MSCs results in expansion of malignant cells and accelerates MPN progression, 
whereas treatment with neuroprotective drugs inhibits the growth of mutated cells. The 
restoration of sympathetic regulation in the BM niche can both prevent the loss of Nestin+ cells 
and block MPN progression, alltogether indicating the critical role of the BM niche damage in 
disease development (Arranz et al., 2014). A study by Mead et al. demonstrates that 
hematopoietic cells with the Flt3/ITD activating mutation can modulate the BM niche, as 
competitive transplantation into healthy recipients leads to a decrease of ECs and MSCs, 
coincided with the loss of normal hematopoietic cells and eventually Flt3-ITD-driven 
myeloproliferation in the recipient mice (Mead et al., 2017). Notably, this study shows that 
TNF, a cell-extrinsic negative regulator of HSCs, is overexpressed in the BM niche cells from 
Flt3-ITD knock-in mice, and that anti-TNF treatment partially rescues the progressive loss of 
HSCs (Mead et al., 2017). 
1.4.2.4 The BM niche remodeling by exosomes  
Moreover, malignant cells can reprogram the BM niche through release of exosomes (Cheng 
et al., 2018). Exosomes are cell membrane–derived vesicles carrying protein and RNA that 
might act as mediators in cell–cell communication (Boyiadzis and Whiteside, 2015). Proof-of-
concept in vitro studies show that primary AML cells release exosomes that can enter 
neighboring cells in co-culture. The uptake of such exosomes causes changes in secretion 
profile, and alters proliferation and migration capacity of the BM stromal cells (Huan et al., 
2013). In addition, the CML blast crisis cell line transfers exosomes containing microRNA 
miR-126 into ECs during co-culture, which leads to reduced VCAM-1 and CXCL12 
expression in ECs, and reduced adhesion capacity of the CML cell line (Taverna et al., 2014). 
Thereafter, it has been shown that injection of AML-derived exosomes increases the numbers 
of MSCs with blocked osteoblast differentiation in the BM niche. Interestingly, wild-type 
recipients transplanted with AML cells with a knockdown of Rab27a, a protein involved in 
exosome release, show significantly prolonged survival compared to control mice (Kumar et 
al., 2017).  
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Taken together, these studies indicate that malignant cells can create a self-reinforcing niche 
by conferring signals to surrounding BM cells. The remodeled BM niche becomes detrimental 
for normal HSCs, but supportive for leukemic cells, and therefore accelerating the malignancy.  
 
 Instructive role of the BM niche in pathogenesis of myeloid 
malignancies 
Not only “malignancy-induced microenvironment” but also a “microenvironment-induced 
oncogenesis” model has been proposed (Shiozawa and Taichman, 2010). Several studies have 
provided the evidence that alterations in the BM niche could be sufficient to trigger 
myeloproliferative disease in mice.  
The first evidence of niche-driven disease appeared in 2007, when two simultaneously 
published studies showed that mice deficient for retinoic acid receptor gamma (Rarγ) (Walkley, 
2007a) and retinoblastoma (Rb) gene (Walkley, 2007b) develop myeloproliferative MPN-like 
disorder. Rarγ is a nuclear hormone receptor acting as transcriptional regulator of gene 
expression (Balmer and Blomhoff, 2002), whereas Rb is a key regulator of the cell cycle. 
(Weinberg, 1995). The former study shows that transplantation of wild-type hematopoietic 
cells into Rarγ knockout recipient mice, but not vice versa, leads to MPN, suggesting that 
disease is not intrinsic to hematopoietic cells, but rather triggered by genetic alterations in the 
BM niche (Walkley et al., 2007a). In the latter study, myeloproliferation and loss of HSCs in 
mice appears only when Rb deficiency occurs in both hematopoietic cells and the BM niche at 
the same time. This finding demonstrates that Rb regulates HSCs extrinsically by maintaining 
the capacity of the BM niche to support normal hematopoiesis, and hence indicates the crucial 
role of interactions between both cell populations (Walkley et al., 2007b). In addition, 
inactivation of Mib1 gene, encoding an enzyme necessary for processing Notch ligands, leads 
to myeloproliferative disease. Similar to Rarγ knockout, only Mib1-/- recipients transplanted 
with wild-type cells develop the disease. Moreover, introducing a constitutively active domain 
of Notch1 into the knockout BM niche can reverse the effects and suppress progression of the 
disease. This findings show that disruption of Notch signaling in the BM niche has an 
instructive role in disease pathogenesis (Kim et al., 2008).  
More recently we and others have observed that deletion of Sipa1, a gene involved in regulation 
of cell proliferation, cell adhesion and cell survival via Rap1 signaling, leads to age-dependent 
MPN in mice (Ishida et al., 2003; Xiao et al., 2018a). Moreover, mutation in SIPA1 can be 
found in the mononuclear cells from patients with juvenile myelomonocytic leukemia (JMML) 
(Yoshida et al., 2008). Interestingly, cellular abnormalities in the BM niche of Sipa1-/- mice, 
including expansion of MSCs and mesenchymal progenitors, occur before onset of the disease. 
Importantly, Sipa1 knockout recipients transplanted with wild-type hematopoietic cells 
develop MDS/MPN, while Sipa1-deficient hematopoietic cells fail to initiate the disease in 
wild-type recipient mice. These findings clearly demonstrate that it is the Sipa1-deficient BM 
niche that causes the neoplasia (Xiao et al., 2018a). Similarly, deficiency of intracellular 
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adhesion molecule (Icam1) in the BM niche, but not HSCs, leads to expansion of HSCs with 
defective repopulation capacity, and increased myelopoiesis in mice (Liu et al., 2018). In line 
with the results from mouse model, neutralization of ICAM-1 increases proliferation of human 
HSCs when co-cultured with the BM stromal cells. Worth noting, culture-selected BM stromal 
cells from CML and AML patients show decreased expression of ICAM1 (Liu et al., 2018). 
These results indicate that alterations in the BM niche can lead to perturbed hematopoiesis and 
myeloid malignancies in mice.  
To identify which cellular components of the BM niche contribute to the hyperproliferation of 
myeloid cells, many studies use genetically modified reporter mice targeting various stromal 
cell populations. One of them has demonstrated that conditional deletion of microRNA-
processing gene Dicer1 from immature Osx+ osteoprogenitors, but not mature Ocn+ 
osteoblasts, results in impaired osteoblast differentiation and leads to MDS and sporadic 
transformation to AML. These results suggest that Osx-expressing osteoblast progenitor cells 
contribute to disease initiation. Moreover, deletion of Dicer1 leads to reduced expression of 
Schwachman-Diamond-Bodian syndrome (Sbds) gene in the osteoprogenitors (Raaijmakers et 
al., 2010). Interestingly, decreased expressions of DICER1 and SBDS, can be also detected in 
MSC-derived osteoprogenitors from MDS patients (Santamaria et al., 2012). In another mouse 
model, a Ctnnb1CAosb mutation in the Wnt pathway results in the constitutive activation of  
β-catenin in Col1-expressing osteoblastic cells, and leads to AML development by inducing 
aberrant Notch signaling in HSCs and progenitor cells. It is important to note that similar 
observations were reported in 38% of analyzed MDS and AML patients, who had increased  
β-catenin signaling in the osteoblasts and increased activation of Notch signaling in the 
hematopoietic cells (Kode et al., 2014; Kode et al., 2015). A recent study has shown that an 
activating mutation in protein tyrosine phosphatase SHP2, Ptpn11E76K, in the BM Prx1+, 
LepR+, Nestin+ MSCs and Osx1+ osteoprogenitors, but not in Ocn+ mature osteoblasts or VE-
Cadherin+ ECs, promotes leukemogenesis (Dong et al., 2016). Moreover, the Ptpn11E76K 
recipient mice develop donor cell-derived MPN after transplantation of wild-type BM cells. 
Altogether, these findings provide an evidence that mutated mesenchymal progenitors, with 
altered expression of CCL3 and other proinflammatory cytokines, have the instructive role in 
the pathogenesis of MPN in mice (Dong et al., 2016). Importantly, the same mutation is found 
in the mononuclear cells of approximately half of the Noonan Syndrome patients, who have 
increased risk of developing leukemia and MPN at young age (Dong et al., 2016). Similarly, 
the prospectively isolated MSCs from low-risk MDS patients show increased expression of 
genes encoding inflammatory factors (Chen et al., 2016), and elevated levels of damage-
associated molecular pattern (DAMP) molecules S100A8/9, which are shown to induce 
genotoxic stress and support leukemic evolution in pre-leukemic mice (Zambetti et al., 2016). 
Moreover, transcriptional activation of S100A8/9 axis in mesenchymal niche can be used as 
predictive factor of disease progression in human MDS (Zambetti et al., 2016). 
Alterations in the BM ECs might also be a predisposing factor in the development of myeloid 
malignancies. For example, loss of Notch signaling in ECs (using Tie2-RBPJ-/- mouse model) 
leads to a lethal MPN-like disease (Wang et al., 2014). Specifically, the loss of Notch/RBPJ 
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signaling upregulates microRNA miR-155 in BM ECs, leading to activation of NF-κB and 
increased production of proinflammatory cytokines. Notably, deletion of miR-155 from 
stromal cells of RBPJ-/- mice prevents disease development, suggesting that activation of miR-
155/NF-κB in the BM niche drives myeloproliferation. Interestingly, increased expression of 
miR-155 can also be found in the BM from MPN patients (Wang et al., 2014). Another study 
shows that the BM vascular niche with a JAK2V617F mutation contributes to expansion of 
malignant cells (Lin et al., 2016). First, the JAK2V617F ECs increase proliferation of JAK2V617F 
HSCs and hematopoietic progenitors compared to JAK2WT counterparts in vitro (Lin et al., 
2016). The competitive BM transplantation experiments further confirm that the JAK2V617F 
vascular niche promotes growth of JAK2V617F malignant cells over JAK2WT HSCs and 
progenitors. In contrast, there are no differences between wild-type recipients transplanted with 
either mutant or normal hematopoietic cells, which indicates a crucial role of altered ECs in 
MPN development (Zhan et al., 2017). The relevance of these findings increases as the same 
mutation can be found in ECs from MPN patients (Rosti et al., 2013; Sozer et al., 2009; Teofili 
et al., 2011), suggesting their potential involvement in disease pathogenesis in patients.  
These studies present strong evidence that mutations in the BM niche can have a causative role 
in malignant transformation in mice. However, it is still unclear whether a single alteration in 
the BM niche can initiate leukemia in humans. 
 
 Disease- and stage-specific BM niche regulation of leukemogenesis  
The BM niche regulation of hematopoiesis and leukemogenesis is stage and disease specific 
(Krause et al., 2013; Lane et al., 2011). For instance, osteoblastic cell-specific activation of the 
PTH receptor has an opposite effect on BCR-ABL+ CML and MLL-AF9+ AML cells. PTH 
signaling attenuates CML-like MPN development, through the suppressive effect of TGF-β1 
derived from the remodeling bone, but it promotes AML progression in a mouse transplantation 
model (Krause et al., 2013). Moreover, the BM niche can regulate AML cells in distinct ways 
during different stages of leukemia progression. It has been shown that the BM niche is required 
in pre-leukemic stage, however it becomes more permissive once leukemia is established (Lane 
et al., 2011).  
These studies illustrate distinct niche requirements for different types of leukemia, and suggest 
that the outcome of niche modulation can be very specific to the disease. Therefore, it is of 
great importance to understand the mechanisms regulating the BM niche interaction with 
hematopoietic cells in patients, as well as their contribution to the pathogenesis of myeloid 
malignancies. 
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2 AIM OF THE THESIS 
The overall aim of this thesis was to investigate the role of the BM niche in development of 
myeloproliferative neoplasms, including CML. 
Specific aims were: 
Study I  
To analyze expression of leukotriene signaling molecules and to study the effect of leukotriene 
inhibitors on survival of human CML leukemic stem and progenitor cells. 
Study II 
To determine the contribution and the underlying mechanisms of BM microenvironment to the 
pathogenesis of MPN in Sipa1 deficient mouse model. 
Study III 
To prospectively characterize human BM niche in patients with CML and identify the disease-
associated niche factors. 
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3 METHODOLOGICAL APPROACHES 
All projects included in this thesis were approved by Ethical Review Board in Stockholm and 
Linköping (2012/4:10, 2013/3:1, S40-14).  
The detailed descriptions of laboratory techniques used in this thesis can be found in study I-
III. Therefore, only the main methods and considerations are listed below. 
3.1 MSC ISOLATION AND ANALYSIS  
When first described, MSC isolation was based on their plastic adherence in culture, the ability 
to form CFU-F, and further selection by subsequent passaging of the cells in vitro. Although 
the method is easy to perform, and generates large number of cells, it has some disadvantages. 
First of all, culture-selected population is very heterogeneous and includes adherent stromal 
cells, which do not have MSC characteristics (Horwitz and Keating, 2000). Moreover, even 
after several passages there can be some residual hematopoietic cells in the culture. Finally and 
notably, in vitro cultivation alters the immunophenotype of native MSCs (by distorting the 
expression of cell surface markers, including CD44), as well as changes the global gene 
expression profile (Qian et al., 2012). Therefore, in study II and III, we used flow cytometry-
based protocols, established by Qian et al. (Qian et al., 2012), to prospectively isolate native 
MSCs from mouse and human tissues.  
Fluorescence-activated cell sorting (FACS) is a technique that allows to analyze and sort 
defined cell populations based on their fluorescent characteristics, one cell at a time as they 
pass through the beam of a laser (Julius et al., 1972). The cells stained by different fluorescence-
conjugated antibodies can be separated by creating distinct gates and sorted into up to four 
subpopulations simultaneously. In the experiments where multicolor flow cytometry panels are 
used, it is important to include fluorescence minus one (FMO) controls in order to distinguish 
positive from negative populations, and place the gates correctly (Baumgarth and Roederer, 
2000; Roederer, 2001).  
 Mouse MSC isolation 
The isolation procedure consists of bone crushing, collagenase II treatment and trypsinization. 
All abovementioned steps are needed to dissociate MSCs and mesenchymal progenitor cells, 
including the cells located at bone surface (the endosteum). To obtain an optimal cell number, 
bone fragments should be mixed well during both enzymatic treatments. In addition, it is 
important to use high (10-20%) serum concentration during isolation procedure, and to keep 
the cells on ice or at 4°C whenever possible to ensure good viability. Prior to FACS, the 
majority of BM hematopoietic cells were depleted using Dynabeads® magnetic separation 
technology. However, before incubation with the BM cells, the beads should be washed, in 
order to remove preservative and biocidal substance present in the product, which might be 
harmful for the cells (Jones et al., 1980). After separation, the remaining hematopoietic cells 
were visualized during FACS, by staining with CD45 and TER119, and omitted when gating. 
The ECs were distinguished from the other stromal cells based on CD31 expression, while the 
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non-hematopoietic and non-endothelial population was further subdivided into mesenchymal 
stem, progenitor and mature cells depend on CD44, CD51 and SCA1 markers expression. All 
the procedures, including FACS, should be performed as quickly as possible to assure good 
viability of freshly sorted stromal cells. 
 Human MSC isolation  
For primary MSC isolation, the BM was collected into EDTA-coated or heparin-containing 
tubes to prevent coagulation. Mononuclear cells (MNCs) were isolated by density gradient 
centrifugation. Diluted BM was layered on top of Lymphoprep slowly and very carefully in 
order to avoid mixing of these two layers. Prepared tubes were centrifuged with slow 
acceleration and deceleration to enable gentle separation of different BM components: plasma, 
buffy coat (upper layer), buffy coat (intermediate layer containing MNCs), the Lymphoprep 
layer (containing some of the granulocytes and MSCs), and red blood cells (bottom layer). To 
increase the number and to include all the MSCs, the buffy coat and underneath Lymphoprep 
layer were collected and further washed in 2mM EDTA solution, to hinder a cell-cell adhesion. 
Thereafter, we used CD45 and CD235A magnetic beads to deplete the majority of 
hematopoietic cells prior to FACS, and to enrich stromal cells. The leftover hematopoietic cells 
were excluded during sorting by staining with CD45, CD235A antibodies, while the ECs were 
detected by CD31 marker expression. Within non-hematopoietic and non-endothelial 
population, we identified MSCs based on the lack of CD44 expression, and co-expression of 
CD146 and CD271. Similarly to murine MSCs, it is important to process fresh BM without 
any delay, to ensure good quality of the sorted cells.  
3.2 CFU-F ASSAY 
CFU-F is an assay used to asses functional MSCs and quantify their number in vitro as each 
colony originates from a single cell (Castro-Malaspina et al., 1980; Friedenstein et al., 1970). 
We performed CFU-F assays on total, unfractionated BM cells to investigate whether 
frequencies of MSCs in Sipa1-/- mice (study II) and CML patient BM (study III) were changed 
compared to normal counterparts (wild-type mice and healthy volunteers, respectively). 
Additionally, we established CFU-F assays on FACS purified MSCs, to compare the 
clonogenic activity between cells derived from Sipa1-/- and wild-type mice (study II), as well 
as CML patients and healthy age-matched donors (study III). Sorted CD44- MSCs from mouse 
and human BM were cultured for 10-12 days or 12-14 days (respectively), under hypoxic 
conditions, to prevent senescence and facilitate cell expansion (Tsai et al., 2011). The clusters 
of more than 50 cells were counted as one colony (Qian et al., 2012).  
3.3 IN VITRO MULTILINEAGE DIFFERENTIATION ASSAY 
Multilineage differentiation potential towards osteoblasts (bone), chondrocytes (cartilage) and 
adipocytes (fat) is one of the MSC characteristics. Although in vitro expanded cell cultures 
might not reflect the multipotency in vivo (reviewed in Bianco et al., 2008), it is still commonly 
used assay to predict differentiation potential of MSCs. It is important to note that high input 
cell density and cell confluence not lower than 80% are crucial for successful osteoblasts 
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differentiation (reflected by calcium deposition stained with Alizarin Red) as recently reported 
(Abo-Aziza and A A, 2017). It is also challenging to induce chondrogenic differentiation in 
monolayer, however optimized culture conditions, including low concentration of serum, and 
hypoxia, allowed us to differentiate MSCs into chondrocytes in vitro as indicated by Toluidine 
Blue staining of proteoglycans.  
We used multilineage differentiation assay in study II and III, to investigate how 
myeloproliferative disorders affect MSC functions. Hence, we sorted MSCs from Sipa1-/- and 
wild-type mice (study II), and compared their potential to differentiate. Similarly, we used this 
approach to study multilineage differentiation capacity of the MSCs derived from CML 
patients and healthy donors (study III). In addition, we compared in vitro results with gene 
expression in freshly isolated MSCs, to predict in vivo functions of the cells.  
3.4 IN VITRO CO-CULTURES AND HEMATOPOIETIC COLONY ASSAYS 
As described in the previous sections, the BM niche, including MSCs, regulates and maintains 
HSCs by providing various signals, soluble factors and through cell-cell interaction. To study 
such hematopoiesis supportive function of BM MSCs in vitro, a co-culture system is required. 
The effects of MSCs on hematopoietic stem/progenitor cells after co-culture, can be assessed 
by applying well described and commonly used HSC assays, namely colony-forming unit cell 
(CFU-C) and long-term culture initiating cell (LTC-IC).  
The CFU-C assay is a rapid, in vitro method used to measure the frequency of hematopoietic 
progenitors and their ability to proliferate and differentiate in response to cytokines (Bradley 
and Metcalf, 1966). CFU-C assays are set by seeding single-cell suspension into semi-solid 
media containing selected cytokines that are important for HSCs and progenitors growth. The 
proliferation and differentiation capacity of each plated hematopoietic cell is measured by their 
ability to form hematopoietic colonies. The viscosity of the media prevents cell migration, and 
thus, ensures that clonal progeny remain in close proximity (within one colony). This, together 
with a low density of plated cells, guarantee that each colony derives from one progenitor cell. 
The differentiation potential of more mature hematopoietic progenitors is restricted to a specific 
lineage, therefore they give rise to morphologically distinct colonies composed of one type of 
the cells, e.g. erythrocytes (CFU-E/BFU-E), granulocytes (CFU-G) or monocytes (CFU-M). 
The more immature, bi- or multipotent HSCs and hematopoietic progenitors usually form 
bigger colonies which contains a mixture of different cell types, e.g. granulocutes and 
monocytes (CFU-GM), as well as erythrocytes (CFU-GME) (Purton and Scadden, 2007; van 
Os et al., 2008). The colony classification and counting is based on morphological and 
phenotypic criteria, therefore, it requires the experience. CFU-E or BFU-E colonies derived 
from mouse cells are difficult to count, because they do not appear red. In this case, to confirm 
the identity of erythroid colonies, the DAF staining of hemoglobin is needed (Worthington et 
al., 1987). As a result, CFU-E and BFU-E colonies turn blue, whereas GM colonies remain 
unstained. 
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In order to identify and quantify even more primitive progenitors, it is necessary to use LTC-
IC assay. LTC-IC requires more extensive self-renewal capacity than CFU-C, and therefore, it 
is used to represent the most primitive hematopoietic cells that can be functionally assayed in 
vitro (Ploemacher et al., 1991; Ploemacher et al., 1989; Sutherland et al., 1989; Sutherland et 
al., 1990). The assay is performed by culturing hematopoietic cells on a feeder (supportive) 
layer of the BM stromal cells for five to six weeks followed by CFU-C assay (Sutherland et al., 
1991; Sutherland et al., 1993; Zandstra et al., 1998). The feeder layer used can be either the 
primary BM stromal cells or a cell line. Well established cell lines used for standard LTC-IC 
assay are murine M2-10B4 and Sl/Sl, both engineered to express human cytokines (IL-3, G-
CSF and SCF) (Hogge et al., 1996). During such a long culture time, only the most primitive 
HSCs can survive and maintain their functional properties, including CFU-C potential. By 
performing LTC-IC assays at limiting dilution, it is also possible to quantify the numbers of 
HSCs and hematopoietic progenitors in the tested population (Miller and Eaves, 2002; 
Szilvassy et al., 1990). Although these culture does not measure the true functional potential 
of HSCs to repopulate a marrow, and variations in the procedures or stromal cell layers can 
affect the results, the LTC-IC assay is regarded as a surrogate measure of multipotent stem 
cells in human, especially when long-term transplantation experiments are impractical. 
Moreover, the LTC-IC assay is useful for screening the effect of a certain treatment, when 
the culture conditions are the same and the only variable is the presence of tested agent. It 
can be used to identify cytokines and other compounds that promote or inhibit hematopoiesis. 
Since transplantation in humans for research purpose is unethical, and patient-derived 
xenotransplantation (PDX) models are challenging (due to low engraftment of human cells, 
particularly primary leukemic cells), the LTC-IC assay is also a valid method to test the 
hematopoiesis supportive function, and interaction of human MSCs with HSCs and 
progenitors.  
In study I, we used limiting dilution LTC-IC assays to test functional response of human 
primitive LSCs to treatment with leukotriene inhibitors (zileuton or montelukast) alone and in 
combination with TKI (imatinib). As a feeder layer, we used irradiated M2-10B4 cell line, to 
prevent their over-proliferation, while still allowing the support for hematopoietic 
progenitors. In this study, we used only one cell line, to avoid the over-growth of LSCs. 
FACS purified CD34+CD38- cells from CML patients were plated directly on top of supportive 
cell layer, and then exposed to tested drugs or DMSO. After 6 weeks followed by CFU-C 
assays, we scored wells as positive (with hematopoietic colonies) or negative (without 
colonies) and calculated frequency of LTC-IC using L-Calc™ software. We achieved high 
frequency of LTC-IC from both, NBM and CML CD34+CD38- cells while testing the drug 
response. 
In study II, we co-cultured normal hematopoietic stem/progenitor cells (LSK) with freshly 
sorted BM stromal cells from young, disease-free Sipa1-/- mice, to evaluate the hematopoiesis 
supportive function of the BM stromal cells. The cells were cultured in direct contact for 2.5 
days, to allow cell-cell interaction (similar to that in bone marrow niche) and avoid the negative 
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effect of long time culture on HSCs and hematopoietic progenitors. Thereafter, we used CFU-
C assay to assess the clonogenic capacity of the cells.  
In study III, we performed LTC-IC assays to investigate hematopoiesis supportive function of 
CML MSCs. Hence, we sorted normal HSCs and progenitor cells (CD34+) and culture them in 
serum-free media, on top of non-irradiated MSCs from either CML patients, or normal donors. 
At the same time we wanted to study whether normal BM niche can “correct” the phenotype 
of leukemic cells, or whether NBM MSCs can support non-leukemic (BCR-ABL-) cells better 
than leukemic cells (BCR-ABL+). Therefore, we plated CD34+ from CML patients on top of 
normal MSCs and CML MSCs for 6 weeks. Thereafter, we subjected the CD34+ cells for  
CFU-C assay and compared their clonogenic potential.  
Additionally, we utilized LTC-IC assay, to understand the effect of CXCL14 on the growth of 
CML LSCs. For that purpose, we FACS purified CD34+CD38- cells from CML patients and 
co-cultured them with murine fibroblast cell line overexpressing human CXCL14 (NIH3-
CXCL14), or control (NIH3-CTRL) for 7 days. After that, CML cells were transferred to 
LTC-IC assay (established as described above, in study I), to evaluate the remaining CML 
LSCs after the co-culture. After 6 weeks, the colony forming potential of the CML LSCs was 
measured by CFU-C assay.  
3.5 TRANSPLANTATION EXPERIMENTS 
The BM transplantation is a gold standard stem cell assay in vivo, used to functionally evaluate 
donor-derived HSCs for their self-renewal and differentiation capacity, by determining the 
blood cell reconstitution after transplantation. However, the outcome of the assay very much 
depends on the normal differentiation capacity of tested cells. Therefore, it is important to 
ensure that genetic alterations in HSCs, if any, does not impair their potential to differentiate 
towards all blood lineages. Otherwise, it might be impossible to observe lineage reconstitution 
in a long term. Moreover, transplantation assay usually requires myeloablative pretreatment, 
e.g. total-body irradiation, to eradicate the endogenous cells and create space for the donor cells 
to engraft (Green and Rubin, 2014). The irradiation doses can differ depends on the scientific 
question and the mouse strain. Nevertheless, it should be noted that such treatment might cause 
tissue damage (e.g. vasculature in BM niche), and elicits inflammatory response, therefore it 
does not fully recapitulate normal conditions. 
In study II, we performed BM transplantation experiments, to investigate whether deficiency 
of Sipa1 in the hematopoietic cells, or in the BM niche led to MDS/MPN development. To 
address that question, we applied two different doses of total-body irradiation before 
transplantation. The sublethal irradiation (6Gy) of Sipa1-/- mice provided enough space in the 
BM for the donor cells engraftment, but still maintained physiological functions of the BM 
niche. This allowed us to study contribution of the Sipa1-/- BM niche to MPN development. On 
the other hand, the lethal irradiation (9.5Gy) of wild-type mice led to eradication of endogenous 
cells to the greatest degree, and gave us the possibility to test the role of Sipa1-/- hematopoietic 
cells in MDS/MPN onset. Thanks to this experimental setting, we could observe whether 
 36 
abnormalities in the hematopoietic cells caused MDS/MPN, or alterations in the BM niche 
resulted in the disease. To monitor transplantation outcome, we analyzed donor cell 
reconstitution in the peripheral blood of recipient mice monthly, using automated cell counter 
for blood components, flow cytometry, and histological staining of blood smears and cytospins.  
3.6 QUANTITATIVE AND SINGLE CELL RT-PCR 
The gene expression can be measured by amount of messenger RNA (mRNA) transcript copies 
of that gene. However, in order to detect and quantify low abundance mRNA, it is necessary 
to amplify the transcripts using RT-PCR (Bustin, 2000). It is rapid and sensitive technique, but 
its accuracy and reliability depends on preceding preparation steps, including quantity and 
quality of nucleic acid and reverse transcriptase efficiency. Therefore, it is very important to 
use the same RNA extraction method, and to normalize the amount of input RNA, to be able 
to compare gene expression between different samples. Moreover, for direct comparisons of 
RT-qPCR data, it is crucial to include a reference (housekeeping) gene, which expression level 
is stable among the samples and not regulated by specific experimental settings. That enables 
the normalization of expression level of target gene. In addition, the specificity of the assay 
relies on the correct design of primers, and selected probes used for transcript amplification, 
which should have an optimal length (90-150bp) and sufficient GC content (20-80%). The 
RNA templates have to be also free from contaminating DNA, which could affect the 
amplification signal (Bustin et al., 2009).  
We here used RT-qPCR to measure mRNA levels of chosen genes, and to validate gene 
expression data obtained from RNA sequencing. In study II and III, we used RNeasy 
MicroKit® (Qiagen) designed for RNA purification from the small number of cells, and 
SuperScript™ III Reverse Transcriptase (ThermoFisher) that offers higher cDNA yields and 
lengths. To normalize the expression data, we chose Hprt/HPRT as a housekeeping gene, due 
to its consistent expression level in the BM stromal cells. In order to avoid detection of non-
specific, double-stranded DNA, we used TaqMan® fluorogenic probes, which require specific 
hybridization between the probes and the targets, to generate fluorescent signal. Therefore,  
RT-qPCR gives low background and detects only the specific amplification product, as it 
accumulates during PCR. The reactions without RNA template were included as a negative 
control, to ensure lack of contamination in tested samples.  
In study I, single CD34+CD38- CML cells were sorted into 96-well plates containing lysis 
buffer, and deposited at -80°C. Cell lysates were reverse-transcribed using multiple pairs of 
gene-specific primers, and subjected to the first-round of PCR. The aliquots of the products 
were further amplified using fully nested, gene-specific primers. The second-round PCR 
products were applied to gel electrophoresis, and visualized by GelRed™ staining (Invitrogen) 
(Hu et al., 1997; Qian et al., 2013). An absence of housekeeping gene (HPRT) product could 
arise from technical errors in sorting, such as failure in cell deposition or deposition of a dead 
cell. Therefore, only the wells with amplification of HPRT, or at least two other gene products 
(if negative for HPRT) were considered informative. Empty wells were used as a negative 
control and never showed signals for tested genes. 
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3.7 RNA SEQUENCING AND DATA ANALYSIS 
RNA sequencing (RNAseq) is a high-throughput technique, used to study the presence and 
quantity of mRNA in the sample at a given time (Wang et al., 2009). It provides information 
on the global gene expression pattern, and therefore can be used to identify dysregulated 
molecules and signaling pathways in the disease (McGettigan, 2013). In brief, the experimental 
work flow includes four steps: RNA extraction, cDNA synthesis, fragmentation and library 
synthesis. The first step is the purification of mRNA from total RNA content. As ribosomal 
RNA (rRNA) represents vast majority of total RNA, it is important to use a good extraction 
protocol and measure mRNA quality (e.g. using bioanalyzer). The next step is the reverse 
transcription of mRNA to more stable cDNA, which is further fragmented into sequences of 
appropriate size (200-300bp) to reduce the influence of primer binding site. Fragmentation is 
followed by ligation of specific synthetic adaptor sequences at the end of the cDNA fragments, 
and thereafter, the libraries are amplified to assure sufficient signal intensity during next 
generation sequencing (NGS). The sequencing starts with adding fluorescent probes to the 
nucleotides in the flow cell. Once the probes are attached, machine scans the fluorescent signals 
and translate them into a nucleotides. After that, the probes are washed off and can bind to the 
next base in the fragment. Such cycle repeats until the machine determines each sequence of 
nucleotides generating millions of reads at desired length. That raw data have to be first filtered, 
in order to remove the low quality base calls (with dim fluorescent signal), the artifact reads 
(e.g. adapter sequences) and the PCR duplicates. Thereafter, the reads are aligned to the 
reference genome and mapped to the specific genes. Number of reads can differ between 
sequenced samples (as it depends on the library quality and sample concentration), hence it is 
important to normalize the raw data, e.g. by calculating reads/fragments per kilobase per 
million (RPKM/FPKM) or trimmed mean of M-values (TMM). Genes with RPKM values 
greater than 0.1 are considered to be actively transcribed, and they are used for Differential 
Gene Expression (DGE) analysis. In addition, TMM normalized data are used to perform Gene 
Set Enrichment Analysis (GSEA).  
We performed RNAseq of freshly sorted stromal cell populations from the BM of Sipa1-/- mice 
(paper II) and CML patients (paper III), in order to compare the gene expression with healthy 
counterparts, and tereby, to identify molecular mechanisms involved in the pathogenesis of 
myeloproliferation.  
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4 RESULTS AND DISCUSSIONS 
4.1 Paper I  
Although TKI treatment has been very effective in inducing deep molecular remission in most 
of the CML patients, it fails to eradicate more quiescent BCR-ABL1+ LSCs. These remaining 
LSCs cause disease persistence and may contribute to relapse after treatment discontinuation. 
Therefore, it is important to identify and target additional pathways to selectively eliminate the 
residual disease. In this study, we tested the effect of leukotriene pathway inhibition on survival 
of human CML leukemic stem and progenitor cells. 
 Leukotriene signaling  
Leukotrienes (LT) are lipid mediators involved in inflammatory processes and indicated in 
malignant diseases (Peters-Golden and Henderson, 2007). LT synthesis can be activated by 
different stimuli (e.g. antigens, microbes, complement, cytokines etc), and it depends on the 
amount of free arachidonate released from cell-membrane phospholipids. Arachidonic acid is 
converted into leukotriene A4 (LTA4) by 5-lipoxygenase (5-LO) accompanied by its activating 
protein FLAP (Peters-Golden and Brock, 2003). Then, LTA4 can be hydrolyzed to LTB4 or 
converted to cysteinyl-containing LTC4, which is further metabolized to cysteinyl LTD4 and 
LTE4. Both products are transported from the cell by specific carrier proteins where they 
interact with their receptors – B leukotriene receptor 1 (BLT1) and 2 (BLT2) or cysteinyl 
leukotriene receptor 1 (CYSLT1) and 2 (CYSLT2). Once ligated, all of the mentioned LT 
receptors activate the Gq or Gi class of G-proteins, thereby causing an increase in intracellular 
calcium or decrease in cycling AMP (Figure 6). These signals, in turn, lead to activation of 
kinase cascades and various biological responses (Peters-Golden and Henderson, 2007).  
Figure 6. Leukotriene signaling, synthesis and receptors; reproduced with permission from Peters-
Golden and Henderson, 2007, copyright Massachusetts Medical Society. 
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In the murine model of CML, Alox5 (the gene encoding 5-LO) was overexpressed in HSCs 
transfected with BCR-ABL (Chen et al., 2009), and the deletion of Alox5 led to impaired 
development of leukemia. Similarly, treatment with 5-LO inhibitor, zileuton, resulted in 
leukemia inhibition without affecting the growth of non-leukemic HSCs (Chen et al., 2009). 
Therefore, zileuton was suggested as a new therapeutic agent with potential to eradicate also 
human LSCs and improve treatment outcome of CML patients (O'Hare et al., 2012). However, 
only low expression level of ALOX5 was detected in hematopoietic progenitor cells (CD34+) 
from CML patients at diagnosis, when compared to normal counterparts (Lucas et al., 2014). 
On the other hand, higher expression and activity of LTC4 synthase was found in myeloid cells 
from CML patients (Roos et al., 2008; Sjölinder et al., 2000). Moreover, expression of CYSLT 
receptors was reported in the CML cell lines, and treatment with CYSLT1 antagonist, 
montelukast, was shown to suppress the growth of the CML blast crisis cell line (Yektaei-Karin 
et al., 2017). 
To better understand the role of LT pathway in regulation of LSCs and progenitors from CML 
patients, we analyzed the expression of LT signaling molecules in BM CD34+CD38- cells, and 
tested the functional response of these cells to zileuton and montelukast treatment in vitro.  
 Key findings 
1. Multiplex single cell PCR analysis of CD34+CD38- cells from CML patients at 
diagnosis revealed low frequency of ALOX5-expressing leukemic BCR-ABL+ cells 
(median 10,6%). 
2. Majority of CML CD34+CD38- express CYSLT1 and CYSLT2 receptors (64,5% and 
57,3%, respectively) as deceted by PCR at single cell level. 
3. However, functional in vitro assays (LTC-IC and CFU-C) demontrated no significant 
differences in the CML CD34+CD38- activity after treatment with neither zileuton, nor 
montelukast alone, indicating that LT inhibition did not suppress the growth of LSCs. 
4. Moreover, no significant reduction in the LTC-IC activity of CML CD34+CD38- was 
found after combine treatment of LT inhibitors and imatinib, suggesting that there is no 
additive effect of the drugs on LSC survival in vitro.  
5. Expectedly, no significant changes in the frequencies of LTC-ICs were seen in the 
normal BM CD34+CD38- cells cultured with imanitib, zileuton or montelukast. 
6. FISH analysis after culture with imatinib and LT inhibitors revealed that there are 
remaining leukemic BCR-ABL+ cells after all types of treatments, indicating that even 
when the total frequencies of LTC-ICs were reduced by imatinib, the LSCs were not 
eradicated. 
 Discussion 
In contrast to previously published mouse studies (Chen et al., 2009), primitive CD34+CD38- 
cells, sorted from the BM of CML patients at diagnosis, show low expression of ALOX5, what 
indicates a distinct regulation of 5-LO/ALOX5 in mouse and human. In addition, zileuton did 
not suppress the LTC-IC activity of primary CML CD34+CD38- cells in functional stem and 
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progenitor cell assays in vitro. These results suggest that targeting the 5-LO to eradicate 
imatinib-resistant LSCs, may not be as promising therapeutic approach as expected based on 
the results from mouse studies. Moreover, in contrast to the results obtained from short term 
liquid cultures (Yektaei-Karin et al., 2017), we did not observe any significant growth 
suppression of primitive CML CD34+CD38- cells in response to montelukast in the presence 
of BM stromal cells. These results suggest that pharmacological inhibition of CYSLT1 might 
not be a sufficient strategy to eliminate persistent LSCs, and to treat CML patients.  
Taken together, our data show that treatment with zileuton, or montelukast has only minor 
effect on the survival of human LSCs, when cultured in the presence of BM stromal cells in 
vitro. The inconsistency with the previous studies using liquid culture systems, might be 
attributed to the BM niche-mediated mechanism of drug resistance. 
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4.2 PAPER II 
Mutations or abnormal expression of signal-induced proliferation-associated gene 1 (SIPA1) 
was reported in the patients with solid cancer and hematopoietic malignancies (Minato and 
Hattori, 2009). In mice, Sipa1 deficiency leads to the development of age-dependent myeloid 
malignancies (Ishida et al., 2003; Xiao et al., 2018a). Since an increasing evidence suggest that 
the BM niche can play an instructive role in development of myeloid malignancies, in this 
study we investigated the role of Sipa1-deficient BM niche in disease initiation. 
 Sipa1 in Rap G protein signaling  
Rap proteins are ones of the small G proteins, which belong to Ras superfamily and control 
various cellular processes, e.g. cell adhesion, cell proliferation and gene activation. 
Importantly, dysregulated Ras activation can lead to senescence and apoptosis in the normal 
cells. 
Rap proteins function as molecular switches with inactive GDP-bound and active GTP-bound 
confirmation, and are regulated by guanine nucleotide exchange factors (GEFs) and GTPase-
activating proteins (GAPs) (Figure 7). GEFs convert Rap-GDP into active form, whereas GAPs 
interact with GTP-loaded Rap and mediate its hydrolysis and inactivation. Sipa1 encodes one 
of RapGAPs. Iniatially Sipa1 was reported to be predominantly expressed in lymphocytes and 
hematopoietic progenitor cells (Hattori et al., 1995), where it regulates expression of many 
growth factors and cytokines, e.g. IL-3, GM-CSF and CXCL12 (Hattori and Minato, 2003; Jin 
et al., 2006a). 
Figure 7. The role of Sipa1 in regulation of Rap signaling. Adapted from Minato and Hattori, 2009.  
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 Key findings 
1. Sipa1 was expressed not only in hematopoietic cells, but also in different BM stromal 
cells (including ECs, MSCs, mesenchymal progenitors and more mature stromal cells), 
suggesting that the BM niche might be involved in the development of MPN in  
Sipa1-/- mice. 
2. Importantly, SIPA1 was expressed in normal BM stromal cells from healthy donors, 
and was downregulated in the BM stromal cells from MPN patients, indicating a that 
altered SIPA1 expression might contribute to the disease pathogenesis in patients too.  
3. FACS analysis and multilineage differentiation assay revealed a decreased frequency 
of MSCs, but increased frequency of MPC population, and impaired osteogenic 
differentiation potential in vitro, demonstrating the presence of phenotypic and 
functional alterations of the BM niche in aged Sipa1-/- mice after MDS/MPN onset. 
4. However, transplantation of Sipa1-/-  BM hematopoietic cells into the wild-type 
recipients did not lead to MPN development, indicating that the loss of Sipa1 in 
hematopoietic cells only was not sufficient to initate the disease. 
5. Interestingly, significant expansion of MSCs and MPCs was found in the young  
Sipa1-/- mice, prior to MDS/MPN onset. In addition, these MSCs and MPCs displayed: 
enhanced capacity to support myeloid cell differentiation in vitro, reduced osteogenic 
differentiation potential in vitro, and reduced femoral volume in vivo, altogether 
suggesting that dramatic alerations in the BM niche composition and functions 
occurred before the abnormal hematopoiesis. 
6. Moreover, transplantation of normal (Sipa1+/+) BM hematopoietic cells into sublethally 
irradiated Sipa1-/- recipients resulted in the ineffective hematopoiesis, dysplastic 
erythropoiesis and significant increase in donor-derived HSCs and progenitors. Even 
more severe MDS/MPN phenotype (with reduced survival, myeloproliferation, and 
increased frequency of MEPs and MK hyperplasia) was observed when normal BM 
hematopoietic cells were transplanted into lethally irradiated Sipa1-/- recipients, 
indicating that normal BM hematopoietic cells transformed into neoplastic cells after 
transplantation into the Sipa1-deficient BM niche. 
7. RNA sequencing of FACS sorted, primary BM MSCs and ECs from young Sipa1-/- 
mice revealed elevated expression of genes involved in G-protein signaling in young 
Sipa1-/-  mice. Moreover, upregulated IL-6/JAK2/STAT3, TGFβ and TNFα signaling 
were found in Sipa1-/-  MSCs and ECs, suggesting inflammation-mediated disease 
mechanisms. In addition, increased expression of Thpo and Epo in Sipa1-/-  MPCs and 
ECs (respectively) might be involved in MEP overproduction and MK dysplasia.  
8. Furthermore, QPCR analysis revealed that genes critical for normal HSC 
maintanance (including Cxcl12, Kitl and Angptl1), as well as lymphogenesis (Il7) 
were downregulated in Sipa1-/-  MSCs and MPCs, indicating impaired hematopoiesis 
supportive function of the Sipa1-deficient BM niche. 
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 Discussion 
Although recent studies suggest that alterations in the BM niche may have an instructive role 
in development of myeloid malignancies, the underlying mechanisms are poorly understood. 
In this study, we discovered that the Sipa1-/- BM niche is absolutely required for MDS/MPN 
development in mice. First of all, alterations in BM niche were found in young, disease-free 
Sipa1-/- mice, what suggests that these changes were attributed to an intrinsic loss of Sipa1 in 
the BM niche, rather than remodeling by malignant hematopoietic cells. Furthermore, young 
Sipa1-/- BM hematopoietic cells failed to induce the disease after transplantation into wild-type 
recipients with normal BM niche. However, reciprocal transplantation of the wild-type BM 
hematopoietic cells into irradiated Sipa1-/- recipient mice led to development of MDS/MPN 
with a phenotype very similar to that observed in the aged Sipa1-/- mice. It indicates that 
MDS/MPN in aged Sipa1-/- mice is actually driven by altered BM niche. Moreover, we 
observed reoccurrence of the disease in secondary wild-type recipients after transplantation of 
the spleen cells from primary Sipa1-/- recipients that developed MDS/MPN. These results 
suggest that Sipa1-deficient BM niche might lead to the neoplastic transformation of normal 
hematopoietic cells. To better understand the molecular mechanisms underlying the niche-
induced MDS/MPN, we performed RNA sequencing. Similarly, to previously reported data 
(Kleppe et al., 2015; Reynaud et al., 2011; Welner et al., 2015), we found increased 
expression of proinflammatory cytokines (TGFβ and TNFα) and IL-6/JAK2/STAT3 
signaling in the BM stromal cells from young Sipa1-/- mice. This elevated inflammatory 
signaling might contribute to the myeloproliferation by altering HSC fate decisions, as 
suggested before (Čokić et al., 2015; Mirantes et al., 2014). Moreover, upregulation of Thpo 
and Epo in the Sipa1-/- BM stromal cells might be associated with enhanced granulopoiesis, 
increased MEP production, and MK hyperplasia. Increased number of MK might, in turn, 
promote disease progression through the secretion of CXCL4, as previously shown (Zhan et 
al., 2016). Furthermore, reduced expression of Il7 might further contribute to the 
myeloproliferation by perturbing lymphopoiesis (Tsapogas et al., 2011), whereas decreased 
expression of Cxcl12, Kitl and Angptl1 in the Sipa1-/-  BM stromal cells may affect quiescence 
of normal HSCs and, eventually, promote myelopoiesis.  
Taken together, we have shown that Sipa1 deficiency in the BM stromal cells induces 
alterations in the BM niche, which might lead to MDS/MPN development in mice. Moreover, 
downregulated expression of SIPA1 in the BM stromal cells from MPN and MDS/MPN 
patients indicates that alterations in SIPA1 might also contribute to disease pathogenesis in 
humans. 
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4.3 PAPER III  
Despite the effective treatment with TKI, the LSCs in CML patients cannot be fully eradicated 
(Holyoake and Vetrie, 2017). These remaining LSCs might contribute to the minimal residual 
disease, and relapse after treatment discontinuation. Recent reports suggest that the remodeled 
BM niche might protect the LSCs, and thereby contribute to disease persistence (Hoggatt, 
2016; Krause and Scadden, 2015). However, little is known about the BM niche alterations in 
CML patients, and the potential effect of abnormal BM niche on the disease progression. In 
this study, we have characterized the BM stromal cells from newly diagnosed CML patients in 
chronic phase, and studied the impact of dysregulated niche factors, particularly CXCL14, on 
the LSC survival.  
 CXCL14  
CXCL14 is a chemokine initially identified in breast and kidney cells, and therefore named the 
breast and kidney-expressed chemokine (BRAK) (Hromas et al., 1999). Up to date, the identity 
of CXCL14 receptor, and thus intracellular signaling pathway, remains poorly understood 
(Benarafa and Wolf, 2015). Nevertheless, CXCL14 has been suggested to act as a potent 
inhibitor of angiogenesis (Shellenberger et al., 2004). Moreover, CXCL14 has been shown to 
execute antimicrobial immunity, and to regulate the migration of immune cells (Lu et al., 2016). 
Therefore, the loss of CXCL14 in tumor site may lead to a low recruitment, and decreased 
number of tumor-infiltrating dendritic cells. That in turn, might inhibit the ability of dendritic 
cells to recognize the tumor, and to initiate specific antitumor immune responses, thereby 
creating a tumor escaping system (Lu et al., 2016). CXCL14 expression is relatively high in 
normal tissues, but lost in various types of malignancies (Hromas et al., 1999; Frederick et al., 
2000; Ozawa et al., 2006). Restoration of CXCL14 expression has been shown to suppress the 
growth of prostate cancer, lung cancer and squamous cell carcinoma (Hata et al., 2015; Ozawa 
et al., 2009a; Ozawa et al., 2009b; Tessema et al., 2010). On the other hand, a number of studies 
show that elevated expression of CXCL14 is involved in increased invasion and tumor 
metastasis (Allinen et al., 2004; Augsten et al., 2009; Lu et al., 2015), together indicating that 
the role of CXCL14 in cancer may be cell-type specific.  
 Key findings 
1. We demonstrated that BM MSCs from CML patients share similar imunophenotype 
with normal BM MSCs, and that the frequency of CML MSCs was comparable to that 
in the normal BM. 
2. However, CML MSCs displayed skewed multilineage differentiation capacity in vitro 
with increased adipogenic, but impaired osteogenic and chondrogenic differentiation 
potential. In addition, we observed that genes associated with osteoblasts and 
chondrocytes differentiation, were downregulated in freshly sorted CML MSCs. 
3. Moreover, normal hematopoietic stem/progenitor cells (CD34+ cells) generated more 
LTC-IC after co-culture with CML MSCs, compared to the cells cultured with NBM 
MSCs. The LTC-IC activity of normal CD34+ after co-culture with CML MSCs was 
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similar to that of CML CD34+ cells, altogether suggesting an enhanced hematopoiesis 
supportive function of CML MSCs in vitro. 
4. In contast, the LTC-IC activity of CML CD34+ cells after co-culture with normal BM 
MSCs and CML MSCs did not differ significantly, suggesting that normal BM MSCs 
cannot control the growth of leukemic CD34+ cells in vitro. 
5. FISH analysis of freshly sorted BM stromal cells from CML patients did not detect 
BCR-ABL1 fusion in ECs, MSCs or mature stromal cells, indicating that CML BM 
stromal cells are not part of malignant clone. 
6. Nevertheless, RNA sequencing of FACS sorted, native BM MSCs revealed 
downregulation of inflammatory cytokines, growth factors and genes involved in HSC 
maintenance, but upregulation of the genes involved in DNA packaging, indicating that 
CML stromal cells have altered gene expression profile. 
7. Moreover, loss of CXCL14 expression (as shown by both RNA sequencing and QPCR 
analysis) was detected in the BM niche (including ECs, MSCs and mature stromal cells) 
from CML patients  
8. Most importantly, co-culture of CML LSCs (CD34+CD38-) in the presence of CXCL14 
resulted in the increase numbers of CML cells, but decreased CFU-C and LTC-IC 
activity of these cells. In line with that, FACS analysis of CML cells after co-culture 
showed a reduced frequency of CD34+CD38- LSCs, but an increased fraction of 
CD15+CD66B+ myeloid cells, indicating that CXCL14 promoted differentiation of 
CML LSCs and supressed their growth in vitro.  
 Discussion 
The BM niche-mediated protection of CML LSCs, through the cell-cell interactions or 
secretion of soluble factors, has been suggested as a potential mechanism involved in disease 
persistence (Tabe and Konopleva, 2017). Therefore, it is of a great importance to understand 
how the leukemic BM niche promotes growth of the LSCs. In our study, we prospectively 
characterized BM niches in CML patients, and we identified dysregulated factors that might 
serve as a new therapeutic targets. The prospective isolation of the BM cellular components, 
especially MSCs, is very important, because culture-selected stromal cells consist of very 
heterogenous population with altered gene expression and cell secretome, compared to freshly 
isolated MSCs. We found an increased frequency of ECs and decreased fraction of mature 
stromal cells in the BM of CML patients, which might indicate altered BM cellular niche 
composition. Although the number of MSCs did not differ between CML and normal BM, 
CML MSCs displayed altered multilineage differentiation potential, which is important in vivo 
for maintaining the structure and composition of normal HSC niche. These in vitro 
observations were further supported by decreased expression of the genes involved in 
osteogenic and chondrogenic differentiation in the freshly sorted MSCs, shown by RNA 
sequencing. Moreover, CML MSCs exhibited a better capacity to support normal 
hematopoietic stem/progenitor cell activity in vitro. On the other hand, the activity of CML 
leukemic stem/progenitor cells was not affected by culture with normal BM MSCs, suggesting 
that leukemic cells became independent from normal BM niche in vitro. Furthermore, it has 
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been controversial whether the CML BM niche harbors the same genetic lesions as the 
leukemic cells, and whether that can be linked to disease pathogenesis. The discrepancy 
between previously published results might be due to the selection of BM stromal cells in 
culture, or because of leukemic cell contamination. Therefore, we used freshly isolated, 
unmanipulated ECs, MSCs and mature stromal cells from CML BM, and performed the FISH 
analysis. We found that CML BM niche cells did not carry BCR-ABL1 fusion gene, and 
therefore they are not part of the malignant clone. To further investigate the molecular 
characteristics, underlying the abnormal function of CML MSCs, we performed RNA 
sequencing, and analyzed the global gene expression pattern. The GSEA analysis indicated 
downregulation of proinflammatory cytokine pathways, chemokine signaling, and decreased 
expression of the genes important for HSC regulation. On the other hand, CML-derived MSCs 
and ECs showed a dramatic upregulation of the genes involved in DNA packaging, and 
increase in epigenetic factors that suppress gene transcription. These results create a possibility 
that decreased expression of the cytokines and growth factors signaling might be associated 
with the epigenetic alterations, however, more work is required to elucidate the mechanisms 
behind molecular alterations in the CML niche. Among downregulated transcripts, we found 
dramatically reduced expression of CXCL14 in all analyzed CML BM stromal cells. Since 
CXCL14 is undetectable in the hematopoietic cells, the stromal cells are the main source of 
CXCL14 in normal BM. Moreover, enforced expression of CXCL14 in culture led to the loss 
of CML LSCs and their increased differentiation. Therefore, similarly to the studies on solid 
tumors (e.g. prostate or lung cancer) (Hata et al., 2015; Ozawa et al., 2009a; Ozawa et al., 2006; 
Ozawa et al., 2009b; Schwarze et al., 2005; Tessema et al., 2010), our data suggest that 
CXCL14 suppresses the growth of cancer cells. 
Taken together, our study revealed molecular and functional characteristics of the CML BM 
niche, including loss of CXCL14 expression, which might contribute to the leukemic cell 
growth. Restoration of CXCL14 has a suppressive effect on the CML LSCs, and thereby, it 
might be a new niche-based therapeutic candidate for complementary treatment of CML 
patients.  
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5 CONCLUDING REMARKS AND OUTLOOK 
The advances in our knowledge over past 10 years led to increased recognition of BM niche 
and its crucial role in the regulation of normal hematopoiesis. Moreover, continuously 
emerging studies suggest an important role of BM niche in development of myeloid 
malignancies. The cross-talk between BM niche and malignant hematopoietic cells, through 
different pathways, may support LSCs survival as well as protect them from treatment. In 
addition, LSCs can confer signals that remodel different BM stromal cells into self-reinforcing 
malignant BM niche. On the other hand, there is an increasing evidence suggesting that BM 
niche might have an instructive role in initiation of myeloid malignancies. However, it remains 
unclear whether BM niche alterations facilitate acquisition of mutations in hematopoietic cells 
or provide a competitive advantage to already mutated clones. Nevertheless, the fact that 
abnormal BM niche can provide a fertile “soil” for LSCs indicates that targeting the BM niche-
derived signals might be a promising therapeutic approach to eradicate minimal residual 
disease and prevent disease relapse.  
Further investigations of the BM niche components and mechanisms regulating hematopoiesis 
are fundamental to dissect cellular and molecular pathways contributing to hematological 
disorders. One of the aspects that we need to understand better is the architecture and the 
cellular interactions in human BM niche. Is there any specific BM niche for LSCs? Or are there 
any cell subsets that sustain LSCs? Moreover, more studies are required to identify the key BM 
niche alteration that can lead to leukemia initiation. What are the alterations in the BM niche 
that contribute to leukemic transformation? Or what kind of abnormalities in the BM niche 
confer LSCs the competitive advantage over normal HSCs? Are there any undiscovered growth 
factors that regulate normal and/or malignant hematopoiesis? Furthermore, it is important to 
elucidate how extramedullary hematopoiesis is regulated and what type of cells and 
mechanisms in the spleen support LSCs. Finally, we need to recognize the differences between 
BM niche in mouse and human. Although mechanisms identified in mouse models have given 
us an important knowledge, they might not fully recapitulate interactions in human. Therefore, 
we need to continue developing new humanized preclinical models. 
Availability of advanced imaging technologies, single cell RNA sequencing as well as genome 
editing technologies open new possibilities for modeling BM complexity and will hopefully 
help to answer some of the remaining questions. 
 
 
 

  51 
6 ACKNOWLEDGEMENTS 
 
I would like to forward my sincere gratitude to everyone who has, in one way or another, 
contributed to this thesis. This research would not have been possible without all the patients 
with blood disorders and healthy volunteers, who have kindly agreed to contribute to our 
studies, as well as support from their nurses and physicians.  
 
Firstly, I would like to thank my main supervisor, Hong Qian for the opportunity to pursue a 
Ph.D. study and related research at Karolinska Institutet, for providing the necessary 
infrastructure and resources, for investing valuable time and energy to supervise me over the 
past four years, and for multiple possibilities to broadcast and discuss our research results with 
scientific community during different conferences and meetings. Thank you for sharing your 
knowledge and experience. I have learnt a lot during this time! 
 
Besides my main supervisor, I would like to thank my co-supervisors: 
Eva Hellström-Lindberg for kind support and important contribution throughout my Ph.D. 
study; Katarina Le Blanc for sharing vast expertise within MSC field; Mohsen Karimi 
Arzenani for practical training in molecular biology techniques. Thank you all for your 
valuable time, insightful comments, but also for the hard questions, which incented me to widen 
my research from various perspectives. 
 
I would like to extend my heartfelt gratitude to Johanna Ungerstedt, the chairperson at my 
defence, for providing all the samples, valuable feedback on our projects, warm 
encouragement, endless enthusiasm and precious advices.  
 
I am also thankful to the past and present colleagues in Hong Qian’s group for the stimulating 
discussions, for the sleepless nights we were working and for the fun moments we have had in 
the last four years. Tusen tack, Anne-Sofie Johansson for your lighthearted nature, and for 
being so supportive whenever needed, for all the hands-on help during long experiments and 
organizing the lab activities in the early days; Pingnan Xiao for your dedication and hard work 
on paper II, as well as nice time we spent at conferences and workshops; Lakshmi Sandhow 
for scientific discussions during our group meetings and journal clubs, and long hours spent in 
the culture room. Good luck with your thesis!; Makoto Kondo for your curiosity, many good 
ideas and being such a funny companion in the lab and during the conference in San Diego; 
Thibault Bouderlique merci for all practical help in the lab, the brainstorms and uplifting 
discussions, your sense of humor and the “H” corner in the office!  
In addition, I would like to thank Eleni Gelali, Alexandre Piccini and Johannis Klang, the 
former students, who have significantly contributed to the projects, but also to a good work 
atmosphere. 
 
 
 52 
 
 
I am very grateful for the assistance given by our collaborators and I would like to offer my 
special thanks to Marja Ekblom for valuable feedback on all the projects and presentations, 
and for the joint effort on paper I; Mikael Sigvardsson for sharing broad expertise and 
providing great help with sample sequencing; Sören Lehmann for genuine interest in my 
projects, and for sharing healthy bone marrow samples; Ulla Strömberg-Olsson and  
Satu Mustjoki for kind attitude and substantial support in providing patient samples;  
Leif Stenke and his research group members for scientific discussions; Henrik Hjorton-
Hansen and the Nordic CML study group for creating a stimulating environment and 
facilitating scientific progress; Arne Östman for insightful feedback and providing CXCL14 
fibroblasts; Xidan Li for aiding the data analysis; Marios Dimitriou for the chance to learn 
from you, and for helping with paper II; Ellen Viveka Iacobaeus for interesting collaboration 
on Multiple Sclerosis project; Magnus Tobiasson for engaging discussions around bone 
marrow microenvironment in MDS; Gunnar Nilsson for great contribution to Systemic 
Mastocytosis project; Göran Karlsson for nice encounters at various meetings, and for inviting 
me to Lund; Rob Welner for encouraging feedback on the CML project during your visit in 
Stockholm, and for the continuous interest in the story! 
 
I would like to thank the Department of Medicine, especially Jan Bolinder, Klas Karlsson, 
Ulrika Markne, Anastasia Urban, Christina Johansson and Therese Lind for taking care of 
all important administrative matters.  
 
I owe my gratitude to the group of PIs and senior scientists at HERM for their scientific 
feedback offered at multiple occasions. In particular, thanks to Petter Höglund for keeping 
track on our progress year by year as a study director; Julian Walfridsson and  
Robert Månsson, for journal and method clubs, and common retreats; Cecilia Götherström, 
Lindsay Davies and Rachael Sugar for sharing your expertise within MSC field;  
Iyadh Douagi for kind introduction to flow cytometry facility, and for sharing your knowledge; 
Sidhin Luc, Petter Woll and Sten Eirik Jacobsen for insightful discussions during mouse 
meetings; Mattias Carlsten, Evren Alici and Yenan Bryceson for critical feedback during SAP 
seminars.  
 
My special appreciation goes to Monika Jansson for your thoughtfulness, and for having a 
solution to all the problems in the lab; Gunilla Walldin for genuine smiles in the mornings, 
and for helping with the samples; Annette Öster Fernström for your kindness, and excellent 
organization skills; Charlotte Gustafsson and Minna Suomela for spreading positive energy; 
Sri Sahlin, Sara von Bahr Grebåck, Dimitra Vasileiadi and Lili Andersson, for aiding the 
administrative matters.  
 
I am also very grateful to HERM members for common lunches, refreshing fikas and many 
laughs throughout the years. Especially, thanks to older HERMies for welcoming me, when I 
  53 
arrived: Shabnam Kharazi, Alexandra Krstić and Eva Hellqvist for sharing your practical 
experience; Nadir Kadri, Stephan Meinke, Thuy Luu Thanh and Gözde Turköz for bringing 
a good mood to the table; Teresa Mortera-Blanco, Ying Qu, Deepika Nair for great company 
during lunch breaks; Yaser Heshmati for helping with work and for all the fun movies;  
Edda Elvasdóttir, Michael Chrobok and my “sister” Simona Conte for great talks and your 
concern! In addition, big thanks to Edyta Wójtowicz, Allegra Matheson Lord and Desmond 
Chin for your exceptional team spirit, and for your supportive attitude (truly admirable)!  
 
I would also like to thank Caroline Gavin for being there to make a right call at the right time, 
and Hani Abdulkadir Ali for often reminding, that nothing is impossible!  
 
I am extremely grateful to Ayla de Paepe for the connection, for sharing important insights, 
and for giving invaluable help, despite your tight schedule.  
 
Huge thanks to Jennine Grootens, Josefine Enneby and twin brothers: Aditya Harisankar 
and Huthayfa Mujahed for being an important part of my Ph.D. journey, for fun at work and 
mostly after work, for sharing ups and downs, for keeping me company when I was sorting late 
and often lending a hand when mine were full. Thank you for all the good times! 
 
My heartfelt appreciation goes to Anna Berglöf for the “Farlig förbindelse”, thank you for 
continuously looking for (and beyond) the horizon, for troubleshooting and all the fun 
moments; Agata Wasik for your mentorship, prioritizing skills, and the trip “in the backseat of 
your Rover ♪”; Monika Klimkowska for your kind help with the pictures for the thesis.  
 
I am also indebted to Emmy Lindedal and Göran Felländer for their great help and guidance. 
 
I would love to thank Susanne and Hans Berg, Elisa Lázaro Ibáñez and Staffan Berg  
for moral support and cheering me on! 
 
Big thanks also goes to my friends Ula Rykaczewska, Maciej Ściepko, Alexandra Jurczak, 
Maciej Banasiewicz and Tomek Kałłas for making Stockholm feel like home away from home. 
I am really glad you are here!  
 
I have also had the great support and encouragement of my friends from overseas. Thanks to 
Ania Waśkiel for countless hours spent on the phone; Katarína Janošková for sticking with 
me all this time; Monika Kosut and Kamil Żyłka for great times together and believing in me!  
 
Last but in no way least, I would like to thank my wonderful family for their unfailing support! 
 
Dziękuję Marcinowi i Karolinie za zastrzyk pozytywnej energii i trzymanie kciuków; Aldonie, 
Danielowi i Uli za dużo cennych rad i wskazówek, nie tylko zawodowych. Serdecznie dziękuję 
również Dziadkom za wsparcie trochę nie z tego świata. 
 54 
 
W szczególny sposób chciałabym podziękować moim Rodzicom. Dziękuję Wam za ogromne 
wsparcie i troskę przez te lata. Wasza wiara we mnie i miłość są nieopisanym źródłem 
motywacji. Dziękuję za wartościowe porady i słowa otuchy, kiedy mierzyłam się z 
trudnościami. I za to, że zawsze mogę na Was polegać.  
 
“A journey is easier when you travel together.” Thank you so much Anders, for making 
it a whole lot easier! Thank you for helping with tables and figures J but, most importantly, 
thank you for always being by my side, through thick and thin. Your love and optimism have 
been a constant source of strength. You should know that your support is worth more than I 
can express on paper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I would like to acknowledge Incyte Biosciences Nordic AB, Cancerfonden, Barncancerfonden, 
Radiumhemmets Forsknings Fonder, Åke Olssons Stiftelse, Wallenberg Institute for 
Regenerative Medicine, Vetenskapsrådet and Karolinska Institutet for the generous financial 
support. 
 
  55 
7 REFERENCES 
Abo-Aziza, F.A.M., and A A, Z. (2017). The Impact of Confluence on Bone Marrow Mesenchymal 
Stem (BMMSC) Proliferation and Osteogenic Differentiation. International journal of hematology-
oncology and stem cell research 11, 121-132. 
Abraham, S.A., Hopcroft, L.E.M., Carrick, E., Drotar, M.E., Dunn, K., Williamson, A.J.K., Korfi, K., 
Baquero, P., Park, L.E., Scott, M.T., et al. (2016). Dual targeting of p53 and c-MYC selectively 
eliminates leukaemic stem cells. Nature 534, 341. 
Acar, M., Kocherlakota, K.S., Murphy, M.M., Peyer, J.G., Oguro, H., and Inra, C.N. (2015). Deep 
imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature 526, 126-
130. 
Adams, G.B., Chabner, K.T., and Aller, I.R. (2006). Stem cell engraftment at the endosteal niche is 
specified by the calcium-sensing receptor. Nature 439, 599-603. 
Adolfsson, J., Mansson, R., and Buza-Vidas, N. (2005). Identification of Flt3+ lympho-myeloid stem 
cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. 
Cell 121, 295-306. 
Afan, A.M., Broome, C.S., Nicholls, S.E., Whetton, A.D., and Miyan, J.A. (1997). Bone marrow 
innervation regulates cellular retention in the murine haemopoietic system. British Journal of 
Haematology 98, 569-577. 
Albiero, M., Poncina, N., Ciciliot, S., Cappellari, R., Menegazzo, L., Ferraro, F., Bolego, C., Cignarella, 
A., Avogaro, A., and Fadini, G.P. (2015). Bone Marrow Macrophages Contribute to Diabetic Stem Cell 
Mobilopathy by Producing Oncostatin M. Diabetes 64, 2957. 
Alexander, K.A., Chang, M.K., Maylin, E.R., Kohler, T., Müller, R., Wu, A.C., Van Rooijen, N., Sweet, 
M.J., Hume, D.A., Raggatt, L.J., et al. (2011). Osteal macrophages promote in vivo intramembranous 
bone healing in a mouse tibial injury model. Journal of Bone and Mineral Research 26, 1517-1532. 
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., 
Chin, L., Richardson, A., et al. (2004). Molecular characterization of the tumor microenvironment in 
breast cancer. Cancer Cell 6, 17-32. 
Ambrosi, T.H., Scialdone, A., Graja, A., Gohlke, S., Jank, A.-M., Bocian, C., Woelk, L., Fan, H., Logan, 
D.W., Schürmann, A., et al. (2017). Adipocyte Accumulation in the Bone Marrow during Obesity and 
Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. Cell Stem Cell 20, 771-
784.e776. 
Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., 
Cazzola, M., and Vardiman, J.W. (2016). The 2016 revision to the World Health Organization 
classification of myeloid neoplasms and acute leukemia. Blood 127, 2391. 
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., 
Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014). Neuropathy of haematopoietic stem cell niche is 
essential for myeloproliferative neoplasms. Nature 512, 78. 
Asada, N., Katayama, Y., Sato, M., Minagawa, K., Wakahashi, K., Kawano, H., Kawano, Y., Sada, A., 
Ikeda, K., Matsui, T., et al. (2013). Matrix-Embedded Osteocytes Regulate Mobilization of 
Hematopoietic Stem/Progenitor Cells. Cell Stem Cell 12, 737-747. 
Asada, N., Kunisaki, Y., Pierce, H., Wang, Z., Fernandez, Nicolas F., Birbrair, A., Ma’ayan, A., and 
Frenette, Paul S. (2017). Differential cytokine contributions of perivascular haematopoietic stem cell 
niches. Nature Cell Biology 19, 214. 
Augsten, M., Hägglöf, C., Olsson, E., Stolz, C., Tsagozis, P., Levchenko, T., Frederick, M.J., Borg, Å., 
Micke, P., Egevad, L., et al. (2009). CXCL14 is an autocrine growth factor for fibroblasts and acts as a 
multi-modal stimulator of prostate tumor growth. Proceedings of the National Academy of Sciences 
106, 3414. 
 56 
Avecilla, S.T., Hattori, K., Heissig, B., Tejada, R., Liao, F., Shido, K., Jin, D.K., Dias, S., Zhang, F., 
Hartman, T.E., et al. (2003). Chemokine-mediated interaction of hematopoietic progenitors with the 
bone marrow vascular niche is required for thrombopoiesis. Nature Medicine 10, 64. 
Bajaj, J., Konuma, T., Lytle, Nikki K., Kwon, Hyog Y., Ablack, Jailal N., Cantor, Joseph M., Rizzieri, 
D., Chuah, C., Oehler, Vivian G., Broome, Elizabeth H., et al. (2016). CD98-Mediated Adhesive 
Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. Cancer Cell 
30, 792-805. 
Balmer, J.E., and Blomhoff, R. (2002). Gene expression regulation by retinoic acid. Journal of Lipid 
Research 43, 1773-1808. 
Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H.M., Vannucchi, A.M., Guglielmelli, P., Orazi, A., 
and Tefferi, A. (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative 
neoplasms: document summary and in-depth discussion. Blood cancer journal 8, 15-15. 
Baumgarth, N., and Roederer, M. (2000). A practical approach to multicolor flow cytometry for 
immunophenotyping. Journal of Immunological Methods 243, 77-97. 
Benarafa, C., and Wolf, M. (2015). CXCL14: the Swiss army knife chemokine. Oncotarget 6, 34065-
34066. 
Bewry, N.N., Nair, R.R., Emmons, M.F., Boulware, D., Pinilla-Ibarz, J., and Hazlehurst, L.A. (2008). 
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model 
of drug resistance. Molecular cancer therapeutics 7, 3169-3175. 
Bhatia, R., McCarthy, J.B., and Verfaillie, C.M. (1996). Interferon-alpha restores normal β1 integrin-
mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in 
chronic myelogenous leukemia. Blood 87, 3883. 
Bhatia, R., Wayner, E.A., McGlave, P.B., and Verfaillie, C.M. (1994). Interferon-alpha restores normal 
adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by 
correcting impaired β1 integrin receptor function. The Journal of clinical investigation 94, 384-391. 
Bianco, P., Robey, P.G., and Simmons, P.J. (2008). Mesenchymal Stem Cells: Revisiting History, 
Concepts, and Assays. Cell stem cell 2, 313-319. 
Bowers, M., Zhang, B., Ho, Y., Agarwal, P., Chen, C.-C., and Bhatia, R. (2015). Osteoblast ablation 
reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. 
Blood 125, 2678. 
Boyiadzis, M., and Whiteside, T.L. (2015). Information transfer by exosomes: A new frontier in 
hematologic malignancies. Blood Reviews 29, 281-290. 
Bradley, T.R., and Metcalf, D. (1966). The growth of mouse bone marrow cells in vitro. Australian 
Journal of Experimental Biology and Medical Science 44, 287-300. 
Bromberg, O., Frisch, B.J., Weber, J.M., Porter, R.L., Civitelli, R., and Calvi, L.M. (2012). Osteoblastic 
N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and 
progenitor cells. Blood 120, 303. 
Bruns, I., Czibere, A., Fischer, J.C., Roels, F., Cadeddu, R.P., and Buest, S. (2009). The hematopoietic 
stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid 
progenitor cells and reflecting loss of quiescence. Leukemia 23, 892-899. 
Bruns, I., Lucas, D., Pinho, S., Ahmed, J., Lambert, M.P., and Kunisaki, Y. (2014). Megakaryocytes 
regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med 20, 1315-1320. 
Bustin, S.A. (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase 
chain reaction assays. Journal of Molecular Endocrinology 25, 169-193. 
  57 
Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., 
Pfaffl, M.W., Shipley, G.L., et al. (2009). The MIQE guidelines - minimum information for publication 
of quantitative real-time PCR experiments. Clinical Chemistry 55, 611. 
Butler, J.M., Nolan, D.J., Vertes, E.L., Varnum-Finney, B., Kobayashi, H., and Hooper, A.T. (2010). 
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic 
stem cells. Cell Stem Cell 6, 251-264. 
Calvi, L.M., Adams, G.B., and Weibrecht, K.W. (2003). Osteoblastic cells regulate the haematopoietic 
stem cell niche. Nature 425, 841-846. 
Camacho, V., McClearn, V., Patel, S., and Welner, R.S. (2017). Regulation of normal and leukemic 
stem cells through cytokine signaling and the microenvironment. International Journal of Hematology 
105, 566-577. 
Caplan, A.I. (1991). Mesenchymal stem cells. Journal of Orthopaedic Research 9, 641-650. 
Carrelha, J., Meng, Y., Kettyle, L.M., Luis, T.C., Norfo, R., Alcolea, V., Boukarabila, H., Grasso, F., 
Gambardella, A., Grover, A., et al. (2018). Hierarchically related lineage-restricted fates of multipotent 
haematopoietic stem cells. Nature 554, 106. 
Casanova-Acebes, M., Pitaval, C., Weiss, Linnea A., Nombela-Arrieta, C., Chèvre, R., A-González, N., 
Kunisaki, Y., Zhang, D., van Rooijen, N., Silberstein, Leslie E., et al. (2013). Rhythmic Modulation of 
the Hematopoietic Niche through Neutrophil Clearance. Cell 153, 1025-1035. 
Castro-Malaspina, H., Gay, R.E., Resnick, G., Kapoor, N., Meyers, P., and Chiarieri, D. (1980). 
Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. 
Blood 56, 289-301. 
Cattoretti, G., Schiro, R., Orazi, A., Soligo, D., and Colombo, M.P. (1993). Bone marrow stroma in 
humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. 
Blood 81, 1726. 
Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N., Kleinman, M.E., Capla, 
J.M., Galiano, R.D., Levine, J.P., and Gurtner, G.C. (2004). Progenitor cell trafficking is regulated by 
hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine 10, 858. 
Ceredig, R., Rolink, A.G., and Brown, G. (2009). Models of haematopoiesis: seeing the wood for the 
trees. Nature Reviews Immunology 9, 293. 
Chan, C.K.F., Lindau, P., Jiang, W., Chen, J.Y., Zhang, L.F., Chen, C.-C., Seita, J., Sahoo, D., Kim, J.-
B., Lee, A., et al. (2013). Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. 
Proceedings of the National Academy of Sciences 110, 12643. 
Chang, M.K., Raggatt, L.-J., Alexander, K.A., Kuliwaba, J.S., Fazzalari, N.L., Schroder, K., Maylin, 
E.R., Ripoll, V.M., Hume, D.A., and Pettit, A.R. (2008). Osteal Tissue Macrophages Are Intercalated 
throughout Human and Mouse Bone Lining Tissues and Regulate Osteoblast Function In Vitro and In 
Vivo. The Journal of Immunology 181, 1232. 
Chen, S., Zambetti, N.A., Bindels, E.M.J., Kenswill, K., Mylona, A.M., Adisty, N.M., Hoogenboezem, 
R.M., Sanders, M.A., Cremers, E.M.P., Westers, T.M., et al. (2016). Massive parallel RNA sequencing 
of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation 
of inflammatory programs. Leukemia 30, 1938-1942. 
Chen, Y., Hu, Y., Zhang, H., Peng, C., and Li, S. (2009). Loss of the Alox5 gene impairs leukemia stem 
cells and prevents chronic myeloid leukemia. Nature genetics 41, 783-792. 
Chen, Y., Peng, C., Abraham, S.A., Shan, Y., Guo, Z., Desouza, N., Cheloni, G., Li, D., Holyoake, T.L., 
and Li, S. (2014). Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell 
survival. The Journal of Clinical Investigation 124, 3847-3862. 
Cheng, H., Sun, G., and Cheng, T. (2018). Hematopoiesis and microenvironment in hematological 
malignancies. Cell Regeneration 7, 22-26. 
 58 
Chomel, J.C., Bonnet, M.-L., Sorel, N., Sloma, I., Bennaceur-Griscelli, A., Rea, D., Legros, L., 
Marfaing-Koka, A., Bourhis, J.-H., Ame, S., et al. (2016). Leukemic stem cell persistence in chronic 
myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the 
impact of therapy discontinuation. Oncotarget 7, 35293-35301. 
Chow, A., Lucas, D., Hidalgo, A., Méndez-Ferrer, S., Hashimoto, D., Scheiermann, C., Battista, M., 
Leboeuf, M., Prophete, C., van Rooijen, N., et al. (2011). Bone marrow CD169+ macrophages promote 
the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. The 
Journal of Experimental Medicine 208, 261. 
Christopher, M.J., Rao, M., Liu, F., Woloszynek, J.R., and Link, D.C. (2011). Expression of the G-CSF 
receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in 
mice. The Journal of Experimental Medicine 208, 251. 
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D.S., and Bhatia, R. (2011). 
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission 
with imatinib treatment. Blood 118, 5565. 
Churchman, S.M., Ponchel, F., Boxall, S.A., Cuthbert, R., Kouroupis, D., Roshdy, T., Giannoudis, P.V., 
Emery, P., McGonagle, D., and Jones, E.A. (2012). Transcriptional profile of native CD271+ 
multipotential stromal cells: Evidence for multiple fates, with prominent osteogenic and Wnt pathway 
signaling activity. Arthritis & Rheumatism 64, 2632-2643. 
Čokić, V.P., Mitrović-Ajtić, O., Beleslin-Čokić, B.B., Marković, D., Buač, M., Diklić, M., Kraguljac-
Kurtović, N., Damjanović, S., Milenković, P., Gotić, M., et al. (2015). Proinflammatory Cytokine IL-6 
and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. Mediators of inflammation 2015, 
453020-453020. 
Corbin, A.S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M.W., and Druker, B.J. (2011). Human 
chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. 
The Journal of clinical investigation 121, 396-409. 
Cordeiro Gomes, A., Hara, T., Lim, V.Y., Herndler-Brandstetter, D., Nevius, E., Sugiyama, T., Tani-
ichi, S., Schlenner, S., Richie, E., Rodewald, H.-R., et al. (2016). Hematopoietic Stem Cell Niches 
Produce Lineage-Instructive Signals to Control Multipotent Progenitor Differentiation. Immunity 45, 
1219-1231. 
Deininger, M.W.N., Goldman, J.M., and Melo, J.V. (2000). The molecular biology of chronic myeloid 
leukemia. Blood 96, 3343. 
Dexter, T.M., Wright, E.G., Krizsa, F., and Lajtha, L.G. (1977). Regulation of haemopoietic stem cell 
proliferation in long term bone marrow cultures. Biomedicine / [publiee pour l'AAICIG] 27, 344-349. 
Dierks, C., Beigi, R., Guo, G.-R., Zirlik, K., Stegert, M.R., Manley, P., Trussell, C., Schmitt-Graeff, A., 
Landwerlin, K., Veelken, H., et al. (2008). Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is 
Dependent on Hedgehog Pathway Activation. Cancer Cell 14, 238-249. 
Ding, L., and Morrison, S.J. (2013a). Haematopoietic stem cells and early lymphoid progenitors occupy 
distinct bone marrow niches. Nature 495, 231-235. 
Ding, L., and Morrison, S.J. (2013b). Haematopoietic stem cells and early lymphoid progenitors occupy 
distinct bone marrow niches. Nature 495, 231-235. 
Ding, L., Saunders, T.L., Enikolopov, G., and Morrison, S.J. (2012). Endothelial and perivascular cells 
maintain haematopoietic stem cells. Nature 481, 457-462. 
Doan, P.L., Himburg, H.A., Helms, K., Russell, J.L., Fixsen, E., Quarmyne, M., Harris, J.R., Deoliviera, 
D., Sullivan, J.M., Chao, N.J., et al. (2013a). Epidermal Growth Factor Regulates Hematopoietic 
Regeneration Following Radiation Injury. Nature medicine 19, 295-304. 
Doan, P.L., Russell, J.L., Himburg, H.A., Helms, K., Harris, J.R., Lucas, J., Holshausen, K.C., 
Meadows, S.K., Daher, P., Jeffords, L.B., et al. (2013b). Tie2(+) bone marrow endothelial cells regulate 
hematopoietic stem cell regeneration following radiation injury. Stem cells (Dayton, Ohio) 31, 327-337. 
  59 
Dolinska, M., Piccini, A., Wong, W.M., Gelali, E., Johansson, A.-S., Klang, J., Xiao, P., Yektaei-Karin, 
E., Strömberg, U.O., Mustjoki, S., et al. (2017). Leukotriene signaling via ALOX5 and cysteinyl 
leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38− stem and progenitor cells in 
chronic myeloid leukemia. Biochemical and Biophysical Research Communications 490, 378-384. 
Domen, J. (2000). The role of apoptosis in regulating hematopoiesis and hematopoietic stem cells. 
Immunologic Research 22, 83-94. 
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., and Krause, D. (2006). 
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for 
Cellular Therapy position statement. Cytotherapy 8, 315-317. 
Dong, L., Yu, W.-M., Zheng, H., Loh, M.L., Bunting, S.T., Pauly, M., Huang, G., Zhou, M., Broxmeyer, 
H.E., Scadden, D.T., et al. (2016). Leukaemogenic effects of Ptpn11 activating mutations in the stem 
cell microenvironment. Nature 539, 304-308. 
Doulatov, S., Notta, F., Eppert, K., Nguyen, L.T., Ohashi, P.S., and Dick, J.E. (2010). Revised map of 
the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid 
development. Nature Immunology 11, 585. 
Doulatov, S., Notta, F., Laurenti, E., and Dick, John E. (2012). Hematopoiesis: A Human Perspective. 
Cell Stem Cell 10, 120-136. 
Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M., and Goldman, J.M. (2001). 
Chronic Myelogenous Leukemia. ASH Education Program Book 2001, 87-112. 
Eaves, C.J. (2015). Hematopoietic stem cells: concepts, definitions, and the new reality. Blood 125, 
2605. 
Eiring, A.M., Page, B.D.G., Kraft, I.L., Mason, C.C., Vellore, N.A., Resetca, D., Zabriskie, M.S., 
Zhang, T.Y., Khorashad, J.S., Engar, A.J., et al. (2015). Combined STAT3 and BCR-ABL1 inhibition 
induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29, 586-597. 
Eliasson, P., and Jönsson, J.-I. (2010). The hematopoietic stem cell niche: Low in oxygen but a nice 
place to be. Journal of Cellular Physiology 222, 17-22. 
Eliasson, P., Rehn, M., Hammar, P., Larsson, P., Sirenko, O., Flippin, L.A., Cammenga, J., and Jönsson, 
J.-I. (2010). Hypoxia mediates low cell-cycle activity and increases the proportion of long-term–
reconstituting hematopoietic stem cells during in vitro culture. Experimental Hematology 38, 301-
310.e302. 
Fleming, H.E. (2008). Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is 
necessary to preserve self-renewal in vivo. Cell Stem Cell 2, 274-283. 
Frederick, M.J., Henderson, Y., Xu, X., Deavers, M.T., Sahin, A.A., Wu, H., Lewis, D.E., El-Naggar, 
A.K., and Clayman, G.L. (2000). <em>In Vivo</em> Expression of the Novel CXC Chemokine BRAK 
in Normal and Cancerous Human Tissue. The American Journal of Pathology 156, 1937-1950. 
Friedenstein, A.J., Chailakhjan, R.K., and Lalykina, K.S. (1970). The development of fibroblast 
colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Proliferation 3, 393-
403. 
Friedenstein, A.J., Petrakova, K.V., Kurolesova, A.I., and Frolova, G.P. (1968). Heterotopic of bone 
marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6, 230-
247. 
Frisch, B.J., Ashton, J.M., Xing, L., Becker, M.W., Jordan, C.T., and Calvi, L.M. (2012). Functional 
inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119, 540. 
Fulzele, K., Krause, D.S., Panaroni, C., Saini, V., Barry, K.J., and Liu, X. (2013). Myelopoiesis is 
regulated by osteocytes through Gsα-dependent signaling. Blood 121, 930-939. 
 60 
Gallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A.D., Jørgensen, H.G., Bhatia, 
R., and Holyoake, T.L. (2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the 
elimination of CML CD34+ cells in vitro and in vivo. Blood 124, 1492. 
Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M., Jørgensen, 
H.G., and Holyoake, T.L. (2013). Autocrine TNF-α production supports CML stem and progenitor cell 
survival and enhances their proliferation. Blood 122, 3335. 
Galy, A., Travis, M., Cen, D., and Chen, B. (1995). Human T, B, natural killer, and dendritic cells arise 
from a common bone marrow progenitor cell subset. Immunity 3, 459-473. 
Gartner, S., and Kaplan, H.S. (1980). Long-term culture of human bone marrow cells. Proceedings of 
the National Academy of Sciences of the United States of America 77, 4756-4759. 
Gimble, J.M. (1990). The function of adipocytes in the bone marrow stroma. New Biol 2, 304-312. 
Gimble, J.M., Robinson, C.E., Wu, X., and Kelly, K.A. (1996). The function of adipocytes in the bone 
marrow stroma: an update. Bone 19, 421-428. 
Goldman, J.M., and Melo, J.V. (2008). BCR-ABL in Chronic Myelogenous Leukemia – How Does It 
Work? Acta Haematologica 119, 212-217. 
Gong, J.K. (1978). Endosteal marrow: a rich source of hematopoietic stem cells. Science 199, 1443. 
Gong, Y., Zhao, M., Yang, W., Gao, A., Yin, X., Hu, L., Wang, X., Xu, J., Hao, S., Cheng, T., et al. 
(2018). Megakaryocyte-derived excessive transforming growth factor β1 inhibits proliferation of 
normal hematopoietic stem cells in acute myeloid leukemia. Experimental Hematology 60, 40-46.e42. 
Gordon, T. (2014). Neurotrophic factor expression in denervated motor and sensory Schwann cells: 
Relevance to specificity of peripheral nerve regeneration. Experimental Neurology 254, 99-108. 
Görgens, A., Radtke, S., Möllmann, M., Cross, M., Dürig, J., Horn, Peter A., and Giebel, B. (2013). 
Revision of the Human Hematopoietic Tree: Granulocyte Subtypes Derive from Distinct Hematopoietic 
Lineages. Cell Reports 3, 1539-1552. 
Goulard, M., Dosquet, C., and Bonnet, D. (2018). Role of the microenvironment in myeloid 
malignancies. Cellular and Molecular Life Sciences 75, 1377-1391. 
Green, D.E., and Rubin, C.T. (2014). Consequences of irradiation on bone and marrow phenotypes, and 
its relation to disruption of hematopoietic precursors. Bone 0, 87-94. 
Greenbaum, A., Hsu, Y.-M.S., Day, R.B., Schuettpelz, L.G., Christopher, M.J., Borgerding, J.N., 
Nagasawa, T., and Link, D.C. (2013). CXCL12 in early mesenchymal progenitors is required for 
haematopoietic stem-cell maintenance. Nature 495, 227-230. 
Guo, P., Poulos, M.G., Palikuqi, B., Badwe, C.R., Lis, R., Kunar, B., Ding, B.-S., Rabbany, S.Y., Shido, 
K., Butler, J.M., et al. (2017). Endothelial jagged-2 sustains hematopoietic stem and progenitor 
reconstitution after myelosuppression. The Journal of Clinical Investigation 127, 4242-4256. 
Hamilton, A., Helgason, G.V., Schemionek, M., Zhang, B., Myssina, S., Allan, E.K., Nicolini, F.E., 
Müller-Tidow, C., Bhatia, R., Brunton, V.G., et al. (2012). Chronic myeloid leukemia stem cells are not 
dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501. 
Hanahan, D., and Coussens, Lisa M. (2012). Accessories to the Crime: Functions of Cells Recruited to 
the Tumor Microenvironment. Cancer Cell 21, 309-322. 
Hanoun, M., Maryanovich, M., Arnal-Estapé, A., and Frenette, Paul S. (2015). Neural Regulation of 
Hematopoiesis, Inflammation, and Cancer. Neuron 86, 360-373. 
Hanoun, M., Zhang, D., Mizoguchi, T., Pinho, S., Pierce, H., Kunisaki, Y., Lacombe, J., Armstrong, 
Scott A., Dührsen, U., and Frenette, Paul S. (2014). Acute Myelogenous Leukemia-Induced 
Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche. Cell 
Stem Cell 15, 365-375. 
  61 
Harichandan, A., Sivasubramaniyan, K., and Bühring, H.J. (2013). Prospective Isolation and 
Characterization of Human Bone Marrow-Derived MSCs. In Mesenchymal Stem Cells - Basics and 
Clinical Application I, B. Weyand, M. Dominici, R. Hass, R. Jacobs, and C. Kasper, eds. (Berlin, 
Heidelberg: Springer Berlin Heidelberg), pp. 1-17. 
Hata, R.-I., Izukuri, K., Kato, Y., Sasaki, S., Mukaida, N., Maehata, Y., Miyamoto, C., Akasaka, T., 
Yang, X., Nagashima, Y., et al. (2015). Suppressed rate of carcinogenesis and decreases in tumour 
volume and lung metastasis in CXCL14/BRAK transgenic mice. Scientific Reports 5, 9083. 
Hattori, M., and Minato, N. (2003). Rap1 GTPase: Functions, Regulation, and Malignancy. The Journal 
of Biochemistry 134, 479-484. 
Hattori, M., Tsukamoto, N., Nur-e-Kamal, M.S., Rubinfeld, B., Iwai, K., Kubota, H., Maruta, H., and 
Minato, N. (1995). Molecular cloning of a novel mitogen-inducible nuclear protein with a Ran GTPase-
activating domain that affects cell cycle progression. Molecular and Cellular Biology 15, 552. 
Hazlehurst, L.A., Argilagos, R.F., and Dalton, W.S. (2007). β1 integrin mediated adhesion increases 
Bim protein degradation and contributes to drug resistance in leukaemia cells. British Journal of 
Haematology 136, 269-275. 
Heazlewood, S.Y., Neaves, R.J., Williams, B., Haylock, D.N., Adams, T.E., and Nilsson, S.K. (2013). 
Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem 
cell proliferation. Stem Cell Research 11, 782-792. 
Heidel, Florian H., Bullinger, L., Feng, Z., Wang, Z., Neff, Tobias A., Stein, L., Kalaitzidis, D., Lane, 
Steven W., and Armstrong, Scott A. (2012). Genetic and Pharmacologic Inhibition of β-Catenin Targets 
Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell 10, 412-424. 
Himburg, H.A., Doan, P.L., Quarmyne, M., Yan, X., Sasine, J., Zhao, L., Hancock, G.V., Kan, J., Pohl, 
K.A., Tran, E., et al. (2016). Dickkopf-1 promotes hematopoietic regeneration via direct and niche-
mediated mechanisms. Nature Medicine 23, 91. 
Himburg, H.A., Harris, J.R., Ito, T., Daher, P., Russell, J.L., Quarmyne, M., Doan, P.L., Helms, K., 
Nakamura, M., Fixsen, E., et al. (2012). Pleiotrophin regulates the retention and self-renewal of 
hematopoietic stem cells in the bone marrow vascular niche. Cell reports 2, 964-975. 
Himburg, H.A., Muramoto, G.G., Daher, P., Meadows, S.K., Russell, J.L., Doan, P., Chi, J.-T., Salter, 
A.B., Lento, W.E., Reya, T., et al. (2010). Pleiotrophin regulates the expansion and regeneration of 
hematopoietic stem cells. Nature Medicine 16, 475. 
Hoermann, G., Greiner, G., and Valent, P. (2015). Cytokine Regulation of Microenvironmental Cells 
in Myeloproliferative Neoplasms. Mediators of Inflammation 2015, 17. 
Hoggatt, J.K., Youmna; Scadden David T (2016). Hematopoietic Stem Cell Niche in Health and 
Disease. Annual Review of Pathology: Mechanisms of Disease 11, 555-581. 
Hogge, D.E., Lansdorp, P.M., Reid, D., Gerhard, B., and Eaves, C.J. (1996). Enhanced detection, 
maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine 
fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating 
factor. Blood 88, 3765. 
Höke, A., Redett, R., Hameed, H., Jari, R., Zhou, C., Li, Z.B., Griffin, J.W., and Brushart, T.M. (2006). 
Schwann Cells Express Motor and Sensory Phenotypes That Regulate Axon Regeneration. The Journal 
of Neuroscience 26, 9646. 
Holyoake, T.L., and Vetrie, D. (2017). The chronic myeloid leukemia stem cell: stemming the tide of 
persistence. Blood 129, 1595. 
Hooper, A.T., Butler, J.M., Nolan, D.J., Kranz, A., Iida, K., Kobayashi, M., Kopp, H.-G., Shido, K., 
Petit, I., Yanger, K., et al. (2009). Engraftment and reconstitution of hematopoiesis is dependent on 
VEGFR2 mediated regeneration of sinusoidal endothelial cells. Cell stem cell 4, 263-274. 
 62 
Horwitz, E.M., and Keating, A. (2000). Nonhematopoietic mesenchymal stem cells: What are they? 
Cytotherapy 2, 387-388. 
Horwitz, E.M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., Deans, 
R.J., Krause, D.S., and Keating, A. (2005). Clarification of the nomenclature for MSC: The International 
Society for Cellular Therapy position statement. Cytotherapy 7, 393-395. 
Hromas, R., Broxmeyer, H.E., Kim, C., Nakshatri, H., Christopherson, K., Azam, M., and Hou, Y.-H. 
(1999). Cloning of BRAK, a Novel Divergent CXC Chemokine Preferentially Expressed in Normal 
versus Malignant Cells. Biochemical and Biophysical Research Communications 255, 703-706. 
Hu, M., Krause, D., Greaves, M., Sharkis, S., Dexter, M., Heyworth, C., and Enver, T. (1997). 
Multilineage gene expression precedes commitment in the hemopoietic system. Genes & Development 
11, 774-785. 
Huan, J., Hornick, N.I., Shurtleff, M.J., Skinner, A.M., Goloviznina, N.A., Roberts, C.T., and Kurre, P. 
(2013). RNA Trafficking by Acute Myelogenous Leukemia Exosomes. Cancer Research 73, 918. 
Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Bolton, 
A.E., van Hoomissen, I.C., Goldman, J.M., et al. (2003). Frequency of Major Molecular Responses to 
Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. New 
England Journal of Medicine 349, 1423-1432. 
Hurtz, C., Hatzi, K., Cerchietti, L., Braig, M., Park, E., Kim, Y.-m., Herzog, S., Ramezani-Rad, P., 
Jumaa, H., Müller, M.C., et al. (2011). BCL6-mediated repression of p53 is critical for leukemia stem 
cell survival in chronic myeloid leukemia. The Journal of experimental medicine 208, 2163-2174. 
Irvine, D.A., Zhang, B., Kinstrie, R., Tarafdar, A., Morrison, H., Campbell, V.L., Moka, H.A., Ho, Y., 
Nixon, C., Manley, P.W., et al. (2016). Deregulated hedgehog pathway signaling is inhibited by the 
smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific 
Reports 6, 25476. 
Isern, J., Martín-Antonio, B., Ghazanfari, R., Martín, Ana M., López, Juan A., del Toro, R., Sánchez-
Aguilera, A., Arranz, L., Martín-Pérez, D., Suárez-Lledó, M., et al. (2013). Self-Renewing Human Bone 
Marrow Mesenspheres Promote Hematopoietic Stem Cell Expansion. Cell Reports 3, 1714-1724. 
Ishida, D., Kometani, K., Yang, H., Kakugawa, K., Masuda, K., Iwai, K., Suzuki, M., Itohara, S., 
Nakahata, T., Hiai, H., et al. (2003). Myeloproliferative stem cell disorders by deregulated Rap1 
activation in SPA-1-deficient mice. Cancer Cell 4, 55-65. 
Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., 
Tomiyama, H., Saito, N., et al. (2007). Chemotherapy-resistant human AML stem cells home to and 
engraft within the bone-marrow endosteal region. Nat Biotech 25, 1315-1321. 
Itkin, T., Gur-Cohen, S., Spencer, J.A., Schajnovitz, A., Ramasamy, S.K., Kusumbe, A.P., Ledergor, 
G., Jung, Y., Milo, I., Poulos, M.G., et al. (2016). Distinct bone marrow blood vessels differentially 
regulate haematopoiesis. Nature 532, 323-328. 
Jacamo, R., and Andreeff, M. (2015). Bone Marrow Microenvironment-mediated Resistance to 
Chemotherapy in Leukemia. Journal of Nature and Science (JNSCI); Vol 1, No 8. 
Jacamo, R., Chen, Y., Wang, Z., Ma, W., Zhang, M., and Spaeth, E.L. (2014). Reciprocal leukemia-
stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood 123, 2691-
2702. 
Jacobson, L.O., Simmons, E.L., Marks, E.K., and Eldredge, J.H. (1951). Recovery from Radiation 
injury (American Association for the Advancement of Science), pp. 510-511. 
Jang, Y.-Y., and Sharkis, S.J. (2007). A low level of reactive oxygen species selects for primitive 
hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110, 3056. 
Janning, M., Ben-Batalla, I., and Loges, S. (2015). Axl inhibition: a potential road to a novel acute 
myeloid leukemia therapy? Expert Review of Hematology 8, 135-138. 
  63 
Jin, A., Kurosu, T., Tsuji, K., Mizuchi, D., Arai, A., Fujita, H., Hattori, M., Minato, N., and Miura, O. 
(2006a). BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling 
pathways and to regulate proliferation, apoptosis, and adhesion. Oncogene 25, 4332. 
Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., and Dick, J.E. (2006b). Targeting of CD44 eradicates 
human acute myeloid leukemic stem cells. Nat Med 12, 1167-1174. 
Jin, Y., Nie, D., Li, J., Du, X., Lu, Y., Li, Y., Liu, C., Zhou, J., and Pan, J. (2017). Gas6/AXL Signaling 
Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin. 
Clinical Cancer Research 23, 2842. 
Jones, E.A., English, A., Kinsey, S.E., Straszynski, L., Emery, P., Ponchel, F., and McGonagle, D. 
(2006). Optimization of a flow cytometry-based protocol for detection and phenotypic characterization 
of multipotent mesenchymal stromal cells from human bone marrow. Cytometry Part B: Clinical 
Cytometry 70B, 391-399. 
Jones, J.A., Starkey, J.R., and Kleinhofs, A. (1980). Toxicity and mutagenicity of sodium azide in 
mammalian cell cultures. Mutation Research/Genetic Toxicology 77, 293-299. 
Julius, M.H., Masuda, T., and Herzenberg, L.A. (1972). Demonstration That Antigen-Binding Cells Are 
Precursors of Antibody-Producing Cells After Purification with a Fluorescence-Activated Cell Sorter. 
Proceedings of the National Academy of Sciences of the United States of America 69, 1934-1938. 
Kalinkovich, A., Spiegel, A., Shivtiel, S., Kollet, O., Jordaney, N., Piacibello, W., and Lapidot, T. 
(2009). Blood-forming stem cells are nervous: Direct and indirect regulation of immature human 
CD34+ cells by the nervous system. Brain, Behavior, and Immunity 23, 1059-1065. 
Karnati, H.K., Raghuwanshi, S., Sarvothaman, S., Gutti, U., Saladi, R.G.V., Komati, J.K., Tummala, 
P.R., and Gutti, R.K. (2015). microRNAs: Key Players in Hematopoiesis. In microRNA: Basic Science: 
From Molecular Biology to Clinical Practice, G. Santulli, ed. (Cham: Springer International Publishing), 
pp. 171-211. 
Karsunky, H., Inlay, M.A., Serwold, T., Bhattacharya, D., and Weissman, I.L. (2008). Flk2+ common 
lymphoid progenitors possess equivalent differentiation potential for the B and T lineages. Blood 111, 
5562. 
Katayama, Y., Battista, M., Kao, W.M., Hidalgo, A., Peired, A.J., and Thomas, S.A. (2006). Signals 
from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 
124, 407-421. 
Kiel, M.J., Radice, G.L., and Morrison, S.J. (2007). Lack of Evidence that Hematopoietic Stem Cells 
Depend on N-Cadherin-Mediated Adhesion to Osteoblasts for Their Maintenance. Cell Stem Cell 1, 
204-217. 
Kiel, M.J., Yilmaz, O.H., Iwashita, T., Yilmaz, O.H., Terhorst, C., and Morrison, S.J. (2005). SLAM 
family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for 
stem cells. Cell 121, 1109-1121. 
Kieslinger, M., Hiechinger, S., Dobreva, G., Consalez, G.G., and Grosschedl, R. (2010). Early B Cell 
Factor 2 Regulates Hematopoietic Stem Cell Homeostasis in a Cell-Nonautonomous Manner. Cell Stem 
Cell 7, 496-507. 
Kim, Y.W., Koo, B.K., Jeong, H.W., Yoon, M.J., Song, R., and Shin, J. (2008). Defective Notch 
activation in microenvironment leads to myeloproliferative disease. Blood 112, 4628-4638. 
Kirito, K., Hu, Y., and Komatsu, N. (2009). HIF-1 prevents the overproduction of mitochondrial ROS 
after cytokine stimulation through induction of PDK-1. Cell Cycle 8, 2844-2849. 
Kleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., Hricik, T., Bhagwat, N., 
McKenney, A.S., Papalexi, E., et al. (2015). JAK-STAT pathway activation in malignant and 
nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer discovery 5, 316-
331. 
 64 
Kobayashi, H., Butler, J.M., O'Donnell, R., Kobayashi, M., Ding, B.-S., Bonner, B., Chiu, V.K., Nolan, 
D.J., Shido, K., Benjamin, L., et al. (2010). Angiocrine factors from Akt-activated endothelial cells 
balance self-renewal and differentiation of haematopoietic stem cells. Nature cell biology 12, 1046-
1056. 
Kode, A., Manavalan, J.S., Mosialou, I., Bhagat, G., Rathinam, C.V., and Luo, N. (2014). 
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506, 240-244. 
Kode, A., Mosialou, I., Manavalan, S.J., Rathinam, C.V., Friedman, R.A., Teruya-Feldstein, J., Bhagat, 
G., Berman, E., and Kousteni, S. (2015). FoxO1-dependent induction of acute myeloid leukemia by 
osteoblasts in mice. Leukemia 30, 1. 
Kohn, L.A., Hao, Q.-L., Sasidharan, R., Parekh, C., Ge, S., Zhu, Y., Mikkola, H.K.A., and Crooks, 
G.M. (2012). Lymphoid priming in human bone marrow begins before expression of CD10 with 
upregulation of L-selectin. Nature Immunology 13, 963. 
Kollet, O. (2006). Osteoclasts degrade endosteal components and promote mobilization of 
hematopoietic progenitor cells. Nat Med 12, 657-664. 
Kondo, M., Weissman, I.L., and Akashi, K. (1997). Identification of clonogenic common lymphoid 
progenitors in mouse bone marrow. Cell 91, 661-672. 
Kopp, H.-G., Avecilla, S.T., Hooper, A.T., Shmelkov, S.V., Ramos, C.A., Zhang, F., and Rafii, S. 
(2005). Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood 106, 
505. 
Krause, D.S., Fulzele, K., Catic, A., Sun, C.C., Dombkowski, D., and Hurley, M.P. (2013). Differential 
regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 19, 1513-1517. 
Krause, D.S., Lazarides, K., Lewis, J.B., von Andrian, U.H., and Van Etten, R.A. (2014). Selectins and 
their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone 
marrow niche. Blood 123, 1361. 
Krause, D.S., Lazarides, K., von Andrian, U.H., and Van Etten, R.A. (2006). Requirement for CD44 in 
homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12, 1175-1180. 
Krause, D.S., and Scadden, D.T. (2015). A hostel for the hostile: the bone marrow niche in hematologic 
neoplasms. Haematologica 100, 1376. 
Kreso, A., and Dick, John E. (2014). Evolution of the Cancer Stem Cell Model. Cell Stem Cell 14, 275-
291. 
Krevvata, M., Silva, B.C., Manavalan, J.S., Galan-Diez, M., Kode, A., Matthews, B.G., Park, D., Zhang, 
C.A., Galili, N., Nickolas, T.L., et al. (2014). Inhibition of leukemia cell engraftment and disease 
progression in mice by osteoblasts. Blood 124, 2834. 
Krock, B.L., Eisinger-Mathason, T.S., Giannoukos, D.N., Shay, J.E., Gohil, M., Lee, D.S., Nakazawa, 
M.S., Sesen, J., Skuli, N., and Simon, M.C. (2015). The aryl hydrocarbon receptor nuclear translocator 
is an essential regulator of murine hematopoietic stem cell viability. Blood 125, 3263. 
Kumar, B., Garcia, M., Weng, L., Jung, X., Murakami, J.L., Hu, X., McDonald, T., Lin, A., Kumar, 
A.R., DiGiusto, D.L., et al. (2017). Acute myeloid leukemia transforms the bone marrow niche into a 
leukemia-permissive microenvironment through exosome secretion. Leukemia 32, 575. 
Kunisaki, Y., Bruns, I., Scheiermann, C., Ahmed, J., Pinho, S., Zhang, D., Mizoguchi, T., Wei, Q., 
Lucas, D., Ito, K., et al. (2013). Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 
502, 637. 
Kusumbe, A.P., Ramasamy, S.K., and Adams, R.H. (2014). Coupling of angiogenesis and osteogenesis 
by a specific vessel subtype in bone. Nature 507, 323. 
  65 
Kusumbe, A.P., Ramasamy, S.K., Itkin, T., Andaloussi Mäe, M., Langen, U.H., Betsholtz, C., Lapidot, 
T., and Adams, R.H. (2016). Age-dependent modulation of vascular niches for haematopoietic stem 
cells. Nature 532, 380-384. 
Kuznetsov, S.A., Krebsbach, P.H., Satomura, K., Kerr, J., Riminucci, M., Benayahu, D., and Robey, 
P.G. (1997). Single-Colony Derived Strains of Human Marrow Stromal Fibroblasts Form Bone After 
Transplantation In Vivo. Journal of Bone and Mineral Research 12, 1335-1347. 
Lai, A.Y., and Kondo, M. (2006). Asymmetrical lymphoid and myeloid lineage commitment in 
multipotent hematopoietic progenitors. The Journal of Experimental Medicine 203, 1867. 
Lane, S.W., Wang, Y.J., Lo Celso, C., Ragu, C., Bullinger, L., Sykes, S.M., Ferraro, F., Shterental, S., 
Lin, C.P., Gilliland, D.G., et al. (2011). Differential niche and Wnt requirements during acute myeloid 
leukemia progression. Blood 118, 2849. 
Laurenti, E., Frelin, C., Xie, S., Ferrari, R., Dunant, Cyrille F., Zandi, S., Neumann, A., Plumb, I., 
Doulatov, S., Chen, J., et al. (2015). CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic 
Stem Cells. Cell Stem Cell 16, 302-313. 
Lee, J., Breton, G., Oliveira, T.Y.K., Zhou, Y.J., Aljoufi, A., Puhr, S., Cameron, M.J., Sékaly, R.-P., 
Nussenzweig, M.C., and Liu, K. (2015). Restricted dendritic cell and monocyte progenitors in human 
cord blood and bone marrow. The Journal of Experimental Medicine 212, 385. 
Levy, A.P., Levy, N.S., Wegner, S., and Goldberg, M.A. (1995). Transcriptional Regulation of the Rat 
Vascular Endothelial Growth Factor Gene by Hypoxia. Journal of Biological Chemistry 270, 13333-
13340. 
Li, B., Bailey, A.S., Jiang, S., Liu, B., Goldman, D.C., and Fleming, W.H. (2010). Endothelial cells 
mediate the regeneration of hematopoietic stem cells. Stem cell research 4, 17-24. 
Li, H., Ghazanfari, R., Zacharaki, D., Ditzel, N., Isern, J., Ekblom, M., Méndez-Ferrer, S., Kassem, M., 
and Scheding, S. (2014). Low/Negative Expression of PDGFR-α Identifies the Candidate Primary 
Mesenchymal Stromal Cells in Adult Human Bone Marrow. Stem Cell Reports 3, 965-974. 
Lin, C.H., Kaushansky, K., and Zhan, H. (2016). JAK2V617F-mutant vascular niche contributes to 
JAK2(V617F) clonal expansion in myeloproliferative neoplasms. Blood Cells Mol Dis 62, 42-48. 
Lin, Q., Lee, Y.-J., and Yun, Z. (2006). Differentiation Arrest by Hypoxia. Journal of Biological 
Chemistry 281, 30678-30683. 
Liu, Y.-f., Zhang, S.-y., Chen, Y.-y., Shi, K., Zou, B., Liu, J., Yang, Q., Jiang, H., Wei, L., Li, C.-z., et 
al. (2018). ICAM-1 Deficiency in the Bone Marrow Niche Impairs Quiescence and Repopulation of 
Hematopoietic Stem Cells. Stem Cell Reports 11, 258-273. 
Lord, B.I., Testa, N.G., and Hendry, J.H. (1975). The relative spatial distributions of CFUs and CFUc 
in the normal mouse femur. Blood 46, 65-72. 
Lu, J., Chatterjee, M., Schmid, H., Beck, S., and Gawaz, M. (2016). CXCL14 as an emerging immune 
and inflammatory modulator. Journal of inflammation (London, England) 13, 1-1. 
Lu, J., Song, G., Tang, Q., Zou, C., Han, F., Zhao, Z., Yong, B., Yin, J., Xu, H., Xie, X., et al. (2015). 
IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. 
The Journal of Clinical Investigation 125, 1839-1856. 
Lucas, C.M., Harris, R.J., Giannoudis, A., McDonald, E., and Clark, R.E. (2014). Low leukotriene B4 
receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. Haematologica 
99, 1710. 
Lucas, D., Battista, M., Shi, P.A., Isola, L., and Frenette, P.S. (2008). Mobilized Hematopoietic Stem 
Cell Yield Depends on Species-Specific Circadian Timing. Cell Stem Cell 3, 364-366. 
 66 
Lucas, D., Scheiermann, C., Chow, A., Kunisaki, Y., Bruns, I., Barrick, C., Tessarollo, L., and Frenette, 
P.S. (2013). Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. 
Nature Medicine 19, 695. 
Lundell, B.I., McCarthy, J.B., Kovach, N.L., and Verfaillie, C.M. (1997). Activation of β1 integrins on 
CML progenitors reveals cooperation between β1 integrins and CD44 in the regulation of adhesion and 
proliferation. Leukemia 11, 822-829. 
Lymperi, S., Ersek, A., Ferraro, F., Dazzi, F., and Horwood, N.J. (2011). Inhibition of osteoclast 
function reduces hematopoietic stem cell numbers in vivo. Blood 117, 1540. 
Mabuchi, Y., Morikawa, S., Harada, S., Niibe, K., Suzuki, S., Renault-Mihara, F., Houlihan, 
Diarmaid D., Akazawa, C., Okano, H., and Matsuzaki, Y. (2013). LNGFR+THY-1+VCAM-1hi+ Cells 
Reveal Functionally Distinct Subpopulations in Mesenchymal Stem Cells. Stem Cell Reports 1, 152-
165. 
Mahmud, N., Petro, B., Baluchamy, S., Li, X., Taioli, S., Lavelle, D., Quigley, J.G., Suphangul, M., and 
Araki, H. (2014). Differential Effects of Epigenetic Modifiers on the Expansion and Maintenance of 
Human Cord Blood Stem/Progenitor Cells. Biology of Blood and Marrow Transplantation 20, 480-489. 
Manshouri, T., Estrov, Z., Quintás-Cardama, A., Burger, J., Zhang, Y., Livun, A., Knez, L., Harris, D., 
Creighton, C.J., Kantarjian, H.M., et al. (2011). Bone Marrow Stroma–Secreted Cytokines Protect 
JAK2(V617F)-Mutated Cells from the Effects of a JAK2 Inhibitor. Cancer Research 71, 3831. 
Manz, M.G., Miyamoto, T., Akashi, K., and Weissman, I.L. (2002). Prospective isolation of human 
clonogenic common myeloid progenitors. Proceedings of the National Academy of Sciences 99, 11872. 
Marlein, C.R., Zaitseva, L., Piddock, R.E., Robinson, S.D., Edwards, D.R., Shafat, M.S., Zhou, Z., 
Lawes, M., Bowles, K.M., and Rushworth, S.A. (2017). NADPH oxidase-2 derived superoxide drives 
mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood 130, 1649. 
Maryanovich, M., Zahalka, A.H., Pierce, H., Pinho, S., Nakahara, F., Asada, N., Wei, Q., Wang, X., 
Ciero, P., Xu, J., et al. (2018). Adrenergic nerve degeneration in bone marrow drives aging of the 
hematopoietic stem cell niche. Nature Medicine 24, 782-791. 
Matsumoto, A., and Nakayama, K.I. (2013). Role of key regulators of the cell cycle in maintenance of 
hematopoietic stem cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1830, 2335-2344. 
Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., and Fujimi (2003). Interaction between 
leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute 
myelogenous leukemia. Nat Med 9, 1158-1165. 
Mazzon, C., Anselmo, A., Cibella, J., Soldani, C., Destro, A., Kim, N., Roncalli, M., Burden, S.J., 
Dustin, M.L., Sarukhan, A., et al. (2011). The critical role of agrin in the hematopoietic stem cell niche. 
Blood 118, 2733. 
McGettigan, P.A. (2013). Transcriptomics in the RNA-seq era. Current Opinion in Chemical Biology 
17, 4-11. 
Mead, A.J., Neo, W.H., Barkas, N., Matsuoka, S., Giustacchini, A., Facchini, R., Thongjuea, S., 
Jamieson, L., Booth, C.A.G., Fordham, N., et al. (2017). Niche-mediated depletion of the normal 
hematopoietic stem cell reservoir by Flt3-ITD–induced myeloproliferation. The Journal of 
Experimental Medicine 214, 2005. 
Méndez-Ferrer, S., Lucas, D., Battista, M., and Frenette, P.S. (2008). Haematopoietic stem cell release 
is regulated by circadian oscillations. Nature 452, 442. 
Mendez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R., Macarthur, B.D., and Lira, S.A. 
(2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 
829-834. 
  67 
Miharada, K., Karlsson, G., Rehn, M., Rörby, E., Siva, K., Cammenga, J., and Karlsson, S. (2011). 
Cripto Regulates Hematopoietic Stem Cells as a Hypoxic-Niche-Related Factor through Cell Surface 
Receptor GRP78. Cell Stem Cell 9, 330-344. 
Miller, C.L., and Eaves, C.J. (2002). Long-term culture-initiating cell assays for human and murine 
cells. Methods in molecular medicine 63, 123-141. 
Miller, P.G., Al-Shahrour, F., Hartwell, K.A., Chu, L.P., Jaras, M., and Puram, R.V. (2013). In vivo 
RNAi screening identifies a leukemia-specific dependence on integrin β3 signaling. Cancer Cell 24, 45-
58. 
Minato, N., and Hattori, M. (2009). Spa-1 (Sipa1) and Rap signaling in leukemia and cancer metastasis. 
Cancer Science 100, 17-23. 
Mirantes, C., Passegué, E., and Pietras, E.M. (2014). Pro-inflammatory cytokines: emerging players 
regulating HSC function in normal and diseased hematopoiesis. Experimental cell research 329, 248-
254. 
Mizoguchi, T., Pinho, S., Ahmed, J., Kunisaki, Y., Hanoun, M., Mendelson, A., Ono, N., Kronenberg, 
Henry M., and Frenette, Paul S. (2014). Osterix Marks Distinct Waves of Primitive and Definitive 
Stromal Progenitors during Bone Marrow Development. Developmental Cell 29, 340-349. 
Morikawa, S., Mabuchi, Y., Kubota, Y., Nagai, Y., Niibe, K., Hiratsu, E., Suzuki, S., Miyauchi-Hara, 
C., Nagoshi, N., Sunabori, T., et al. (2009a). Prospective identification, isolation, and systemic 
transplantation of multipotent mesenchymal stem cells in murine bone marrow. The Journal of 
Experimental Medicine 206, 2483-2496. 
Morikawa, S., Mabuchi, Y., Niibe, K., Suzuki, S., Nagoshi, N., Sunabori, T., Shimmura, S., Nagai, Y., 
Nakagawa, T., Okano, H., et al. (2009b). Development of mesenchymal stem cells partially originate 
from the neural crest. Biochemical and Biophysical Research Communications 379, 1114-1119. 
Morrison, S.J., and Scadden, D.T. (2014). The bone marrow niche for haematopoietic stem cells. Nature 
505, 327-334. 
Moschoi, R., Imbert, V., Nebout, M., Chiche, J., Mary, D., and Prebet, T. (2016). Protective 
mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during 
chemotherapy. Blood 128, 253-264. 
Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., and Kondo, Y. (2010). TGF-β-FOXO 
signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463, 676-680. 
Nakamura, Y., Arai, F., Iwasaki, H., Hosokawa, K., Kobayashi, I., Gomei, Y., Matsumoto, Y., 
Yoshihara, H., and Suda, T. (2010). Isolation and characterization of endosteal niche cell populations 
that regulate hematopoietic stem cells. Blood 116, 1422. 
Nakamura-Ishizu, A., Takubo, K., Fujioka, M., and Suda, T. (2014). Megakaryocytes are essential for 
HSC quiescence through the production of thrombopoietin. Biochemical and Biophysical Research 
Communications 454, 353-357. 
Naveiras, O., Nardi, V., Wenzel, P.L., Fahey, F., and Daley, G.Q. (2009). Bone marrow adipocytes as 
negative regulators of the hematopoietic microenvironment. Nature 460, 259-263. 
Nervi, B., Ramirez, P., Rettig, M.P., Uy, G.L., Holt, M.S., and Ritchey, J.K. (2009). Chemosensitization 
of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 
113, 6206-6214. 
Nestorowa, S., Hamey, F.K., Pijuan Sala, B., Diamanti, E., Shepherd, M., Laurenti, E., Wilson, N.K., 
Kent, D.G., and Göttgens, B. (2016). A single-cell resolution map of mouse hematopoietic stem and 
progenitor cell differentiation. Blood 128, e20. 
Nilsson, S.K., Johnston, H.M., Whitty, G.A., Williams, B., Webb, R.J., and Denhardt, D.T. (2005). 
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive 
hematopoietic progenitor cells. Blood 106, 1232-1239. 
 68 
Nishioka, C., Ikezoe, T., and Yokoyama, A. (2015). Blockade of CD82 by a monoclonal antibody 
potentiates anti-leukemia effects of AraC in vivo. Cancer medicine 4, 1426-1431. 
Noone AM, H.N., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, 
Chen HS, Feuer EJ, Cronin KA. (2018). SEER Cancer Statistics Review, 1975-2015, National Cancer 
Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/. 
O'Hare, T., Zabriskie, M.S., Eiring, A.M., and Deininger, M.W. (2012). Pushing the limits of targeted 
therapy in chronic myeloid leukaemia. Nature Reviews Cancer 12, 513. 
Olson, T.S., Caselli, A., Otsuru, S., Hofmann, T.J., Williams, R., Paolucci, P., Dominici, M., and 
Horwitz, E.M. (2013). Megakaryocytes promote murine osteoblastic HSC niche expansion and stem 
cell engraftment after radioablative conditioning. Blood 121, 5238. 
Omatsu, Y., Seike, M., Sugiyama, T., Kume, T., and Nagasawa, T. (2014). Foxc1 is a critical regulator 
of haematopoietic stem/progenitor cell niche formation. Nature 508, 536. 
Omatsu, Y., Sugiyama, T., Kohara, H., Kondoh, G., Fujii, N., Kohno, K., and Nagasawa, T. (2010). 
The Essential Functions of Adipo-osteogenic Progenitors as the Hematopoietic Stem and Progenitor 
Cell Niche. Immunity 33, 387-399. 
Osawa, M., Hanada, K., Hamada, H., and Nakauchi, H. (1996). Long-term lymphohematopoietic 
reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273, 242-245. 
Ozaki, A., Nagai, A., Lee, Y., Myong, N., and Kim, S. (2008). Expression of cytokines and cytokine 
receptors in human Schwann cells. Neuroreport 19, 31-35. 
Ozawa, S., Kato, Y., Ito, S., Komori, R., Shiiki, N., Tsukinoki, K., Ozono, S., Maehata, Y., Taguchi, T., 
Imagawa-Ishiguro, Y., et al. (2009a). Restoration of BRAK / CXCL14 gene expression by gefitinib is 
associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer 
Science 100, 2202-2209. 
Ozawa, S., Kato, Y., Komori, R., Maehata, Y., Kubota, E., and Hata, R.-I. (2006). BRAK/CXCL14 
expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochemical and 
Biophysical Research Communications 348, 406-412. 
Ozawa, S., Kato, Y., Kubota, E., and Hata, R.-I. (2009b). BRAK/CXCL14 expression in oral carcinoma 
cells completely suppresses tumor cell xenografts in SCID mouse. Biomedical Research 30, 315-318. 
Park, D., Spencer, Joel A., Koh, Bong I., Kobayashi, T., Fujisaki, J., Clemens, Thomas L., Lin, 
Charles P., Kronenberg, Henry M., and Scadden, David T. (2012a). Endogenous Bone Marrow MSCs 
Are Dynamic, Fate-Restricted Participants in Bone Maintenance and Regeneration. Cell Stem Cell 10, 
259-272. 
Park, D., Sykes, D.B., and Scadden, D.T. (2012b). The hematopoietic stem cell niche. Frontiers in 
bioscience (Landmark edition) 17, 30-39. 
Park, S.-M., Deering, R.P., Lu, Y., Tivnan, P., Lianoglou, S., Al-Shahrour, F., Ebert, B.L., Hacohen, 
N., Leslie, C., Daley, G.Q., et al. (2014). Musashi-2 controls cell fate, lineage bias, and TGF-β signaling 
in HSCs. The Journal of Experimental Medicine 211, 71-87. 
Parmar, K., Mauch, P., Vergilio, J.-A., Sackstein, R., and Down, J.D. (2007). Distribution of 
hematopoietic stem cells in the bone marrow according to regional hypoxia. Proceedings of the National 
Academy of Sciences 104, 5431. 
Pellicano, F., and Holyoake, T.L. (2011). Assembling defenses against therapy-resistant leukemic stem 
cells: Bcl6 joins the ranks. The Journal of experimental medicine 208, 2155-2158. 
Pellicano, F., Scott, M.T., Helgason, G.V., Hopcroft, L.E.M., Allan, E.K., Aspinall-O'Dea, M., Copland, 
M., Pierce, A., Huntly, B.J.P., Whetton, A.D., et al. (2014). The antiproliferative activity of kinase 
inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem cells 
(Dayton, Ohio) 32, 2324-2337. 
  69 
Penserga, E.T.P., and Skorski, T. (2006). Fusion tyrosine kinases: a result and cause of genomic 
instability. Oncogene 26, 11. 
Peters-Golden, M., and Brock, T.G. (2003). 5-Lipoxygenase and FLAP. Prostaglandins, Leukotrienes 
and Essential Fatty Acids 69, 99-109. 
Peters-Golden, M., and Henderson, W.R. (2007). Leukotrienes. New England Journal of Medicine 357, 
1841-1854. 
Pettit, A.R., Chang, M.K., Hume, D.A., and Raggatt, L.J. (2008). Osteal macrophages: a new twist on 
coupling during bone dynamics. Bone 43, 976-982. 
Pietras, E.M., Warr, M.R., and Passegué, E. (2011). Cell cycle regulation in hematopoietic stem cells. 
The Journal of Cell Biology 195, 709. 
Pinho, S., Lacombe, J., Hanoun, M., Mizoguchi, T., Bruns, I., Kunisaki, Y., and Frenette, P.S. (2013). 
PDGFRα and CD51 mark human Nestin+ sphere-forming mesenchymal stem cells capable of 
hematopoietic progenitor cell expansion. The Journal of Experimental Medicine 210, 1351. 
Ploemacher, R.E., van der Sluijs, J.P., van Beurden, C.A., Baert, M.R., and Chan, P.L. (1991). Use of 
limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and 
spleen colony-forming hematopoietic stem cells in the mouse. Blood 78, 2527. 
Ploemacher, R.E., van der Sluijs, J.P., Voerman, J.S., and Brons, N.H. (1989). An in vitro limiting-
dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood 74, 2755. 
Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and Therapeutic Aspects of Angiogenesis. 
Cell 146, 873-887. 
Poulos, Michael G., Guo, P., Kofler, Natalie M., Pinho, S., Gutkin, Michael C., Tikhonova, A., Aifantis, 
I., Frenette, Paul S., Kitajewski, J., Rafii, S., et al. (2013). Endothelial Jagged-1 Is Necessary for 
Homeostatic and Regenerative Hematopoiesis. Cell Reports 4, 1022-1034. 
Poulos, M.G., Ramalingam, P., Gutkin, M.C., Kleppe, M., Ginsberg, M., Crowley, M.J.P., Elemento, 
O., Levine, R.L., Rafii, S., Kitajewski, J., et al. (2016). Endothelial-specific inhibition of NF-κB 
enhances functional haematopoiesis. Nature Communications 7, 13829. 
Poulos, M.G., Ramalingam, P., Gutkin, M.C., Llanos, P., Gilleran, K., Rabbany, S.Y., and Butler, J.M. 
(2017). Endothelial transplantation rejuvenates aged hematopoietic stem cell function. The Journal of 
Clinical Investigation 127, 4163-4178. 
Pronk, C.J.H., Rossi, D.J., Månsson, R., Attema, J.L., Norddahl, G.L., Chan, C.K.F., Sigvardsson, M., 
Weissman, I.L., and Bryder, D. (2007). Elucidation of the Phenotypic, Functional, and Molecular 
Topography of a Myeloerythroid Progenitor Cell Hierarchy. Cell Stem Cell 1, 428-442. 
Purton, L.E., and Scadden, D.T. (2007). Limiting Factors in Murine Hematopoietic Stem Cell Assays. 
Cell Stem Cell 1, 263-270. 
Qian, H., Badaloni, A., Chiara, F., Stjernberg, J., Polisetti, N., Nihlberg, K., Consalez, G.G., and 
Sigvardsson, M. (2013). Molecular Characterization of Prospectively Isolated Multipotent 
Mesenchymal Progenitors Provides New Insight into the Cellular Identity of Mesenchymal Stem Cells 
in Mouse Bone Marrow. Molecular and Cellular Biology 33, 661-677. 
Qian, H., Buza-Vidas, N., Hyland, C.D., Jensen, C.T., Antonchuk, J., and Mansson, R. (2007). Critical 
role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 1, 671-
684. 
Qian, H., Le Blanc, K., and Sigvardsson, M. (2012). Primary Mesenchymal Stem and Progenitor Cells 
from Bone Marrow Lack Expression of CD44 Protein. Journal of Biological Chemistry 287, 25795-
25807. 
Quéré, R., Andradottir, S., Brun, A.C.M., Zubarev, R.A., Karlsson, G., Olsson, K., Magnusson, M., 
Cammenga, J., and Karlsson, S. (2010). High levels of the adhesion molecule CD44 on leukemic cells 
 70 
generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 
25, 515. 
Quirici, N., Soligo, D., Bossolasco, P., Servida, F., Lumini, C., and Deliliers, G.L. (2002). Isolation of 
bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Experimental 
Hematology 30, 783-791. 
Raaijmakers, M., Mukherjee, S., Guo, S.Q., Zhang, S.Y., Kobayashi, T., and Schoonmaker, J.A. (2010). 
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857. 
Ramasamy, S.K., Kusumbe, A.P., Wang, L., and Adams, R.H. (2014). Endothelial Notch activity 
promotes angiogenesis and osteogenesis in bone. Nature 507, 376. 
Rankin, E.B., Wu, C., Khatri, R., Wilson, T.L., Andersen, R., and Araldi, E. (2012). The HIF signaling 
pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 149, 63-
74. 
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., and Jeanne, M. (2011). IL-6 
controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia 
development. Cancer Cell 20, 661-673. 
Riether, C., Schürch, C.M., Flury, C., Hinterbrandner, M., Drück, L., Huguenin, A.-L., Baerlocher, 
G.M., Radpour, R., and Ochsenbein, A.F. (2015). Tyrosine kinase inhibitor–induced CD70 expression 
mediates drug resistance in leukemia stem cells by activating Wnt signaling. Science Translational 
Medicine 7, 298ra119. 
Roederer, M. (2001). Spectral compensation for flow cytometry: Visualization artifacts, limitations, and 
caveats. Cytometry 45, 194-205. 
Rohrbacher, M., and Hasford, J. (2009). Epidemiology of chronic myeloid leukaemia (CML). Best 
Practice & Research Clinical Haematology 22, 295-302. 
Rojas-Sutterlin, S., Lecuyer, E., and Hoang, T. (2014). Kit and Scl regulation of hematopoietic stem 
cells. Curr Opin Hematol 21, 256-264. 
Roos, C., Stenke, L., Ohm, L., Widell, S., Kumlin, M., Lindgren, J.Å., and Tornhamre, S. (2008). 
Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 
synthase expression and activity in chronic myeloid leukaemia. British Journal of Haematology 142, 
992-995. 
Rosti, V., Villani, L., Riboni, R., Poletto, V., Bonetti, E., and Tozzi, L. (2013). Spleen endothelial cells 
from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 121, 360-368. 
Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, 
S., Robey, P.G., Riminucci, M., et al. (2007). Self-Renewing Osteoprogenitors in Bone Marrow 
Sinusoids Can Organize a Hematopoietic Microenvironment. Cell 131, 324-336. 
Salter, A.B., Meadows, S.K., Muramoto, G.G., Himburg, H., Doan, P., Daher, P., Russell, L., Chen, B., 
Chao, N.J., and Chute, J.P. (2009). Endothelial progenitor cell infusion induces hematopoietic stem cell 
reconstitution in vivo. Blood 113, 2104-2107. 
Sanjuan-Pla, A., Macaulay, I.C., Jensen, C.T., Woll, P.S., Luis, T.C., Mead, A., Moore, S., Carella, C., 
Matsuoka, S., Jones, T.B., et al. (2013). Platelet-biased stem cells reside at the apex of the 
haematopoietic stem-cell hierarchy. Nature 502, 232. 
Santamaria, C., Muntion, S., Roson, B., Blanco, B., Lopez-Villar, O., and Carrancio, S. (2012). Impaired 
expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from 
myelodysplastic syndrome patients. Haematologica 97, 1218-1224. 
Saussele, S., Richter, J., Guilhot, J., Gruber, F.X., Hjorth-Hansen, H., Almeida, A., Janssen, J.J.W.M., 
Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018). Discontinuation of tyrosine kinase inhibitor 
therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, 
multicentre, non-randomised, trial. The Lancet Oncology 19, 747-757. 
  71 
Schaniel, C., Sirabella, D., Qiu, J., Niu, X., Lemischka, I.R., and Moore, K.A. (2011). Wnt-inhibitory 
factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 118, 2420-
2429. 
Schepers, K., Campbell, Timothy B., and Passegué, E. (2015). Normal and Leukemic Stem Cell Niches: 
Insights and Therapeutic Opportunities. Cell Stem Cell 16, 254-267. 
Schepers, K., Pietras, Eric M., Reynaud, D., Flach, J., Binnewies, M., Garg, T., Wagers, Amy J., Hsiao, 
Edward C., and Passegué, E. (2013). Myeloproliferative Neoplasia Remodels the Endosteal Bone 
Marrow Niche into a Self-Reinforcing Leukemic Niche. Cell Stem Cell 13, 285-299. 
Scherr, M., Chaturvedi, A., Battmer, K., Dallmann, I., Schultheis, B., Ganser, A., and Eder, M. (2006). 
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia 
(CML). Blood 107, 3279. 
Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S., Barreyro, L., Bhagat, T., Bhattacharyya, S., 
Ramachandra, N., Bartenstein, M., et al. (2015). IL8-CXCR2 pathway inhibition as a therapeutic 
strategy against MDS and AML stem cells. Blood 125, 3144. 
Schmidt, T., Masouleh, Behzad K., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., 
De Keersmaecker, K., Kleppe, M., Tjwa, M., et al. (2011). Loss or Inhibition of Stromal-Derived PlGF 
Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell 19, 740-753. 
Schofield, R. (1978). The relationship between the spleen colony-forming cell and the haemopoietic 
stem cell. Blood Cells 4, 7-25. 
Schürch, C., Riether, C., Matter, M.S., Tzankov, A., and Ochsenbein, A.F. (2012). CD27 signaling on 
chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. 
The Journal of Clinical Investigation 122, 624-638. 
Schwarze, S.R., Luo, J., Isaacs, W.B., and Jarrard, D.F. (2005). Modulation of CXCL14 (BRAK) 
expression in prostate cancer. The Prostate 64, 67-74. 
Semenza, G.L. (2014). Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology. 
Annual Review of Pathology: Mechanisms of Disease 9, 47-71. 
Shellenberger, T.D., Wang, M., Gujrati, M., Jayakumar, A., Strieter, R.M., Burdick, M.D., Ioannides, 
C.G., Efferson, C.L., El-Naggar, A.K., Roberts, D., et al. (2004). BRAK/CXCL14 Is a Potent Inhibitor 
of Angiogenesis and a Chemotactic Factor for Immature Dendritic Cells. Cancer Research 64, 8262. 
Shiozawa, Y., and Taichman, R.S. (2010). Dysfunctional Niches as a Root of Hematopoietic 
Malignancy. Cell Stem Cell 6, 399-400. 
Sjölinder, M., Stenke, L., Näsman-Glaser, B., Widell, S., Doucet, J., Jakobsson, P.-J., and Lindgren, 
J.Å. (2000). Aberrant expression of active leukotriene C&lt;sub&gt;4&lt;/sub&gt; synthase in 
CD16&lt;sup&gt;+&lt;/sup&gt; neutrophils from patients with chronic myeloid leukemia. Blood 95, 
1456. 
Sozer, S., Fiel, M.I., Schiano, T., Xu, M., Mascarenhas, J., and Hoffman, R. (2009). The presence of 
JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113, 
5246-5249. 
Spencer, J.A., Ferraro, F., Roussakis, E., Klein, A., Wu, J., Runnels, J.M., Zaher, W., Mortensen, L.J., 
Alt, C., Turcotte, R., et al. (2014). Direct measurement of local oxygen concentration in the bone 
marrow of live animals. Nature 508, 269. 
Spiegel, A., Shivtiel, S., Kalinkovich, A., Ludin, A., Netzer, N., Goichberg, P., Azaria, Y., Resnick, I., 
Hardan, I., Ben-Hur, H., et al. (2007). Catecholaminergic neurotransmitters regulate migration and 
repopulation of immature human CD34+ cells through Wnt signaling. Nat Immunol 8, 1123-1131. 
Spindler, T.J., Tseng, A.W., Zhou, X., and Adams, G.B. (2013). Adipocytic Cells Augment the Support 
of Primitive Hematopoietic Cells In Vitro But Have No Effect in the Bone Marrow Niche Under 
Homeostatic Conditions. Stem Cells and Development 23, 434-441. 
 72 
Stier, S., Cheng, T., Dombkowski, D., Carlesso, N., and Scadden, D.T. (2002). Notch1 activation 
increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage 
outcome. Blood 99, 2369-2378. 
Stier, S., Ko, Y., Forkert, R., Lutz, C., Neuhaus, T., and Grunewald, E. (2005). Osteopontin is a 
hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201, 
1781-1791. 
Sugiyama, T., Kohara, H., Noda, M., and Nagasawa, T. (2006). Maintenance of the hematopoietic stem 
cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 
977-988. 
Sutherland, H.J., Eaves, C.J., Eaves, A.C., Dragowska, W., and Lansdorp, P.M. (1989). Characterization 
and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. 
Blood 74, 1563. 
Sutherland, H.J., Eaves, C.J., Lansdorp, P.M., Thacker, J.D., and Hogge, D.E. (1991). Differential 
regulation of primitive human hematopoietic cells in long- term cultures maintained on genetically 
engineered murine stromal cells. Blood 78, 666. 
Sutherland, H.J., Hogge, D.E., and Eaves, C.J. (1993). Growth factor regulation of the maintenance and 
differentiation of human long-term culture-initiating cells (LTC-IC). Leukemia 7 Suppl 2, 1222-1225. 
Sutherland, H.J., Lansdorp, P.M., Henkelman, D.H., Eaves, A.C., and Eaves, C.J. (1990). Functional 
characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive 
marrow stromal layers. Proceedings of the National Academy of Sciences of the United States of 
America 87, 3584-3588. 
Swerdlow, S.H., Campo, E., Harris, N.L., Pileri, S.A., Jaffe, E.S., Stein, H., and Thiele, J. (2017). WHO 
Classification of Tumours of Haematopoietic and Lymphoid Tissues (International Agency for 
Research on Cancer). 
Szilvassy, S.J., Humphries, R.K., Lansdorp, P.M., Eaves, A.C., and Eaves, C.J. (1990). Quantitative 
assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. 
Proceedings of the National Academy of Sciences of the United States of America 87, 8736-8740. 
Tabe, Y., Jin, L., Iwabuchi, K., Wang, R.Y., Ichikawa, N., Miida, T., Cortes, J., Andreeff, M., and 
Konopleva, M. (2011). Role of stromal microenvironment in nonpharmacological resistance of CML 
to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia 26, 883. 
Tabe, Y., and Konopleva, M. (2017). Leukemia Stem Cells Microenvironment. In Stem Cell 
Microenvironments and Beyond, A. Birbrair, ed. (Cham: Springer International Publishing), pp. 19-32. 
Taichman, R., Reilly, M., and Emerson, S. (1996). Human osteoblasts support human hematopoietic 
progenitor cells in vitro bone marrow cultures. Blood 87, 518-524. 
Taichman, R.E., SG (1994). Human osteoblasts support hematopoiesis through the production of 
granulocyte colony-stimulating factor. The Journal of Experimental Medicine 179, 1677-1682. 
Takubo, K., Goda, N., Yamada, W., Iriuchishima, H., Ikeda, E., Kubota, Y., Shima, H., Johnson, R.S., 
Hirao, A., Suematsu, M., et al. (2010). Regulation of the HIF-1α Level Is Essential for Hematopoietic 
Stem Cells. Cell Stem Cell 7, 391-402. 
Taverna, S., Amodeo, V., Saieva, L., Russo, A., Giallombardo, M., De Leo, G., and Alessandro, R. 
(2014). Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities 
of chronic myelogenous leukemia cells. Molecular cancer 13, 169-169. 
Tavor, S., Petit, I., Porozov, S., Avigdor, A., Dar, A., Leider-Trejo, L., Shemtov, N., Deutsch, V., 
Naparstek, E., Nagler, A., et al. (2004). CXCR4 Regulates Migration and Development of Human Acute 
Myelogenous Leukemia Stem Cells in Transplanted NOD/SCID Mice. Cancer Research 64, 2817. 
Tefferi, A., and Pardanani, A. (2015). Myeloproliferative neoplasms: A contemporary review. JAMA 
Oncology 1, 97-105. 
  73 
Teofili, L., Martini, M., Iachininoto, M.G., Capodimonti, S., Nuzzolo, E.R., and Torti, L. (2011). 
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic 
patients with Ph-negative myeloproliferative neoplasms. Blood 117, 2700-2707. 
Tessema, M., Klinge, D.M., Yingling, C.M., Do, K., Van Neste, L., and Belinsky, S.A. (2010). Re-
expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor 
necrosis. Oncogene 29, 5159. 
Thein, M.S., Ershler, W.B., Jemal, A., Yates, J.W., and Baer, M.R. (2013). Outcome of older patients 
with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer 119, 2720-2727. 
Till, J.E., and McCulloch, E.A. (1961). A Direct Measurement of the Radiation Sensitivity of Normal 
Mouse Bone Marrow Cells. Radiation Research 14, 213-222. 
Tormin, A., Li, O., Brune, J.C., Walsh, S., Schütz, B., Ehinger, M., Ditzel, N., Kassem, M., and 
Scheding, S. (2011). CD146 expression on primary nonhematopoietic bone marrow stem cells is 
correlated with in situ localization. Blood 117, 5067. 
Traer, E., MacKenzie, R., Snead, J., Agarwal, A., Eiring, A.M., O'Hare, T., Druker, B.J., and Deininger, 
M.W. (2012). Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells 
to ABL inhibitors. Leukemia 26, 1140-1143. 
Tsai, C.-C., Chen, Y.-J., Yew, T.-L., Chen, L.-L., Wang, J.-Y., Chiu, C.-H., and Hung, S.-C. (2011). 
Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation 
of E2A-p21 by HIF-TWIST. Blood 117, 459. 
Tsapogas, P., Zandi, S., Åhsberg, J., Zetterblad, J., Welinder, E., Jönsson, J.I., Månsson, R., Qian, H., 
and Sigvardsson, M. (2011). IL-7 mediates Ebf-1–dependent lineage restriction in early lymphoid 
progenitors. Blood 118, 1283. 
Tuljapurkar, S.R., McGuire, T.R., Brusnahan, S.K., Jackson, J.D., Garvin, K.L., Kessinger, M.A., Lane, 
J.T., O' Kane, B.J., and Sharp, J.G. (2011). Changes in human bone marrow fat content associated with 
changes in hematopoietic stem cell numbers and cytokine levels with aging. Journal of Anatomy 219, 
574-581. 
van Os, R., Kamminga, L.M., and de Haan, G. (2008). Stem Cell Assays: Something Old, Something 
New, Something Borrowed. STEM CELLS 22, 1181-1190. 
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le 
Beau, M.M., Hellström-Lindberg, E., Tefferi, A., et al. (2009). The 2008 revision of the World Health 
Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important 
changes. Blood 114, 937. 
Velten, L., Haas, S.F., Raffel, S., Blaszkiewicz, S., Islam, S., Hennig, B.P., Hirche, C., Lutz, C., Buss, 
E.C., Nowak, D., et al. (2017). Human haematopoietic stem cell lineage commitment is a continuous 
process. Nature cell biology 19, 271-281. 
Vianello, F., Villanova, F., Tisato, V., Lymperi, S., Ho, K.-K., Gomes, A.R., Marin, D., Bonnet, D., 
Apperley, J., Lam, E.W.F., et al. (2010). Bone marrow mesenchymal stromal cells non-selectively 
protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. 
Haematologica 95, 1081. 
Visnjic, D., Kalajzic, Z., and Rowe, D.W. (2004). Hematopoiesis is severely altered in mice with an 
induced osteoblast deficiency. Blood 103, 3258-3264. 
Walkley, C.R. (2007a). A microenvironment-induced myeloproliferative syndrome caused by retinoic 
acid receptor [ggr] deficiency. Cell 129, 1097-1110. 
Walkley, C.R. (2007b). Rb regulates interactions between hematopoietic stem cells and their bone 
marrow microenvironment. Cell 129, 1081-1095. 
 74 
Walkley, C.R., Olsen, G.H., Dworkin, S., Fabb, S.A., Swann, J., and McArthur, G.A. (2007a). A 
microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma 
deficiency. Cell 129, 1097-1110. 
Walkley, C.R., Shea, J.M., Sims, N.A., Purton, L.E., and Orkin, S.H. (2007b). Rb Regulates Interactions 
between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment. Cell 129, 1081-1095. 
Wang, L., Zhang, H., Rodriguez, S., Cao, L., Parish, J., Mumaw, C., Zollman, A., Kamoka, 
Malgorzata M., Mu, J., Chen, Danny Z., et al. (2014). Notch-Dependent Repression of miR-155 in the 
Bone Marrow Niche Regulates Hematopoiesis in an NF-κB-Dependent Manner. Cell Stem Cell 15, 51-
65. 
Wang, Z., Gerstein, M., and Snyder, M. (2009). RNA-Seq: a revolutionary tool for transcriptomics. 
Nature Reviews Genetics 10, 57. 
Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330. 
Welner, Robert S., Amabile, G., Bararia, D., Czibere, A., Yang, H., Zhang, H., Pontes, 
Lorena Lobo De F., Ye, M., Levantini, E., Di Ruscio, A., et al. (2015). Treatment of Chronic 
Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells. 
Cancer Cell 27, 671-681. 
Winkler, I.G., Barbier, V., Nowlan, B., Jacobsen, R.N., Forristal, C.E., and Patton, J.T. (2012a). 
Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and 
chemoresistance. Nat Med 18, 1651-1657. 
Winkler, I.G., Barbier, V., Nowlan, B., Jacobsen, R.N., Forristal, C.E., Patton, J.T., Magnani, J.L., and 
Levesque, J.-P. (2012b). Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self 
renewal and chemoresistance. Nat Med 18, 1651-1657. 
Winkler, I.G., Barbier, V., Wadley, R., Zannettino, A.C.W., Williams, S., and Lévesque, J.-P. (2010a). 
Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially 
reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 116, 375. 
Winkler, I.G., Sims, N.A., Pettit, A.R., Barbier, V., Nowlan, B., Helwani, F., Poulton, I.J., van Rooijen, 
N., Alexander, K.A., Raggatt, L.J., et al. (2010b). Bone marrow macrophages maintain hematopoietic 
stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815. 
Worthington, R.E., Bossie-Codreanu, J., and Van Zant, G. (1987). Quantitation of erythroid 
differentiation in vitro using a sensitive colorimetric assay for hemoglobin. Exp Hematol 15, 85-92. 
Worthley, Daniel L., Churchill, M., Compton, Jocelyn T., Tailor, Y., Rao, M., Si, Y., Levin, D., 
Schwartz, Matthew G., Uygur, A., Hayakawa, Y., et al. (2015). Gremlin 1 Identifies a Skeletal Stem 
Cell with Bone, Cartilage, and Reticular Stromal Potential. Cell 160, 269-284. 
Xiao, M., Wang, Y., Tao, C., Wang, Z., Yang, J., Chen, Z., Zou, Z., Li, M., Liu, A., Jia, C., et al. (2017). 
Osteoblasts support megakaryopoiesis through production of interleukin 9. Blood 129, 3196. 
Xiao, P., Dolinska, M., Sandhow, L., Kondo, M., Johansson, A.-S., Bouderlique, T., Zhao, Y., Li, X., 
Dimitriou, M., Rassidakis, G.Z., et al. (2018a). Sipa1 deficiency–induced bone marrow niche alterations 
lead to the initiation of myeloproliferative neoplasm. Blood Advances 2, 534-548. 
Xiao, P., Sandhow, L., Heshmati, Y., Kondo, M., Bouderlique, T., Dolinska, M., Johansson, A.-S., 
Sigvardsson, M., Ekblom, M., Walfridsson, J., et al. (2018b). Distinct roles of mesenchymal stem and 
progenitor cells during the development of acute myeloid leukemia in mice. Blood Advances 2, 1480-
1494. 
Yamamoto, R., Morita, Y., Ooehara, J., Hamanaka, S., Onodera, M., Rudolph, Karl L., Ema, H., and 
Nakauchi, H. (2013). Clonal Analysis Unveils Self-Renewing Lineage-Restricted Progenitors 
Generated Directly from Hematopoietic Stem Cells. Cell 154, 1112-1126. 
Yamamoto-Sugitani, M., Kuroda, J., Ashihara, E., Nagoshi, H., Kobayashi, T., Matsumoto, Y., Sasaki, 
N., Shimura, Y., Kiyota, M., Nakayama, R., et al. (2011). Galectin-3 (Gal-3) induced by leukemia 
  75 
microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous 
leukemia. Proceedings of the National Academy of Sciences 108, 17468. 
Yamazaki, S., Ema, H., Karlsson, G., Yamaguchi, T., Miyoshi, H., Shioda, S., Taketo, Makoto M., 
Karlsson, S., Iwama, A., and Nakauchi, H. (2011). Nonmyelinating Schwann Cells Maintain 
Hematopoietic Stem Cell Hibernation in the Bone Marrow Niche. Cell 147, 1146-1158. 
Yamazaki, S., Iwama, A., Takayanagi, S.-i., Eto, K., Ema, H., and Nakauchi, H. (2009). TGF-β as a 
candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113, 1250. 
Yao, L., Yokota, T., Xia, L., Kincade, P.W., and McEver, R.P. (2005). Bone marrow dysfunction in 
mice lacking the cytokine receptor gp130 in endothelial cells. Blood 106, 4093. 
Ye, D., Wolff, N., Li, L., Zhang, S., and Ilaria, R.L., Jr. (2006). STAT5 signaling is required for the 
efficient induction and maintenance of CML in mice. Blood 107, 4917-4925. 
Yektaei-Karin, E., Zovko, A., Nilsson, A., Näsman-Glaser, B., Kanter, L., Rådmark, O., Wallvik, J., 
Ekblom, M., Dolinska, M., Qian, H., et al. (2017). Modulation of leukotriene signaling inhibiting cell 
growth in chronic myeloid leukemia. Leukemia & Lymphoma 58, 1903-1913. 
Yi, H., Zeng, D., Shen, Z., Liao, J., Wang, X., Liu, Y., Zhang, X., and Kong, P. (2016). Integrin αvβ3 
enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal 
tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. 
Oncotarget 7, 40387-40397. 
Yoshida, N., Yagasaki, H., Takahashi, Y., Kudo, K., Manabe, A., and Kojima, S. (2008). Mutation 
analysis of SIPA1 in patients with juvenile myelomonocytic leukemia. British Journal of Haematology 
142, 850-851. 
Yu, V.W.C., and Scadden, D.T. (2016). Heterogeneity of the bone marrow niche. Current Opinion in 
Hematology 23, 331-338. 
Yue, R., Zhou, Bo O., Shimada, Issei S., Zhao, Z., and Morrison, Sean J. (2016). Leptin Receptor 
Promotes Adipogenesis and Reduces Osteogenesis by Regulating Mesenchymal Stromal Cells in Adult 
Bone Marrow. Cell Stem Cell 18, 782-796. 
Zambetti, Noemi A., Ping, Z., Chen, S., Kenswil, Keane J.G., Mylona, Maria A., Sanders, Mathijs A., 
Hoogenboezem, Remco M., Bindels, Eric M.J., Adisty, Maria N., Van Strien, Paulina M.H., et al. 
(2016). Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts 
Disease Evolution in Human Pre-leukemia. Cell Stem Cell 19, 613-627. 
Zandstra, Conneally, Piret, and Eaves (1998). Ontogeny-associated changes in the cytokine responses 
of primitive human haemopoietic cells. British Journal of Haematology 101, 770-778. 
Zeng, Z., Xi Shi, Y., Samudio, I.J., Wang, R.-Y., Ling, X., Frolova, O., Levis, M., Rubin, J.B., Negrin, 
R.R., Estey, E.H., et al. (2009). Targeting the leukemia microenvironment by CXCR4 inhibition 
overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215. 
Zhan, H., Lin, C.H.S., Segal, Y., and Kaushansky, K. (2017). The JAK2V617F-bearing vascular niche 
promotes clonal expansion in myeloproliferative neoplasms. Leukemia 32, 462-469. 
Zhan, H., Ma, Y., Lin, C.H., and Kaushansky, K. (2016). JAK2V617F-mutant megakaryocytes 
contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. 
Leukemia 30, 2332-2341. 
Zhang, B., Chu, S., Agarwal, P., Campbell, V.L., Hopcroft, L., Jørgensen, H.G., Lin, A., Gaal, K., 
Holyoake, T.L., and Bhatia, R. (2016). Inhibition of interleukin-1 signaling enhances elimination of 
tyrosine kinase inhibitor–treated CML stem cells. Blood 128, 2671. 
Zhang, B., Ho, Yin W., Huang, Q., Maeda, T., Lin, A., Lee, S.-u., Hair, A., Holyoake, Tessa L., 
Huettner, C., and Bhatia, R. (2012). Altered Microenvironmental Regulation of Leukemic and Normal 
Stem Cells in Chronic Myelogenous Leukemia. Cancer Cell 21, 577-592. 
 76 
Zhang, B., Li, M., McDonald, T., Holyoake, T.L., Moon, R.T., Campana, D., Shultz, L., and Bhatia, R. 
(2013). Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase 
inhibitors through N-cadherin and Wnt–β-catenin signaling. Blood 121, 1824. 
Zhang, J., Niu, C., Ye, L., Huang, H., He, X., and Tong, W.G. (2003). Identification of the 
haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841. 
Zhao, C., Blum, J., Chen, A., Kwon, H.Y., Jung, S.H., Cook, J.M., Lagoo, A., and Reya, T. (2007). 
Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo. Cancer Cell 12, 528-
541. 
Zhao, C., Chen, A., Jamieson, C.H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H.Y., Kim, J., 
Chute, J.P., Rizzieri, D., et al. (2009). Hedgehog signalling is essential for maintenance of cancer stem 
cells in myeloid leukaemia. Nature 458, 776. 
Zhao, M., Perry, J.M., Marshall, H., Venkatraman, A., Qian, P., and He, X.C. (2014). Megakaryocytes 
maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat 
Med 20, 1321-1326. 
Zhou, B.O., Ding, L., and Morrison, S.J. (2015). Hematopoietic stem and progenitor cells regulate the 
regeneration of their niche by secreting Angiopoietin-1. eLife 4, e05521. 
Zhou, B.O., Yu, H., Yue, R., Zhao, Z., Rios, J.J., Naveiras, O., and Morrison, S.J. (2017). Bone marrow 
adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nature Cell 
Biology 19, 891. 
Zhou, Bo O., Yue, R., Murphy, Malea M., Peyer, J.G., and Morrison, Sean J. (2014). Leptin-Receptor-
Expressing Mesenchymal Stromal Cells Represent the Main Source of Bone Formed by Adult Bone 
Marrow. Cell Stem Cell 15, 154-168. 
Zhou, X., Zhang, Z., Feng, J.Q., Dusevich, V.M., Sinha, K., Zhang, H., Darnay, B.G., and de 
Crombrugghe, B. (2010). Multiple functions of Osterix are required for bone growth and homeostasis 
in postnatal mice. Proceedings of the National Academy of Sciences 107, 12919. 
Zhu, J., Garrett, R., Jung, Y., Zhang, Y., Kim, N., and Wang, J. (2007). Osteoblasts support B-
lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 109, 3706-3712. 
Zhu, R.-J., Wu, M.-Q., Li, Z.-J., Zhang, Y., and Liu, K.-Y. (2013). Hematopoietic recovery following 
chemotherapy is improved by BADGE-induced inhibition of adipogenesis. International Journal of 
Hematology 97, 58-72. 
Zon, L.I. (2008). Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 453, 
306. 
 
